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SUMMARY 
 Ligament/tendon tissue engineering has the potential to provide therapies that 
overcome the limitations of incomplete natural healing responses and inadequate graft 
materials.  While ligament/tendon fibroblasts are an obvious choice of cell type for these 
applications, difficulties associated with finding a suitable cell source have limited their 
utility.  Mesenchymal stem cells/marrow stromal cells (MSCs) are seen as a viable 
alternative since they can be harvested through routine medical procedures and can be 
differentiated toward a ligament/tendon fibroblast lineage.  Further study is needed to 
create an optimal biomaterial/biomechanical environment for ligament/tendon 
fibroblastic differentiation of MSCs.  The overall goal of this dissertation was to improve 
the understanding of the role that biomechanical stimulation and the biomaterial 
environment play, both independently and combined, on human MSC (hMSC) 
differentiation toward a ligament/tendon fibroblast phenotype. 
 Specifically, the effects of cyclic tensile stimuli were studied in a biomaterial 
environment that provided controlled presentation of biological moieties.  The influence 
of an enzymatically-degradable biomaterial environment on hMSC differentiation was 
investigated by creating biomaterials containing enzymatically-cleavable moieties.  The 
role that preculture may play in tensile responses of hMSCs was also explored.  Together, 
these studies provided insights into the contributions of the biomaterial and 







 Ligaments and tendons are tissues that are important in inducing and guiding joint 
movement.
1
  Thousands of people seek medical attention each year for injuries to these 
tissues.
2
 Acute ruptures of ligaments and tendons stimulate a natural healing response 
that often fails to provide complete regeneration.
3,4
  In modern repair, autografts from the 
patient can result in painful donor site morbidity while allografts from cadavers can 
provoke immune responses, disease transmission, and are in limited supply.
5-9
  Often 
neither graft type completely restores pre-injury functionality.
5
  Therefore, tissue 
engineered grafts that employ a biomaterial scaffold, cells, and bioactive factors are being 
investigated to overcome these significant challenges.  Fibroblasts, the major cell type of 
ligaments and tendons,
4
 are a major candidate cell type for these studies.  However, 
difficulties associated with finding an acceptable source of autologous ligament/tendon 
fibroblasts has led to the investigation of mesenchymal stem cells/marrow stromal cells 
(MSCs) as a possible alternative cell type.
10
  MSCs have been employed in many 
biomaterial environments and are often cultured under tensile strain to promote 
differentiation toward a ligament/tendon fibroblast phenotype.
11
  However, understanding 
of how the local extracellular environment, in combination with mechanical loading, 
influences cellular differentiation and production of appropriate extracellular matrix is 
limited.  Therefore, controlled experiments that elicit the effects of the composition of the 
extracellular environment on MSC phenotype in the presence and absence of tensile 
 2 
stimulation can provide fundamental knowledge needed for the rational design of future 
ex vivo systems to promote fibrous differentiation of MSCs.  
1.2 Research Objectives 
 The objective of the research presented in this dissertation was to investigate the 
role that the biomaterial environment has on the response of human MSCs (hMSCs) to 
cyclic tensile strains.  A model system with well-controlled presentation of bioactive 
extracellular cues to encapsulated hMSCs was employed to investigate the effects of 
tensile loading on the promotion of a ligament fibroblast phenotype.  In addition, an 
enzymatically-degradable biomaterial environment was employed to explore the 
influence of cell-mediated, localized carrier degradation on the production of major 
ligament/tendon extracellular matrix (ECM) proteins by encapsulated hMSCs.  These 
enzymatically-degradable biomaterials were used with a preculture period or without 
preculture to create diverse cell-biomaterial environments that facilitated the study of the 
contribution of preculture on hMSC responses to short duration (1 day) tensile strain. The 
goal of these studies was to improve the understanding of the role of the local 
extracellular environment and biomechanical loading on hMSC differentiation toward a 
ligament/tendon fibroblast phenotype.  The central hypothesis was that culture in an 
enzymatically-cleavable biomaterial carrier would increase relevant ligament/tendon 
ECM production by encapsulated hMSCs and increase key ligament/tendon gene 
expression levels in response to cyclic tensile strain.  This hypothesis was explored 
through three specific hypotheses and research aims. 
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Hypothesis I: Cyclic tensile loading will promote a ligament/tendon fibroblastic 
phenotype in hMSCs encapsulated in OPF hydrogels over 21 days of in vitro culture. 
Specific Aim I: Investigate the effect of cyclic tensile loading on hMSCs in an OPF-
based biomaterial environment. 
 While tensile stimulation has previously been used to encourage differentiation of 
hMSCs toward a ligament/tendon fibroblastic phenotype, optimization of MSC 
differentiation to ligament/tendon fibroblasts has been hampered by a lack of knowledge 
of how biomechanical cues regulate this process.  For these experiments, hMSCs were 
encapsulated in a hydrogel environment consisting of OPF and PEG-diacrylate (PEG-
DA).  This PEG-based biomaterial presents an environment with limited biological 
interaction, but with the inclusion of a tethered adhesive peptide glycine-arginine-
glycine-aspartate-serine (GRGDS), the material could be designed for specific interaction 
with integrin cell surface receptors.   hMSC-seeded hydrogels containing GRGDS were 
exposed to cyclic tensile strain (10% strain, 1Hz, 3 hours of cyclic tensile stimulation 
followed by 3 hours without stimulation) over 21 days using a custom tensile culture 
bioreactor.  After days 1, 7, 14 and 21 of culture, cell number, gene expression, and 
protein production was examined.  Comparisons were made with static controls to 
characterize the effect of tensile stimulation on hMSCs in OPF-based hydrogels. 
 
Hypothesis II: Culture in an enzymatically-degradable biomaterial environment will 
promote the production of major ligament/tendon extracellular matrix (ECM) proteins by 
encapsulated hMSCs over 21 days of culture. 
 4 
Specific Aim II:  Determine whether hMSCs in hydrogels that are susceptible to 
enzymatic degradation are induced toward expression and production of a 
ligament/tendon ECM compared to hMSCs in hydrogels that are not susceptible to 
enzymatic degradation. 
 Remodeling of the ECM is an important part in the normal maturation of 
ligament/tendon tissues.  Collagenases such as matrix metalloproteinase-1 (MMP-1) and 
MMP-13 can degrade fibrous ECMs and thus play an important role in tissue 
reorganization.  Synthetic biomaterials, such as OPF, are not susceptible to cell-mediated 
enzymatic degradation.  This insensitivity to enzymatic cleavage along with a relatively 
small mesh size may limit the ability of encapsulated cells to produce a ligament/tendon 
ECM throughout the hydrogel.  Since degradation of the external environment is integral 
to natural tissue formation, it was hypothesized that a biomaterial carrier that is 
susceptible to enzymatic cleavage could encourage gene expression and ECM production 
in hMSCs that is characteristic of a ligament fibroblastic phenotype.  To explore this 
possibility, hMSCs were encapsulated in enzymatically-cleavable hydrogels that were 
designed to be susceptible to MMP-mediated degradation.  A range of enzymatically-
cleavable sequence concentrations (0%, 25%, 75%, or 100%) were used to create 
biomaterial environments with different levels of susceptibility to enzyme-mediated 
degradation.  After days 1, 7, 14, and 21 of culture, cell number and viability, cell 
morphology, MMP production, gene expression, and protein production were examined.  
The behavior of the hMSCs was compared across hydrogel types and to human anterior 
cruciate ligament (hACL) fibroblasts encapsulated in similar environments in order to 
determine whether hMSCs would exhibit upregulation of gene expression and ECM 
 5 
production similar to an hACL fibroblast phenotype in hydrogels containing 
enzymatically-cleavable motifs compared to non-enzymatically cleavable hydrogels. 
Hypothesis III: Preculture of hMSCs in enzymatically-cleavable hydrogels will 
upregulate gene expression of ligament/tendon fibroblastic genes (collagen I, collagen III, 
tenascin-C) in response to short-term tensile strain. 
Specific Aim III: Examine the effect of preculture on the response of encapsulated 
hMSCs to short-term tensile strain (24 hours). 
 Multiple weeks of strain can be required before upregulation of characteristic 
ligament/tendon fibroblastic genes are seen in hMSCs.  During this time period gene 
expression patterns in hMSCs can change and ECM proteins can be secreted even in 
static cultures.  Since these and other changes in the local extracellular environment occur 
in a cell-biomaterial system exposed to multiple weeks of tensile culture, it is unclear 
whether multi-week strain periods are required for characteristic gene expression changes 
to manifest or if shorter strain periods are interacting with changes in the cell-biomaterial 
environment that occur after over multiple weeks of culture.  Because this enzyme-
sensitive biomaterial promoted ECM deposition by embedded MSCs over 21 days of 
static culture, it was hypothesized that a static preculture period before exposure of 
hMSCs to short term strain would stimulate ligament/tendon fibroblast phenotypic gene 
expression responses that are normally seen with longer tensile culture periods.  To 
investigate this hypothesis hMSCs were encapsulated in 100% enzymatically-cleavable 
hydrogels with a preculture period or without preculture.  Differences in baseline gene 
expression levels and ECM production between precultured and non-precultured samples 
were confirmed.  After baseline culture, constructs were exposed to 24 hours of cyclic 
 6 
tensile strain (10% strain, 1Hz, 3 hours without stimulation followed by 3 hours of cyclic 
tensile stimulation).  Constructs cultured statically at 0% strain were used as controls.  
Gene expression of major ligament/tendon ECM proteins was examined to determine 
whether a preculture period, would affect MSC responses to short-term tensile strains. 
1.3 Significance and Scientific Contributions 
The studies detailed in this dissertation provide insights into how the interactions 
of mechanical and biomaterial cues affect the promotion of a characteristic 
ligament/tendon fibroblast phenotype in hMSCs.  The controlled environment of the 
PEG-based hydrogel systems allowed addition of specific bioactive moieties to provide 
adhesive cues and localized matrix degradation in systems where needed.  This controlled 
environment also facilitated mechanical stimulation of hydrogel constructs that may be 
needed to promote a ligament/tendon fibroblast phenotype in hMSCs while minimizing 
confounding effects from biological signaling that is seen with natural scaffolds.  The use 
of preculture to create diverse cell-biomaterial environments facilitated the investigation 
of how changes in the local extracellular environment that occur even without mechanical 
stimulation may be interacting with cyclic tensile strains to produce observed cell 
responses. 
In addition to elucidating effects of preculture and tensile loading on hMSC 
phenotype, behavioral differences between hMSCs and hACL fibroblasts were uncovered 
that may be related to the susceptibility of the biomaterial environment to enzymatic 
degradation.  These results highlight the need for biomaterial systems that can adapt to 
the distinct biomaterial environments that may be needed for differentiating stem cells 
and terminally differentiated cells.  Together, these findings provide a strong framework 
 7 
for further elucidation of hMSC responses to biomaterial and mechanical environments 
and furnish information needed for the design of next generation biomaterials and 
bioreactors that may be needed to pre-differentiate MSCs to a ligament/tendon fibroblast-
like phenotype.  As such, results from this thesis contribute important key concepts that 
must be addressed to move toward the goal of making stem cells a feasible source for 
regeneration of tendons and ligaments.  Therefore, these findings may have significant 
clinical applications in overcoming the limitations currently associated with harvesting 





BACKGROUND AND LITERATURE REVIEW
†
 
2.1 Tendon and Ligament 
2.1.1 Function 
 Tendons and ligaments are dense, regularly arranged, connective tissues that 
induce or guide joint movement.
1
  Tendons attach muscle to bone and are what couples 
the force of a muscle to a movement in the skeletal structure.
12
  Ligaments attach bone to 
bone in order to regulate and guide the movement of bones with respect to each other and 
also provide support for the internal organs.
12
  Both tissues function primarily in tension 
and therefore have similar structural characteristics.
12,13
 
2.1.2 Structure and Composition 
 Tendon and ligament tissues are comprised of a cellular component and an 
extracellular matrix (ECM) component.
14
  The cellular component consists of fibroblasts 
with small amounts of other cell types, while the ECM is primarily composed of 
collagen, proteoglycans, tenascin-C, and small amounts of other proteins.
13
 
 The largest component of the ECM of tendon and ligament tissue is collagen 
(primarily types I and III).
1,12,15
  Collagen is the most abundant protein in the body, 
comprising one-third of the total protein mass.
16
  There are at least nineteen different 
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 with collagen type I being the most common.
17
  In normal cruciate ligament 
tissue, the ratio of collagen I ECM to collagen III ECM  is about 9:1.
18
  
 The ability of collagen to provide strength to tissues is an important characteristic, 
and is directly related to the structure of the molecule.  Collagen forms a right-handed 
superhelix in a coiled-coil structure.  In fibrillar collagens, such as collagen I and III, 
these superhelices form long fibers,
19
 whose organization and diameter modulate tissue 
strength and stiffness.
20
  The superhelix consists of three smaller left-handed helices 
whose structure provides high tensile strength through their rigidity and relative 
inelasticity.
12
    The basic peptide sequence of these smaller helices consists of glycine-X-
Y repeats, where X and Y are proline and hydroxyproline, respectively, in 10% of these 
repeats.
1
  The small size of the glycine amino acid allows for close packing of the 
collagen helices
3
 while the proline and hydroxyproline components of collagen influence 
the coil structure, thereby affecting the rigidity of the protein.
1
 
 Another important aspect of collagen is its ability to form cross-links.  Cross-links 
mechanically stabilize the fibers and improve the tensile strength of the tissue.
21,22
  
Disulfide bonds are a cross-link that forms at cysteine residues and are found in type III 
and other collagens.
23
  Other important cross-links include the immature cross-links 
dihydroxylysinonorleucine (DHLNL) and hydroxylysinonorleucine (HLNL).  DHLNL 
cross-links are formed by condensation of a lysine-derived aldehyde with hydroxylysine 
or a hydroxylysine derived aldehyde with lysine.  HLNL cross-links are formed by 
condensation of hydroxyallysine and hydroxylysine.
24
  The degree of hydroxylation of 




Both of these cross-links are reducible by sodium borohydride
1
 and are generally 
found in younger collagen.  Over time, these reducible cross-links are converted to non-
reducible pyridinoline and pyrrole forms.
22,25
  Pyridinoline cross-links are proposed to 
form by condensation between two divalent keto-amine cross-links
26
 while pyrrole cross-
links are proposed to form from a lysine aldehyde and an immature cross-link.
27
 
 Proteoglycans are another important component of the tendon and ligament ECM 
due to their contribution to viscoelastic and other mechanical properties of the tissue.
13
  
Proteoglycans consist of at least one glycosaminoglycan (GAG) chain attached to a 
protein core.  One of the functions of proteoglycans in ligament tissues is to attract water 
through the GAG chains and thus lubricate the tissue and enhance gliding function.
1
  This 
hydration causes the proteoglycans to swell and become trapped among the collagen in 
the matrix leading to compressive strength and allowing rapid diffusion of water soluble 
molecules.
20
  As such, proteoglycans add viscous properties to the matrix in the form of a 
hydraulic damper.
17
   
 The most abundant proteoglycan in tendon tissue is decorin.
20,28
  Decorin inhibits 
formation of large collagen fibrils,
20,28,29
 and thus prevents abnormal packing of collagen 
that can lead to reduced tensile strength.
30
  Another proteoglycan, aggrecan, is found 
abundantly in areas where the tissue is subject to compressive forces,
20,28,29
 such as where 
the tendon wraps around bone or at tendon to bone insertion sites.
28
  Aggrecan‟s large 
size and negative charge creates an osmotic gradient that allows it to hold water and swell 
the collagen network, promoting a structure that resists compressive loading.
20,28
  Other 
proteoglycans such as biglycan, fibromodulin, lumican, and versican can also influence a 
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Figure 2.1.  The relationship between a 
collagen bundle and fibroblasts.  The collagen 
bundle is comprise of individual collagen 
fibrils that tightly surround the cells. 
wide range of the tissue properties, including fibril diameter, cellular proliferation and 
migration, and the viscoelasticity of the pericellular matrix.
20,29
 
 Tendon and ligament tissue also contains other proteins such as the matricellular 
protein tenascin-C.  Tenascin-C associates with fibronectin
31
 and its expression is 
upregulated in response to mechanical loading.
10
  It has been shown to modulate growth 
factor activity
31
 and inhibit β1 integrin-dependent cell adhesion.
32
  Since this protein is 
found in higher amounts in tendons and ligaments than in other orthopedic tissues, it has 
been used as a tissue specific marker.
10
 
 The ECM components described above are organized in a hierarchical fashion in 
tendon and ligament tissue, primarily to improve the tensile properties of the matrix.
12
  
The overall tissue structure consists of fibroblasts surrounded by collagen fibrils along 
with small amounts of proteoglycans.
1,12
  The collagen fibrils comprise a collagen fiber 
(Fig. 2.1), which in turn constitutes a fiber bundle.
12
  Fascicles, the main subdivision of 
the tissue, are groups of fiber bundles.  These structures are aligned parallel to each other 
along the direction of principal force.  The sinusoidal wave-like structure of the collagen 
 12 
fascicles is known as the “crimp” structure and is thought to allow the tissue to elongate 
without causing damage.
1
  The presence of the highly-hydrated proteoglycans provides 




 While all tendons and ligaments have these basic structural components, 
characteristics of each component can vary between different tendon and ligament 
tissues.  For example, the size and morphology of the fibroblasts is not consistent for all 
tendons and ligaments.
3
  The collagen bundle width, amplitude and period of the crimp, 




 The main cell type found in tendon and ligament tissue is the fibroblast.  
Fibroblasts have a spindle-shaped morphology, are sparsely distributed throughout the 
tissue, and align in columns along the direction of the collagen fibers (Figure 2.1).
4
  
While the fibroblasts themselves do not comprise a large volume of tendon/ligament 
tissue, they are responsible for secreting and maintaining the ECM that makes up the 
remainder of the tissue.  However, the relatively low numbers of fibroblasts, along with 
their low mitotic activity, leads to a relatively low tissue turnover rate and may explain 




 Pathologies of ligament and tendon tissue can be classified as acute or chronic 
according to the persistence of the pathological factors and as intrinsic or extrinsic 
according to the source of the injury stimulus.
33
  Acute injuries are generally caused by 




  This rupture may lead to further degeneration of the tissue.
35
  Chronic 
disorders of ligament/tendon, are often caused by both intrinsic and extrinsic factors such 
as repetitive loading of the tissue beyond its physiological threshold
36
 or microtrauma due 
to non-uniform stress fields within the tissue.
37
  These factors can result in degeneration 
that includes inflammation of the sheath and degradation of the tissue.
33
 
 Over 800,000 people seek medical attention each year for injuries to ligaments, 
tendons, or the joint capsule.
2
  Ruptures and other damage to tendons and ligaments can 
cause great pain and decrease the functionality of the joint complex.
33
  There are 
numerous areas throughout the body where tendons and ligaments experience such 
injuries.  These include the patellar tendon,
38





 and the medial collateral ligament
40
 in the knee; the 
Achilles tendon
4
 at the heel; the anterior talofibular ligament
41
 and the calcaneofibular 
ligament
42
 in the ankle; the radial ulnohumeral ligament
43
 and the lateral ulnar collateral 
ligament
44
 in the elbow; the digital flexor tendon
4,12
 and the ulnar collateral ligament
45
 in 
the hand; the scapholunate ligament
46





, the coracoclavicular ligament
48
, and the coracohumeral 
ligament
49
 at the shoulder; and the gluteus medius tendon
50
 at the hip. 
 In chronic ligament/tendon injuries natural repair mechanisms appear to involve 
constant regeneration of the tissue through ligament/tendon fibroblasts.
33
  In acute tendon 
injuries three overlapping phases of healing are seen: inflammation, cellular proliferation 
with initial matrix deposition, and remodeling.
34
  The inflammation phase of healing is 
characterized by the migration of inflammatory cells to the injury site.  The cellular 
proliferation phase is characterized by an increase in the number of fibroblasts.
34,51
  The 
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fibroblasts initially produce a provisional matrix consisting mainly of collagen III with 
some collagen I also present.
33,34,52
  In the remodeling stage, a decrease in the cellularity 
of the wound site is seen and the ECM is reorganized as greater amounts of collagen I are 
produced to replace the collagen III matrix.
53
  Remodeling is facilitated through an 
increase in the levels of matrixmetalloproteinases (MMPs) after injury.
54
  While the 
intensity of healing responses can vary, natural healing is often insufficient since many 
tendons and ligaments possess a limited capacity to regenerate.
3,4
 
2.1.5 Current Treatment Options 
 In the absence of sufficient natural healing, surgical interventions are commonly 
used to repair ruptured ligaments and tendons.  While certain ligaments and tendons can 
be repaired by suturing the injured tissue back together, some heal poorly in response to 
this type of surgery, so the use of grafts is required.
55
  While there has been a lot of 
success in restoring functionality after ligament/tendon injury,
9
 complications related to 
graft choice often arise.  Autografts from the patient may result in donor site morbidity 
and laxity of the joint, while cadaveric allografts may cause a harmful response from the 
immune system, retroviral transmission, and are not readily avialable.
5-9
  Both autografts 
and allografts often fail to restore the full strength of undamaged tissue.
5
   
2.2 Engineered Tendon and Ligament 
2.2.1 Previous Approaches 
 In response to the shortcomings of current treatment options, a number of 
synthetic graft materials have been investigated from as early as the 1970s.
56
  Early 




  While the high strength of these grafts lead to initial 
success, poor integration with existing tissue eventually led to abrasion and failure of the 
grafts.  The design of ligament/tendon replacements was advanced with the invention of a 
polypropylene graft designed to promote tissue ingrowth.
56
  However, inflammation 
caused by the non-degradable graft material caused eventual failure of this prosthesis.  
While newer grafts that facilitate tissue ingrowth such as the “LARS” artificial ligament 
have showed some encouraging results,
58
 the past failures of synthetic grafts have 




2.2.2 Current Tissue Engineering Strategies 
 While many approaches for the tissue engineering of ligaments and tendons are 
being investigated, current tissue engineering strategies often involve the use of a 
biomaterial carrier, cells, and/or bioactive factors to promote tissue healing by harnessing 
the regeneration potential of natural processes in the body.
60
  The biomaterial carrier is 
usually a three dimensional scaffold used in an effort to direct pre-seeded cells to create 
viable tendon/ligament tissue.
61-65
  Scaffolds are often chosen/designed to be degradable 
in order to adapt to tissue production inside the scaffold and to encourage cellular 
recruitment and external tissue ingrowth.
2
  In addition, to ensure final clinical use, 
biomaterials are selected that are not harmful to the surrounding tissue and do not result 
in unresolved inflammation or other deleterious biological responses. 
2.2.3 Biomaterials 
 A number of scaffold materials, both natural and synthetic, have been explored.  
One advantage of natural scaffolds is that they are inherently bioactive and facilitate 
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interactions with seeded cells that may be necessary for tissue engineering strategies.  
Another advantage of is that components of the natural ECM can be used.
66
  The use of 
ECM components facilitates the presentation of bioactive moieties that are similar to 
those present in the tissue that is being engineered.  Given that collagen is the largest 
component of tendon and ligament tissues, it is no surprise that the most commonly used 
natural scaffolds are primarily composed of collagen.
67-80
  Other natural scaffolds include 









 and fibronectin/fibrinogen fibers.
89
  Unfortunately, the inherent 
bioactivies of natural scaffolds can present a complex signaling environment that is not 
well defined.  Consequently, control of bioactive moieties presented in natural matrices is 
limited.  In addition, issues related to biocompatibility can arise depending on the source 
of the scaffold material.
56
 
 In contrast, synthetic materials provide greater control over the chemical and 
physical properties of the scaffold with a high degree of reproducibility.
66
  One way to 
tailor the properties of the biomaterial are the polymer used.  For example, polymers can 
be produced with specific molecular weights, cross-linking modes, degradation 
characteristics, and mechanical properties.
66,90
  A large number of synthetic scaffolds are 
being investigated for tendon and ligament tissue engineering.  The most commonly used 





  Synthetic materials lack the inherent biological activity that 
natural scaffolds possess and may require the introduction of biological moieties to 
facilitate suitable cellular interactions.  In addition, synthetic scaffolds may need to be 




While the lack of biological moieties can be a disadvantage of synthetic materials, they 
also provide a well-defined environment that can facilitate controlled experiments 
examining the effects of biological moieties that are introduced in a discrete manner. 
 Biomaterial fibers that are organized using textile structures are a common type of 
graft that is explored for ligament/tendon tissue engineering.
96
  Both natural and synthetic 
materials have been used with these structures.  The main types of textile structures are 
woven structures such as the Leeds-Keio PET graft,
97
 knitted structures such as the 
Stryker-Dacron PET graft,
98
 and braided structures such as the Gore-Tex PTFE graft.
99
  
The polymer fibers provide a structure that is similar to ligament/tendon tissue and the 
textile organization can increase the elastic modulus and ultimate tensile strength of the 
graft to a point where it approaches that of natural tissue.
96
  While the high tensile 
strength of these grafts makes them attractive as a possible ligament/tendon substitute, 
they may not be able to serve as long term solutions as they can be susceptible to 
abrasion, undergo fatigue failure, and their wear products can cause inflammation.
59
 
 Hydrogels, which can be fabricated from natural or synthetic polymers, are also 
used for ligament/tendon tissue engineering.
100
  Hydrogels are highly hydrated scaffolds 
(at least 30% by weight) that are formed through cross-linking between polymer chains.
66
  
These scaffolds can be used to encapsulate cells in a three dimensional environment that 
can be formed in situ in a minimally invasive manner.
101
  While hydrogels do not 
generally possess the mechanical properties that woven, knitted, or braided fibers can 
achieve, they are often designed to be replaced by natural tissue as they degrade.
66,96
  
Since hydrogels are often intended to be transient structures, the initial mechanical 
strength of the scaffold may not be a disadvantage. 
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 This work employed synthetic hydrogel scaffolds to create a biomaterial model 
system.  Specifically, oligo(poly(ethylene glycol) fumarate (OPF) was used with 
poly(ethylene glycol)-diacrylate (PEG-DA) as a cross-linker (Fig. 2.2).  These synthetic, 
PEG-based polymers can be cross-linked to form hydrogels with cross-linking 
accomplished though a chain-growth polymerization mechanism.
102
  OPF-based 
hydrogels can be used as a injectable,
103





 biomaterial scaffold.  In addition, this polymer and its degradation products 
have been found to be cytocompatible in in vitro studies.
105,106
 
 Both OPF and PEG-DA contain PEG repeat units.  The number of repeats is 
represented in the figure by the letter “n”.  OPF-3K, PEG-DA-3K, OPF-10K, etc. are 
named according to the size of these repeats- i.e. OPF with PEG chain of 10 kDa results 
Figure 2.2.  Cross-linking of OPF and PEG-DA.  Step growth of the polymer 
network is achieved through the use of thermal radial initiators. 
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in OPF-10K and OPF with a PEG chain of 3 kDa results in OPF-3K.  The size of this 
PEG chain can be modified to influence swelling, degradation, and mechanical properties 
of the resultant OPF hydrogels.
104,106,107
  These PEG-repeat units are responsible for the 






 Encapsulation experiments have shown that cells remain in the constructs after a 
four week period that can continue to produce matrix proteins.
110
   The ability 
encapsulate cells into these synthetic hydrogels and to present bioactive factors provides 
a versatile synthetic model system.  Since the OPF biomaterial does not promote cell 
adhesion or other biochemical responses it can be used as a “blank slate” that does not 
introduce confounding biological signals into controlled experiments.  Biological 
functionalities, can later be added in a discrete, controlled manner to effect cellular 
responses.  One commonly employed functionality is the RGD peptide which has been 
used to modulate cell adhesion in a dose dependent manner.
111
  Enzymatically-degradable 
sequences have also been incorporated in PEG-based biomaterials to facilitate 
remodeling of the hydrogel environment and migration of encapsulated cells.
112,113
 
 To enable cell-mediated degradation of the biomaterial environment the 
enzymatically-degradable peptide, glycine-glycine-glycine-leucine-glycine-proline-
alanine-glycine-glycine-lysine (GGGL↓GPAGGK) was conjugated on both ends to 3,400 
Da MW A-PEG-SVA (Fig. 2.3).  The GGGL↓GPAGGK peptide is cleaved between L 
and G.
114
  Cleavage of this peptide is believed to occur through matrix metalloproteinases 
(MMPs) and can be achieved by collagenase from Clostridium histolyticum.
113
  This 




  GM6001 is a broad based 
MMP inhibitor that is known to reduce the activity of a number of MMPs (including 1, 2, 
3, 7, 8, 9, 10, 12, 13, 14, 15, 17, 20, 21, 26).
115
  The inhibition by GM6001 suggests that 
the GGGL↓GPAGGK peptide is indeed sensitive to MMP-mediated degradation 
although the susceptibility to any specific MMP is uncertain.  GM6001 can also inhibit 
other enzymes including ADAMs
115
 so it is possible that non-MMP enzymes that may be 
present in the bacterial collagenase used are actually responsible for cleavage.  Since the 
GGGLGPAGGK peptide can be degraded enzymatically, its incorporation into hydrogel 
networks provides a synthetic model system where the total susceptibility to enzymatic 
degradation can be controlled. 
2.2.4 Cells 
 Multiple cell types have been seeded within scaffolds in an effort to promote cell-
mediated tissue regeneration.  The most common cell types employed are 
ligament/tendon fibroblasts
62,63,70,72,74-77,84,85,94,95,116-122
 and mesenchymal stem 
cells/marrow stromal cells (MSCs).
10,64,67-69,84,86,91,93,119,123
  Since fibroblasts are the 
predominant cell type in tendon/ligament tissue they are often used for these 
applications.
4
  Unfortunately, allogeneic ligament/tendon fibroblasts can provoke a 
foreign body response by the host and often there is not a suitable source of autologous 
cells.
10
   MSCs are seen as a promising alternative since they can be harvested from 
Fig. 2.3.  Chemical structure of acrylated GGGLGPAGGK peptide (LGPA). 
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adults using a routine needle biopsy, expanded to large numbers,
10




2.2.5 Tensile Loading 
 Tensile loading is often employed with ligament/tendon tissue engineering 
constructs in order to promote a ligament fibroblast phenotype in MSCs.
11
  This approach 
has seen some success in promoting upregulation of genes commonly associated with 
ligament/tendon fiboroblasts.
11,125
  Strain regimens are often oscillatory in nature and are 
characterized by the strain amplitude, frequency of strain, and the timeframe of strain 
cycles and rest periods without strain.  While a large variety of strain protocols have been 
investigated,
11,126-137
 certain values for different parameters are often employed.  A peak 
to peak amplitude of 10% and a frequency of 1 Hz are commonly used in an effort to 
simulate a physiological loading regimen.
129,130
  Increased gene expression and protein 
production of collagen I in tendon fibroblasts has also been correlated to increasing the 
peak to peak amplitudes up to 10%.
138
  A loading protocol consisting of 3 hours of cyclic 
strain followed by 3 hours of 0% strain has been employed, to upregulate collagen I gene 
expression and overall collagen content in fibrin constructs with encapsulated MSCs.
139
  
While preculture periods for strain regimens have not been widely investigated, a static 
preculture period of 1-2 days after cell seeding, but before strain is initiated, has been 
used in order to provide time for cells to spread and attach to the biomaterial matrix.
129,130
 
2.2.6 Matrix Metalloproteinases 
 Normal maturation of ligament/tendon ECM requires degradation of the 
environment for reorganization of ECM components.
4,51,140
  MMPs are one category of 




 are a family of enzymes secreted by fibroblasts and MSCs that 
facilitate ECM reorganization,
141
 making them crucial for normal embryonic 
development
141,142
 and the maintenance of healthy tissue.
142-144
  MMPs play a major role 
in the cleavage of ECM molecules, although other proteases can also facilitate ECM 
degradation.
145
  After ligament injuries MMPs are upregulated and may play an important 
role in the healing process.
146
  While the structure of these enzymes can vary, all MMPs 
contain sequence homology to the catalytic domain of MMP-1
145
 and include a 
propeptide and a catalytic domain.
147
  These proteases are generally secreted in a latent 
form and are activated extracellularly.
141
  Activation occurs through cleavage of the 
propeptide or its displacement from the catalytic site.
148





 for activity which is where they get the name „metalloproteinases.‟ 
 Regulation of MMPs occurs through many mechanisms.  MMP amounts are 
regulated at both the transcriptional and post-transcriptional level.
149
  In addition, the 
activity of MMPs can be controlled through the activation of latent MMPs or through the 
inhibition of active MMPs.
150
  One of the major inhibitors of active MMPs is α2-
macroglobulin.
151
  α2-macroglobulin is a glycoprotein found in blood and tissue fluids
151
 
that entraps enzymes within the macroglobulin.  As a result it will inhibit most 
endopeptidases.
152
  Tissue inhibitors of metalloproteinases (TIMPs) are the other major 
class of MMP inhibitors
151
 which prevent the function of a wide range of MMPs.
153
  In 
addition to the regulation of MMP production and activity, the spatial localization of 
MMPs can also be regulated by cells.
147
 
 There are 23 different MMP genes in the human genome.
145
  These MMPs are 




  The categories are collagenases (MMP-1 aka interstitial collagense or 
collagenase 1, MMP-8 aka neutrophil collagenase or collagenase 2, MMP-13 aka 
collagenase 3), gelatinases (MMP-2 aka gelatinase A, MMP-9 aka gelatinase B), 
stromolysins (MMP-3 aka stromelysin 1, MMP-10 aka stromelysin 2), matrilysins 
(MMP-7 aka matrilysin 1, MMP-26 aka matrilysin 2, MMP-11 aka stromelysin 3), 
transmembrane-type MMPs (MMP-14 aka MT1-MMP, MMP-15 aka MT2-MMP, MMP-
16 aka MT3-MMP, MMP-24 aka MT5-MMP), GPI-anchored membrane type MMPs 
(MMP-17 aka MT4-MMP, MMP-25 aka MT6-MMP), and others (MMP-12 aka 
macrophage elastase, MMP-19, MMP-20 aka enamelysin, MMP-21, MMP-23 aka CA-
MMP, MMP-27, MMP-28 aka epilysin). 
 Collagenases may be important in ligament/tendon tissue as they target a number 
of collagens including collagen I and collagen III
145,147
 which are the most prevalent 
components of ligament/tendon tissue.
154
  The collagenases function by unwinding the 
triple helical fibrillar collagen chains
155
 before cleaving the chains into characteristic ¾ 
and ¼ fragments.
145
  Collagenases, such as MMP-1 and MMP-13 contain propetide, 
catalytic and hemopexin domains.
145
  Both MMP-1 and MMP-13 are known to target 
collagen I, collagen II, collagen III, collagen X, gelatin, aggrecan, tenascin, and MMP-9 
(Table 2.1).
147
  However, there is variation between other known substrates of MMP-1 
(collagen VII, collagen VIII, proteoglycan link protein, versican, entactin, α1-PI, ILb-1, 
pro-TNF, IGFBP-3, MMP-2) and MMP-13 (collagen IV, collagen IX, collagen XIV, 
perlecan, fibronectin, osteonectin, MMP-9, plasminogen activator inhibitor-2).  In 
addition, when MMP-1 and MMP-13 target the same substrate their specificities can vary 
greatly.
156
  MMP-1 and MMP-13 also possess different levels of susceptibility to 
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inhibitors which are related to structural differences in the S1‟ subsite of the catalytic 
domain.
157,158
  In addition to collagenases, gelatinases may be important in 
ligaments/tendons as they target denatured collagen.
145
  MMPs from other categories may 
also play a role in ligament/tendon tissue as they have shown some specificity to collagen 





















Chromosomal location 11q22-q23 11q22.3
s1’ subsite structure Small, closed Long, open
ECM substrate Collagens (I, II, III, VII, X), gelatin, 
proteoglycan link protein, 
aggrecan, versican, tenascin, 
entactin
Collagens (I, II, III, IV, IX, X, XIV), 
gelatin, aggrecan, perlecan, large 
tenascin-C, fibronectin, 
osteonectin
Non ECM substate α1-PI, ILb-1, pro-TNF, IGFBP-3, 
MMP-2, MMP-9
MMP-9, plasminogen activator 
inhibitor-2
Activated by MMP-3, MMP-10, plasmin, 
kallikrein, chymase
MMP-2, MMP-3, MMP-10, MMP-
14, MMP-15, plasmin





CYCLIC TENSILE CULTURE PROMOTES LIGAMENT/TENDON 
FIBROBLASTIC DIFFERENTIATION OF MARROW STROMAL 
CELLS ENCAPSULATED IN POLY(ETHYLENE GLYCOL)-BASED 
HYDROGELS 
3.1  Introduction 
 Over 800,000 people seek medical attention each year for injuries to ligaments, 
tendons, or the joint capsule.
159
  Tendon and ligament tissues, composed of collagen 
bundles organized in a hierarchical fashion, function primarily in tension to induce or 
guide joint movement.
12
  Fibroblasts maintain this ECM, but their low cell numbers and 
low mitotic activity lead to a reduced tissue turnover rate that may explain the poor 
natural healing of some tendons and ligaments.
4
  While tissue grafts can improve function 
after injury, current graft fixation procedures do not completely recapitulate normal joint 
mechanics, leading to potential for secondary pathologies such as osteoarthritis.
160
  Thus, 
there is a need for new regenerative medicine-based strategies to improve healing of 
tendon/ligament injuries and provide alternatives to current autograft transplantation 
techniques. 
 Over the past 15 years, a variety of tissue engineering approaches have been 
explored for tendon and ligament regeneration.  Many of these center on combining cells 




 This chapter has been adapted from Doroski, D.M., Levenston, M.E., Temenoff, J.S. Cyclic tensile 
culture promotes fibroblastic differentiation of marrow stromal cells encapsulated in poly(ethylene glycol)-
based hydrogels. Tissue Eng Part A 16, 3457-66, 2010. 
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with a 3-dimensional biomaterial scaffold,
161,162
 and may also add exogenous bioactive 
factors, such as growth factors or mechanical (usually tensile) stimulation.
162-164
   
Progenitor cells, such as MSCs, are often selected as the cell source for these studies
162,165
 
since this overcomes the difficulty of isolating autologous tendon/ligament fibroblasts in 
sufficient numbers to seed on scaffolds for eventual clinical applications.
10
  MSCs can be 
expanded many times
166
 and subsequently differentiate into multiple lineages associated 
with orthopedic tissues, including tendon/ligament fibroblasts.
124
  In addition, this 
flexibility provides the future possibility of using a single cell source to form all the 
tissues associated with tendon/ligaments and their insertions to bone/muscle, and thus 
potentially provides a true counterpart to the bone-ligament-bone autografts currently 
employed in reconstruction procedures.
167
  However, optimization of MSC differentiation 
to tendon/ligament fibroblasts for these applications has been hampered by lack of 
knowledge of how both loading and biochemical cues simultaneously regulate this 
process.  A well-controlled model system with the ability to alter both external loading 
parameters and local extracellular cues to better study MSC response to both stimuli 
concurrently was therefore developed. 
 For these studies, an OPF-based biomaterial was combined with a custom tensile 
culture bioreactor (Fig. 3.2A and 3.2B).  Tensile strain has been employed to stimulate 
MSC differentiation toward a tendon/ligament fibroblast phenotype.
11
  This system has 
the advantage of being able to develop strains in a three dimensional environment, which 
may be important since cells respond differently in two dimensional compared to three 
dimensional culture.
168
  In addition, the tensile constructs are designed to create a 
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uniform strain field across the hydrogel
169
 to provide a well-defined mechanical 
environment. 
 While the long-term goal is to employ this model system to examine the 
formation of ligaments/tendons as well as their interfaces with surrounding tissues, a first 
step was to determine if layered (laminated) acellular OPF hydrogels would withstand 
Figure 3.1.  A: Custom tensile culture system.  Up to 24 biomaterial constructs can 
be cultured in tensile wells (dotted line arrows) and strained by the tensile rakes 
(double arrow shows direction of tensile strain) at the same time.  The rake is 
moved by a linear motor with positional accuracy monitored by an optical encoder.  
Inset: Individual construct with hydrogel (bracket) flanked by end blocks 
(arrowhead).  B: Laminated hydrogel constructs in culture wells.  Polyethylene end 
blocks (arrowhead) are interfaced with the tensile rake to allow mechanical 
stimulation to be transduced to the hydrogel section (bracket) and create a uniform 
strain field in the construct during culture.  Double arrow indicates direction of 
strain.  C: Diagram demonstrating possibilities for future use of this culture system 
with laminated hydrogels.  For example, this permits co-culture of two different 
cell types (top) or two biomaterial environments with different bioactive factors 
(bottom).  Double arrow represents direction of strain.  D: Overall experimental 
design for hMSC loading studies. 
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cyclic loading over 28 days in vitro.  After this was ascertained, differentiation of hMSCs 
encapsulated in non-laminated OPF hydrogels in response to cyclic tensile loading was 
examined as a proof-of-concept before moving to more sophisticated co-culture 
conditions in future experiments.  In particular, for these experiments, hMSCs were 
encapsulated in a mixture of OPF and PEG-DA with the tethered adhesive peptide 
GRGDS using a radical-induced gelation process
170
 and cultured in a cyclic tensile 
bioreactor for 21 days. Based on previous work with tensile stimulation of MSCs,
11,171,172
 
constructs were cultured under a repeating cyclic strain regimen of 10% strain, 1 Hz, and 
3 hours of strain followed by 3 hours without strain.  After days 1, 7, 14 and 21 of 
culture, cell number, gene expression (particularly collagen I, III, and tenascin-C), and 
protein production was compared between constructs containing encapsulated hMSCs 
exposed to tensile stimulation and MSCs embedded in identical OPF hydrogels without 
mechanical stimulation to investigate the effects of cyclic tension on cellular 
differentiation in this hydrogel environment.  More specifically, the hypothesis of this 
study was that cyclic tensile loading would promote a ligament/tendon fibroblastic 
phenotype in encapsulated hMSCs over 21 days of in vitro culture. 
3.2 Materials and Methods 
3.2.1 Polymer Synthesis 
 OPF with a 3 kDa PEG chain (OPF-3K) or a 10 kDa PEG chain (OPF-10K) was 
synthesized according to previous protocols.
173
  Briefly, calcium hydride (CaH2, Thermo 
Fisher Scientific, Waltham, MA) was mixed with methylene chloride (MeCl, Thermo 
Fisher Scientific) and distilled to produce anhydrous MeCl.  To produce the OPF 
polymer, fumaryl chloride (FuCl, Sigma-Aldrich, St. Louis, MO) and triethylamine 
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(TEA, Sigma-Aldrich)) were slowly added dropwise to PEG (3 kDa; Mn: 3,300 ± 10 Da, 
PI: 1.1 or 10 kDa; Mn: 12,400 ± 20 Da, PI: 1.1, Sigma-Aldrich) that had been 
azeotropically distilled in toluene (Thermo Fisher Scientific) and dissolved in MeCl.  
FuCl and TEA were added at molar ratios of 0.9:1 FuCl:PEG and 1:2 FuCl:TEA under 
nitrogen gas and cooled over ice.  MeCl was removed from the resultant OPF product by 
rotovapping (Buchi, New Castle, DE).  Recrystalization of the OPF was carried out twice 
in ethyl acetate (Thermo Fisher Scientific) to remove salts produced by the conjugation 
reaction.  Ethyl acetate was removed by three consecutive washes in ethyl ether (Thermo 
Fisher Scientific).  Polymers were vacuum dried to remove ethyl ether and stored at -
20°C before use.  The molecular weight of the OPF polymer was determined through gel 
permeation chromatography (GPC, Shimadzu, Columbia, MD).  The resultant OPF-3K 
polymer was found to have a molecular weight (Mn) of 8,900 ± 530 with a polydispersity 
index of 3.1 ± 0.4 and the OPF-10K had an approximate Mn of 18,300 ± 90 with a 
polydispersity index of 4.8 ± 0.2.  NMR spectra of similar OPF macromers and the 
number of double bonds present in the macromer has been reported previously.
108,173
  The 
same batch of OPF-3K and OPF-10K was used for all hydrogels in these experiments.  
Further details regarding this synthesis are found in appendix A.1. 
3.2.2 Peptide Conjugation 
 To allow presentation of arginine-glycine-aspartate (RGD) ligands to 
encapsulated cells, the GRGDS adhesion peptide (PeproTech, Rocky Hill, NJ) was 
conjugated to a 3,400 Da MW acrylated-PEG-succinimidyl valerate spacer (A-PEG-
SVA, Laysan Bio, Arab, AL) according to previous protocols.
108
  Briefly, conjugation 
was achieved by adding the A-PEG-SVA to the GRGDS adhesion peptide dissolved in a 
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sodium bicarbonate (Sigma-Aldrich) buffer solution under gentle stirring over a three 
hour period.  The mixed solution was transferred into 1,000 Da molecular weight cut-off 
dialysis tubing (Spectrum Laboratories, Rancho Dominguez, CA) and dialyzed for two 
days to remove unreacted peptides.  Conjugated peptide was then lyophilized (Labconco, 
Kansas City, MO) and stored at -20°C.  Further details regarding this conjugation are 
found in appendix A.4. 
3.2.3 Tensile Culture Bioreactor 
 The tensile culture device employed in this study is a modification of one 
previously used with fibrin hydrogels.
174
  Major components include a linear motor, 
optical encoder, tension rakes, and stationary culture chambers (Fig. 3.1A and 3.1B).  
Movement of the tensile rake is imparted through the linear motor.  The linear motor is 
computer controlled by a user defined displacement protocol and is monitored through 
readings of the optical encoder.  This system facilitates simultaneous culture of up to 24 
constructs in individualized tensile culture wells (Fig. 3.2B).  In addition, the components 
that interface with the tensile constructs (rakes and culture chambers) can be autoclaved 
for easy sterilization. 
 The tensile constructs are fabricated by injecting polymer solutions into a mold 
between two polyethylene end blocks (75-110 µm pore size, Interstate Specialty, Sutton, 
MA).  The polymer solution invades the porous end blocks and forms an integrated 
tensile construct hydrogel after cross-linking.  The final tensile construct (Fig. 3.2A, 
inset) contains a cell-hydrogel section (12.5 mm x 9.5 mm, 1.6 mm) flanked by the 
porous end blocks.  One end block is placed over a stationary peg in the culture wells and 
the other end block interfaces with the tensile rake of this bioreactor (Fig. 3.2B).  The 
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high stiffness of the end blocks compared to the hydrogel allows a uniform strain field to 
be imparted across the sample during tensile culture.
169,174
 
3.2.4 Hydrogel Degradation Study 
 To examine hydrogel degradation under tensile loading, OPF (3K or 10K) and 
PEG-DA (nominal MW 3400, Laysan Bio) were combined in a 1:1 wt/wt ratio.  





(PBS, Invitrogen, Carlsbad, CA) were injected into a custom fabricated mold and cross-
linked for 10 min at 37°C with 0.018 M of the thermal radical initiators ammonium 
persulfate (APS, Sigma-Aldrich) and N,N,N‟,N‟-tetramethylethylenediamine (TEMED, 
Sigma-Aldrich).  For laminated hydrogels, an OPF-10K solution was injected into one 
half of the mold and cross-linked for 6 min at 37°C.  Subsequently, the OPF-3K solution 
was injected into the other half of the mold and cross-linked for an additional 6 min to 
form the laminated construct (seen in Fig. 3.2B and 3.2C).  After fabrication, constructs 
were loaded under a sinusoidal cyclic strain regimen of 10% strain (5% offset, 5% 
amplitude) at 1 Hz for 12h, followed by 12h at 0% strain.  After 1, 7, 14, and 28 days of 
culture, constructs were removed (n≥3).  Fold swelling was calculated by Ww/Wd where 
Ww is the weight of the hydrogel after culture and before drying, and Wd is the weight of 
the hydrogel after vacuum-drying. 
3.2.5 Cell Culture 
 hMSCs (PT-2501, Lonza) obtained at passage 0 were seeded into tissue culture 
flasks at 3,333 cells/cm
2
 and grown in mesenchymal stem cell growth medium (Lonza, 
Switzerland).  Cells were passaged after reaching approximately 80% confluency using a 
one to three expansion.  At passage 5 (p5), cells were cryopreserved for future use.  
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Culture medium was changed every 2-3 days.  hMSCs from four unique donors were 
pooled in equal numbers at p5 and cultured in Dulbecco‟s modified Eagle‟s medium with 
4.5 g/L glucose and sodium pyruvate (Mediatech, Manassas, VA), 10% fetal bovine 
serum (FBS, Thermo Fisher Scientific), 1% non-essential amino acids (Mediatech), and 
1% antibiotic/antimycotic (Mediatech).  Four different donors were used in order to 
minimize effects that could be due to variation between donors.  Donor information as 
provided by the supplier is listed in Table 3.1.  Medium was changed every 2-3 days 
(Note: FBS was pre-screened for the highest promotion of cell growth and collagen I, 
collagen III, and tenascin-C gene expression, with cell growth being the primary criteria).  
Ascorbic acid (50 µg/ml, Sigma-Aldrich) was added to the medium composition 
described above for the immunohistochemistry studies. 
3.2.6 Cell Encapsulation in Constructs 
 For experiments involving encapsulated hMSCs, constructs were fabricated from 
OPF-3K and PEG-DA hydrogel solutions with acrylated-PEG GRGDS adhesion peptide 
at a concentration of (1 µmol GRGDS)/(g of hydrogel after swelling).  After the solutions 
were filter sterilized using a 0.2 µm filter (Nalgene, Rochester, NY) hMSCs were added 
at 10 x 10
6
 cells/ml and the hydrogel solution was cross-linked as described above.  After 
Table 3.1.  hMSC donor demographics 
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fabrication, the tensile constructs were placed into 6-well plates in culture medium and 
allowed to swell overnight. 
3.2.7 Tensile Culture 
 After swelling overnight, constructs with encapsulated hMSCs were loaded into 
the tensile culture bioreactor (Fig. 3.2A and 3.2B).    A loading regimen for these studies 
was chosen based on parameters commonly used in tendon/ligament tissue engineering 
and parameters previously used with this system to promote collagen expression and 
production.
171,172
  Specifically, constructs were maintained under a sinusoidal cyclic 
strain regimen of 10% strain (5% offset, 5% amplitude) at 1 Hz for 3h, followed by 3 
hours at 0% strain, repeated continuously.  Control hydrogels were loaded into a similar 
culture system, but held at 0% strain.  Culture medium was replaced every 2-3 days.   
3.2.8 Cell Viability 
 After 21 days of culture, constructs were removed from the device and soaked in 
PBS for 1h to remove medium.  After medium was removed, the hydrogels were 
incubated in the LIVE/DEAD fluorescent staining solution (1 nM calcein AM, 1 nM 
ethidium homodimer-1 in PBS; Invitrogen) for 1h.  After staining, hydrogel constructs 
were removed from the LIVE/DEAD solution and washed in PBS for 10 minutes to 
remove excess dye before imaging.  Images from the center of each hydrogel were 
acquired (n=4, Fig. 3.2D) using a confocal microscope (Zeiss Axiovert 100M with LSM 




3.2.9 Cell Number 
 At 1, 7, 14, and 21 days after initiation of mechanical stimulation, constructs were 
removed from the tensile device and washed in PBS.  After washing, the end blocks were 
removed and the wet weight of the hydrogel was recorded.  Hydrogel portions were 
mechanically disrupted using a pellet grinder (VWR International, West Chester, PA) and 
suspended in 750 µl of distilled, deionized water (ddH2O).  To disrupt cells and release 
DNA into solution, samples were subjected to three cycles of freezing at -80°C for 1h, 
thawing at room temperature for 30 min., and sonicating for 30 min.  DNA content, 
which can be correlated to cell number, was determined (n=4, Fig. 3.2D) by assaying the 
resulting supernatant via PicoGreen (Invitrogen) with lambda DNA used for standards 
(included in kit).  The PicoGreen assay uses the Hoescht 33258 fluorophore which binds 
to double stranded DNA.  The fluorescent signal, which is proportional to the amount of 
double stranded DNA, was measured and compared to standards.  The results were 
normalized to the weight of the hydrogel after culture to account for potential differences 
in the mass of individual hydrogels.  Further details regarding the lab protocol used for 
this assay are found in appendix A.7. 
3.2.10 Gene Expression 
 At 1, 7, 14, and 21 days after initiation of tensile stimulation, constructs were 
removed from the tensile device for gene expression analysis.  After washing with PBS, 
the end blocks were removed and the hydrogel portion of the construct was mechanically 
disrupted using a DNase, RNase-free pellet grinder.  RNA was isolated from the 
hydrogels with the QiaShredder column (Qiagen, Valencia, CA).  Purification of RNA 
was achieved using the RNeasy mini kit (Qiagen).  cDNA was synthesized with 
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Superscript III RT (Invitrogen) in the presence of a nucleotide mix (Promega, Madison, 
WI). 
 Amplification of cDNA through real time reverse transcriptase polymerase chain 
reaction (real time RT-PCR) was performed using custom designed primers and SYBR 
Green (Applied Biosystems, Foster City, CA).  To design primers, a search for the gene 
sequence of interest was conducted using the National Center for Biotechnology 
Information (NCBI, http://www.ncbi.nlm.nih.gov/guide/) database.  After the gene 
sequence was obtained, the sequence was input into Primer3 
(http://fordo.wi.mit.edu/primer3/), a primer design tool.  Default values were used to 
create candidate primer sequences.  Candidate sequences were examined using the NCBI 
BLAST nucleotide database (http://blast.ncbi.nlm.nih.gov/) for known homologies with 
other genes.  Pairs of primers were chosen to limit homology with other genes.  Primers 
where both pairs in the set registered homology to the same non-target gene were not 
considered.  After design, candidate primer pairs were obtained (Invitrogen) and used to 
create melt curves from cDNA previously isolated from hMSCs.  Primer pairs that 
produced melt curves with multiple peaks were rejected.  Amplification of cDNA and 
melt curve production was conducted and recorded using the StepOnePlus
TM
 Real-Time 
PCR System (Applied Biosystems).  A cycle time (Ct) value for a given gene was 
determined based on when the amplification curve crossed a threshold value.  The 
threshold was set at the same value for all runs. 
 For statistical analysis, dCt values (cycle time for glyceraldehyde phosphate 
dehydrogenase (GAPDH) subtracted from the cycle time for the given gene) were used 
(n≥6).  For a given gene, if half or more of the samples in a group did not amplify, that 
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group was recorded as not amplifying and excluded from figures.  Genes examined 
included collagen I, collagen III, and tenascin-C as markers for tendon/ligament 
fibroblast gene expression.
11
  To explore the potential for differentiation down alternate 
pathways, genes from other lineages were examined including collagen II (chondrogenic 
differentiation
175
), osteocalcin (osteoblastic differentiation
175
), α-smooth muscle actin (α-
SMA, myofibrogenic differentiation
176
), and peroxisome proliferator-activated receptor-
gamma 2 (PPARγ, adipocytic differentiation
177
). Sequences for the forward and reverse 
primers used are listed in Table 3.2.  Further details regarding the lab protocol used for 
this assay are found in appendix A.10. 
3.2.11 Histology 
 After 21 days, samples cultured in medium with ascorbic acid were collected for 
histological staining.  After washing in PBS, the end blocks were removed and the 
hydrogel portion of the construct was held under a -20 mmHg vacuum in optimal cutting 
Gene Forward Primer Reverse Primer
Collagen I gaaaacatcccagccaagaa gccagtctcctcatccatgt
Collagen III tacggcaatcctgaacttcc gtgtgtttcgtgcaaccatc 
TNC ccacaatggcagatccttct gttaacgccctgactgtggt






Table 3.2.  Primer sequences used for real time RT-PCR analysis. 
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temperature compound (OCT, VWR) for 4 hours to enhance penetration, then frozen over 
dry ice and stored at -80°C until sectioning.  OCT-embedded hydrogels were cut into 30 
µm sections on glass slides.  Sections were fixed using acetone and 
immunohistochemistry was performed for genes that were significantly upregulated in 
real time RT-PCR (n=2, Fig. 3.1D).  Primary antibody binding to proteins of interest was 
accomplished using monoclonal IgG mouse anti-human antibodies (Abcam, Cambridge, 
MA).  Secondary antibody binding to primary antibodies was accomplished using 
polyclonal goat anti-mouse IgG antibodies conjugated to horseradish peroxidase 
(Abcam).  Sections were exposed to diaminobenzidine (DAB) chromogen (Abcam) for 
15 minutes to elicit a color change.  Negative controls included samples immunostained 
with the primary antibody omitted. 
3.2.12 Statistics 
 Results are reported as mean ± standard deviation.  A Box-Cox transformation for 
normality was used on dCt values of gene expression data.  Data were analyzed using a 
two-way ANOVA.  If both factors were significant, but interactions were not significant, 
a Tukey‟s post hoc test with significance set at p ≤ 0.05 was used for pairwise 
comparisons.  If only one factor was significant and interactions were not significant one-
way ANOVAs were run on the significant factor with each level of the non-significant 
factor fixed.  A Tukey‟s post hoc test with significance set at p ≤ 0.05 was used for 
pairwise comparisons.  If interactions were significant, one way ANOVAs were run on 
the first (or second) factor with each level of the second (or first) factor fixed.  A Tukey‟s 
post hoc test with significance set at p ≤ 0.05 was used for pairwise comparisons.  For the 
hydrogel degradation study, the factors were day and hydrogel type.  For the cell number 
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study and gene expression analysis, the factors were day and mechanical condition.  
Statistical analysis was carried out using Systat (Chicago, IL). 
3.3 Results 































Figure 3.2.  OPF-3K, OPF-10K, and laminated hydrogel constructs all 
maintained structural integrity over 28 days of cyclic tensile culture with 
minimal degradation (n≥3 ± std. dev.).  Fold swelling (left) was normalized to day 
1 for each construct type.  Dry weight is shown in the right graph.  
#
Indicates 





























Table 3.3.  Non-normalized fold swelling values for OPF-3K, OPF-10K, and 
laminated hydrogel constructs over 28 days of cyclic tensile culture (n≥3 ± std. 
dev.). 
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 OPF-3K, OPF-10K, and 3K-10K laminated hydrogels remained well integrated 
with their end blocks with no visible breaks through 28 days.  This is particularly 
noteworthy because it has been shown in previous work that OPF-10K hydrogels swell 
significantly more than OPF-3K gels.
170
  The maintenance of hydrogel integrity over 28 
days suggests that the laminated gels were sufficiently bonded to withstand internal 
pressures generated from differential swelling, as well as strains imparted in tensile 
culture.  Fold swelling of laminated constructs was significantly lower on days 14 and 28 
compared to day 1 (Fig. 3.2 and Table 3.3), however, there was no significant change in 
dry weight after 28 days for any construct type (Fig. 3.2 and Table 3.3), indicating no loss 
of material over time. 
3.3.2 Cell Viability and Number 
Figure 3.3.  A majority of live (green cells) was observed, in both cyclically 
(3.4A) and statically (3.4B) cultured OPF hydrogels over 21 days (n=4).  No 
significant difference in cell number was found between static conditions and 




























 Cells in both cyclically (Fig. 3.3A) and statically (Fig. 3.3B) cultured hydrogels 
generally demonstrated green staining, indicating viability.  DNA content/hydrogel wet 
weight (an indicator of cell number per construct) showed no significant differences 
between samples cultured under cyclic tension compared to those cultured statically (Fig. 
3.3C).  Overall, DNA content was relatively constant in both static and cyclic hydrogel 
constructs over 21 days, with only the comparison between day 7 and day 21 cyclic 
constructs showing significance. 
3.3.3 Gene Expression 
 No significant difference was seen in mRNA expression between cyclically and 
statically cultured constructs for the non-tendon/ligament fibroblast genes (collagen II, α-
*Significantly different from static constructs at same time point (p ≤ 0.05). 
#
Significantly different from d1 for the same sample type (p ≤ 0.05). 
Col I, collagen I; col III, collagen III; TNC, tenascin-C; col II, collagen II; α-
SMA, α-smooth muscle actin; OCN, osteocalcin; PPARγ, peroxisome 
proliferator-activated receptor-gamma 2.  Values for day 7, day 14 and day 21 
are not listed for PPARγ as this gene did not amplify at those time points for 
most samples. 
 




SMA, osteocalcin, PPARγ - Table 3.3 and Fig. 3.5) at each time point.  PPARγ was not 
expressed at detectable levels after day 1 as it did not amplify in most samples after that 
time point.  In addition, collagen II demonstrated no significant differences in expression 
across time.  Similarly, α-SMA expression showed no significant change across time in 
cyclic samples, although upregulation was seen in static samples on days 14 and 21 
compared to day 1.  Upregulation was also seen in osteocalcin in both static and cyclic 
samples on days 14 and 21 compared to day 1.   
 In contrast with non-tendon/ligament fibroblast genes, significant differences 
were seen for tendon/ligament fibroblast lineage genes between cyclic and static culture, 
particularly at later time points.  Specifically, collagen I mRNA was significantly 
upregulated in cyclically strained constructs on days 7, 14, and 21 as compared to static 
constructs, although no difference was observed on day 1 (Fig. 3.4A).  Upregulation of 





















































Figure 3.4.  Collagen I (A), collagen III (B), and tenascin-C (C), markers for 
tendon/ligament fibroblastic differentiation, were upregulated in hMSCs 
encapsulated in constructs under cyclic tensile strain compared to static 
constructs by day 21 (n≥6 ± std. dev.).  Expression normalized to GAPDH was 
then normalized to d1 static results for all genes (note: y-axis is different for each 
graph).  *Indicates significance over static constructs at same time point (p ≤ 
0.05).  Significant from d1 (+); d1 and d7 (++); or d1, d7, and d14 (+++); for the 

























































strained samples on day 7 in comparison to day 1.   Collagen III mRNA was significantly 
upregulated in cyclically strained constructs on day 21 as compared to static constructs 
(Fig. 3.4B).  Upregulation of collagen III mRNA was also observed in both strained and 
static samples on days 14 and 21 in comparison to day 1.  Tenascin-C mRNA was 
significantly upregulated in cyclically strained constructs on day 21 as compared to static 
constructs at that time point (Fig. 3.4C).  Upregulation of tenascin-C was also found in 




































































Figure 3.5.  Gene expression levels of hMSCs for collagen II (A), α-SMA (B), 
osteocalcin (C), and PPARγ (D) in constructs under cyclic tensile strain 
compared to static constructs over 21 days (n≥6 ± std. dev.).  Expression 
normalized to GAPDH was then normalized to d1 static results for all genes 
(note: y-axis is different for each graph).  Significant from d1 (+); d1 and d7 












































































 Immunohistochemistry revealed the presence of collagen I and tenascin-C after 21 
days of culture in both static and cyclic constructs (Fig. 3.6), indicating that gene 
expression of these tendon/ligament fibroblast markers was translated into protein 
production in the hydrogel constructs.  Minimal staining for collagen III (Fig. 3.6C and 
3.6F) was also detected.  As seen in Fig. 3.6, staining generally appeared to be 
concentrated pericellularly and tenascin-C seemed to be more prevalent in cyclic 
constructs.  No staining was evident in control sections with the primary antibody omitted 
(Fig. 3.6 inset) suggesting that there was no significant non-specific binding of the 
secondary antibody or endogenous staining from the contrast agent.  However it should 
be noted that no isotype control was used so the possibility of non-specific binding of the 
primary antibody can not be eliminated. 
Figure 3.6.  Immunohistochemistry (n=2) for collagen I (A and D), tenascin-C (B 
and E), and collagen III (C and F) after 21 days of culture in both static and 
cyclic constructs.  Collagen I and tenascin-C were detected mainly pericellularly 
(arrows).  No staining was evident for collagen III or in control sections with the 




  Our three dimensional OPF hydrogels and novel tensile culture system provide a 
versatile scaffold-bioreactor system for the study of biological and mechanical influences 
on cells.  The ability to incorporate ECM moieties and create hydrogel laminates that are 
stable through at least 28 days of cyclic tensile culture (Fig. 3.2) provides a versatile 
system  for studying the formation of tendons/ligaments as well as their interfaces with 
muscle/bone.  While culture periods longer than 3-4 weeks can lead to hydrolytic 
degradation of OPF-based hydrogels, minimal degradation was seen in this system after 4 
weeks, in agreement with prior reports.
178
  As a result the mechanical properties (i.e. 
elastic modulus) of the hydrogel constructs and presentation of adhesive motifs would not 
be expected to change due to degradation of the polymers.  This stability provides an 
advantage in these studies as no change in loading of the embedded cells would be 
expected due to polymer degradation, although other changes in the cell-biomaterial 
environment, such as ECM production, could change the loading transferred to individual 
cells.  In addition, these OPF-based hydrogels provided a biomaterial environment where 
no alteration in construct geometry (shrinkage) was observed up to 21 days in the 
presence of cells, as has been reported previously with naturally-based polymers.
179,180
 
 For these experiments, our custom bioreactor system was used to examine the 
differentiation of hMSCs in OPF hydrogels modified with RGD adhesion peptides over 
21 days of culture.  OPF-3K based hydrogels were specifically chosen due to their greater 
ability to facilitate cell adhesion in 2D culture compared to OPF-10K hydrogels 
(Supplementary Fig. B.1).  These data were in agreement with previous work which 
showed that cells can detect and adhere to RGD in OPF hydrogels.
108
  This peptide was 
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employed in these studies to avoid the lowered viability seen with hMSCs in hydrogels 
without RGD.
181
  This provided the foundation for a scaffold that would permit cell 
survival so this study could focus on the effect of cyclic strain on encapsulated cells.  As 
expected, the system demonstrated high cell viability (Fig. 3.3A and 3.3B), with no 
significant change in cell number between day 1 and day 21 constructs in either static or 
strained conditions (Fig. 3.3C).  It should be noted that, neither samples without RGD 
peptides, nor samples containing a scrambled peptide (such as RDG), were used in these 
studies so the specific contribution of the RGD adhesion peptides to the cell viability or 
to other cell responses can not be specified for this system. 
 While this study showed no change in cell number due to strain, other groups 




 cell numbers over time.  
Cell proliferation in this study may have been prevented by the small mesh size of these 
hydrogels.  Mesh sizes of between 76 and 160 Å have previously been reported for 
similar OPF hydrogels
186
 and sizes ranging from 20-60 Å were calculated for PEG-DA 
hydrogels.
187,188
  While OPF hydrogel mesh size increases with the molecular weight of 
the PEG chain, the mesh size of an OPF-10K hydrogel is still orders of magnitude 
smaller than a cell,
186
  allowing only limited space for cellular division in the dense 
polymer matrix.  Modifications of the hydrogel environment to facilitate local cell-
mediated degradation may be a target for further studies in an effort to provide the void 
space needed for proliferation inside the gel. 
 Upregulation of collagen I, collagen III, and tenascin-C gene expression was 
observed in the constructs, particularly under cyclic loading (Fig. 3.4).  This upregulation 




  The upregulation of collagen I, collagen III, and/or tenascin-C mRNA 
is often used as a marker for a tendon/ligament fibroblast phenotype due to the 
prevalence of these proteins in tendon/ligament tissue.
4,10,190
  Collagens make up the 
majority of tendon/ligament and give the tissue its high tensile strength.
12
  Tenascin-C is 
an antiadhesive protein and may increase tissue elasticity in response to heavy loading.
191
  
Other work using collagen I gels to encapsulate hMSCs has shown an upregulation of 
collagen III, but not collagen I, in response cyclic strain.
179
  The differences in the 
response of collagen I may be due in part to variations in the cyclic strain regimen, since 
the studies that reported upregulation of collagen I in response to cyclic strain employed 
higher amplitudes and durations of strain.
11,100,189
  Overall, the upregulation of collagen I, 
collagen III, and tenascin-C in cyclic constructs compared to static samples by day 21 
suggests that, under the loading conditions chosen for this study, cyclic strain promoted a 
ligament/tendon fibroblastic phenotype in hMSCs by 21 days.  While some upregulation 
was seen over time in certain non-tendon/ligament fibroblast genes (Table 3.3), the lack 
of upregulation of any of these genes under cyclic conditions suggest that cyclic strain 
did not promote differentiation down alternative pathways. 
 Collagen I gene expression in this study correlated with pericellular matrix 
deposition (Fig. 3.4A, 3.6A and 3.6D), although differences in staining were not apparent 
between cyclically- and statically-cultured hydrogels, in contrast with previous results.
100
   
In addition, in our experiments, little collagen III staining was observed at day 21, despite 
upregulation of collagen III expression levels at this time point.  Previous reports have 
demonstrated collagen III production in response to cyclic strains when marrow stromal 
cells were cultured in collagen I gels.
11,100
  However, in these prior studies, the presence 
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of the collagen-based scaffold, as well as differences in the exact loading parameters 
used, which in some cases applied a combination of translation and rotational forces,
11
 
could have affected the level of deposition of both collagen I and III around the cells.  
One possible explanation for the minimal collagen III staining in our system is that a 
large fold change in gene expression was not observed until day 21, and therefore there 
may not have been enough time to observe increased production of this molecule in this 
study.  While the collagen production seen may indicate that the cells are not following a 
normal healing response, where collagen III is deposited initially and later replaced by 
collagen I,
33
 the results are encouraging since collagen I is more prevalent than collagen 
III in mature tissue.
140
  Further work, including studies to examine the time course of 
collagen production in this system, will be required to better understand and optimize 
culture conditions to promote optimal ratios of collagen I and collagen III. 
 Tenascin-C was also observable by immunostaining at day 21, especially in 
cyclically cultured constructs (Fig. 3.6B and 3.6E).  During development, tenascin-C is 
expressed highly at insertion sites of ligaments and tendons to bone
192
 and is localized 
immediately surrounding cells,
192
 similar to the pericellular staining that was observed.  
Culture methods that encourage production of both collagen I and tenascin-C, similar to 
our system, may be promising avenues for pursuit of tissue engineering of insertion sites 
of ligament and tendon to bone. 
 One factor that may have played an important role in the distribution and ratios of 
the proteins produced is the physical constraints imposed by the biomaterial environment.  
Hydrogels with small mesh sizes and limited degradability, similar to the OPF hydrogels 
used in this study, have produced a pericellular matrix deposition
101
 like that observed in 
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this system.  In those experiments, degradation of the scaffold led to larger mesh sizes 
that facilitated a change in the ratio and distribution of matrix proteins, most likely by 
allowing greater diffusion of the proteins that make up the ECM.  Investigation of the 
effect of PEG-based hydrogels with larger mesh sizes or degradation of the OPF hydrogel 
matrix may be necessary to facilitate a distribution of matrix proteins throughout the 




 In addition to confirming the responsiveness of hMSCs to tensile loading, the 
studies described here demonstrate the feasibility of this novel system in examining 
cellular differentiation under tensile loading in response to controlled physicochemical 
changes in the extracellular environment, including the possibility of co-culture using the 
laminated structures tested in these experiments.  Significant additional work is required 
to find the correct combination of cell types, bioactive factors, and loading parameters to 
regenerate both fibrous tissue and its interfaces.  However, such a model system may 
prove valuable in identifying key parameters for next-generation tissue engineering 
approaches to recreating these complex structures. 
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CHAPTER 4 
HUMAN MARROW STROMAL CELLS PRODUCE 
COLLAGENOUS EXTRACELLULAR MATRIX IN 
ENZYMATICALLY-DEGRADABLE HYDROGELS 
4.1 Introduction 
 A variety of synthetic biomaterial scaffolds using MSCs have been employed for 
ligament/tendon tissue engineering.
193,194
  These systems often seek to promote a 
phenotype in MSCs that is similar to that of ligament/tendon fibroblasts which are the 
most prevalent cell type in ligament/tendon tissues.
4
  Collagen I, collagen III, and 
tenascin-C are major ligament/tendon ECM components that are often examined as signs 
of this differentiation.
11,193,195
  Unfortunately, the elaboration of such ECM components 
by encapsulated cells may be hindered if the scaffold does not undergo sufficient 
degradation as matrix proteins are produced.
56,101
  While a low rate of degradation can 
hinder ECM production, degradation that occurs too quickly could result in a loss of 
scaffold integrity before sufficient replacement tissue is produced.
66
  Normal maturation 
of the ligament/tendon ECM takes advantage of cell-mediated enzymatic 
degradation.
4,51,140
  A biomaterial carrier that is susceptible to biological enzymatic 
cleavage may provide a natural balance of degradation and ECM production since the 
encapsulated cells would control the degradation rate.  While there has been some study 
on the effect of hydrolytic degradation on ECM production,
101
 there has not been much 
study on the effect of the susceptibility of the biomaterial carrier to cell-mediated 
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enzymatic degradation on the deposition of matrix proteins, which is the main objective 
of this study.   
 Before investigating the effects on encapsulated cells of a biomaterial carrier 
susceptible to enzymatic degradation, hydrogels were created with increasing proportions 
of covalently incorporated, enzymatically-cleavable GGGLGPAGGK peptides (see 
section 2.2.4).  In particular, in these studies, hydrogels were created without any 
GGGLGPAGGK sequences (0%), or with 25%, 75%, or 100% of the hydrogel composed 
of polymers containing these enzymatically-cleavable peptides by weight.  To determine 
whether increasing the portion of the GGGLGPAGGK sequences used to create 
hydrogels would raise the total susceptibility of the construct to enzymatic degradation, 
the hydrogels were cultured in bacterial collagenase or in saline.  Results from these 
preliminary experiments suggested that the various ratios of enzymatically-degradable 
peptides provided hydrogels with different total amounts of degradation when exposed to 
exogenous bacterial collagenase. 
After variations in total susceptibility that resulted from the hydrogel formulations 
were elucidated, hMSCs were encapsulated in each of these formulations.  After days 1, 
7, 14, and 21 of culture, cell number and viability, cell morphology, MMP production 
(specifically MMP-1 and MMP-13), gene expression (particularly collagen I, collagen 
III, and tenascin-C), and protein production were examined.  The behavior of the hMSCs 
was compared across hydrogel types and to hACL fibroblasts encapsulated in similar 
environments.  The particular hypothesis of this study was that culture in an 
enzymatically-degradable biomaterial environment would promote increased ECM 
production in encapsulated hMSCs over 21 days of culture, with the most ECM 
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production expected in the most degradable hydrogel, and decreaseing ECM amounts 
expected as the total degradability of the hydrogel decreased. 
4.2 Materials and Methods 
4.2.1 Polymer Synthesis 
OPF-3K was synthesized according to previous protocols.
173
  Briefly, CaH2 was 
mixed with MeCl and distilled to produce anhydrous MeCl.  To produce the OPF 
polymer, FuCl and TEA were slowly added dropwise to PEG (3 kDa; Mn: 3,300 ± 10 Da, 
PI: 1.1) that had been azeotropically distilled in toluene and dissolved in MeCl.  FuCl and 
TEA were added at molar ratios of 0.9:1 FuCl:PEG and 1:2 FuCl:TEA under nitrogen gas 
and cooled over ice.  MeCl was removed from the resultant OPF product by rotovapping.  
Recrystalization of the OPF was carried out twice in ethyl acetate to remove salts 
produced by the conjugation reaction.  Ethyl acetate was removed by three consecutive 
washes in ethyl ether.  Polymers were vacuum dried to remove ethyl ether and stored at -
20°C before use.  The molecular weight of the OPF polymer was determined through 
GPC.  The resultant OPF-3K polymer was found to have a molecular weight (Mn) of 
8,900 ± 530 with a polydispersity index of 3.1 ± 0.4.  NMR spectra of similar OPF 
macromers and the number of double bonds present in the macromer has been reported 
previously.
108,173
  The same batch of OPF-3K that was synthesized and used in the 
previous study (Chapter 3) was also used in this study.  Further details regarding this 
synthesis are found in appendix A.1. 
To synthesize PEG-DA, CaH2 was mixed with MeCl and distilled to produce 
anhydrous MeCl.   Under nitrogen gas, TEA was added to PEG(3 kDa; Mn: 3,300 ± 10 
Da, PI: 1.1) that had been dissolved in MeCl at a molar ratio of 2:1 TEA:PEG.  Acryloyl 
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chloride (AcCl) dissolved in MeCl was slowly added dropwise at a molar ratio of 2:1 
AcCl:PEG under nitrogen gas in order to acrylate the PEG.  After allowing the reaction to 
proceed overnight, 2M K2CO3 was added to remove TEA-Cl by forming KCl and 
allowing it to separate out in the aqueous phase overnight.  The solution of PEG-DA was 
separated from the aqueous phase of KCl and MgSO4 was added to remove any 
additional aqueous solution.  PEG-DA was then precipitated in ethyl ether and stored at -
20°C before use.  The resultant PEG-DA has a typical molecular weight of 3,759±18 with 
a polydispersity index of 1.071 ± 0.001.  Further details regarding this synthesis are 
found in appendix A.2. 
4.2.2 Peptide Conjugation 
To allow presentation of arginine-glycine-aspartate (RGD) ligands to 
encapsulated cells, the GRGDS adhesion peptide was conjugated to a 3,400 Da MW 
acrylated-PEG-succinimidyl valerate spacer (A-PEG-SVA, Laysan Bio, Arab, AL) 
according to previous protocols.
108
  Briefly, conjugation was achieved by adding the A-
PEG-SVA to the GRGDS adhesion peptide dissolved in a sodium bicarbonate buffer 
solution under gentle stirring over a three hour period.  The mixed solution was 
transferred into 1,000 Da molecular weight cut-off dialysis tubing and dialyzed for two 
days to remove unreacted peptides.  Conjugated peptide was then lyophilized and stored 
at -20°C.  The same batch of acrylated GRGDS peptide was used in all of these studies. 
Further details regarding this conjugation are found in appendix A.4. 
To enable cell-mediated degradation of the biomaterial environment the 
enzymatically-degradable peptide, glycine-glycine-glycine-leucine-glycine-proline-
alanine-glycine-glycine-lysine (GGGL↓GPAGGK) was conjugated on both ends to 3,400 
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Da MW A-PEG-SVA (Fig. 2.3) using the peptide conjugation protocol mention above.  
Briefly, conjugation was achieved by adding A-PEG-SVA to the GGGL↓GPAGGK 
peptide dissolved in a sodium bicarbonate buffer solution under gentle stirring over a 
three hour period.  The mixed solution was transferred into 3,500-5,000 Da molecular 
weight cut-off dialysis tubing (Spectrum Laboratories, Rancho Dominguez, CA) and 
dialyzed for two days to remove unreacted peptides.  Conjugated GGGL↓GPAGGK 
peptide (LGPA) was then lyophilized and stored at -20°C.  All batches of LGPA were 
subjected to fold swelling measurements to screen out poorly conjugated batches.  The 
exact same set of LGPA batches were used when possible and at least 4 batches of LGPA 
were used in each group of hydrogels in order to minimize the effects of batch to batch 
variability.  Further details regarding this conjugation are found in appendix A.3.  
4.2.3 Hydrogel Degradation Study 
 To confirm the availability of the enzymatically-degradable GGGL↓GPAGGK 
sequences for enzyme mediated degradation, hydrogel formulations were chosen that 
were expected to provide a wide range of susceptibility to enzymatic-degradation.  OPF-
3K:PEG-DA in a 1:1 ratio and LGPA were combined to create polymer mixtures 
containing 0%, 25%, 75%, or 100% LGPA by weight (Fig. 4.1 and Table 4.1).  Polymers 
suspended at high or low saline content (75wt% PBS or 90wt% PBS) were injected into a 
custom fabricated mold and cross-linked in the shape of a thin disc (30 µl, 6 mm dia) for 
10 min at 37°C with 0.018 M of the thermal radical initiators APS and TEMED.  After 
cross-linking the hydrogels were placed into wells of a 12-well plate containing 2 ml of a 
collagenase II solution consisting of PBS with collagenase II (1 mg/ml, Invitrogen), 
CaCl2 (3 mM, Thermo Fisher Scientific), and 1% antibiotic/antimycotic and placed on an 
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orbital shaker plate (VWR) in an incubator (Heracell® 150, Thermo Fisher Scientific).  
Hydrogels cultured in PBS alone were used as a control.  Solutions were changed every 
day.  
After 7 days of culture, constructs were removed (n=5).  Fold swelling was 
calculated by Ww/Wd where Ww is the weight of the hydrogel after culture and before 
drying, and Wd is the weight of the hydrogel after vacuum-drying.  The mesh size of the 
hydrogels, which is an indicator of the distance between crosslinks, or how tightly the 
polymer network was formed, was calculated using polymer theory according to 
previously reported methods.
186,196
  Briefly, a hanging pan balance was used to measure 
Table 4.1.  Hydrogel Formulations. 
% LGPA Saline Content LGPA:OPF:PEG-DA(wt%) PBS:Total Polymer (wt%)
0% Low (75 wt%) 0:50:50 75:25
25% Low (75 wt%) 25:37.5:37.5 75:25
75% Low (75 wt%) 75:12.5:12.5 75:25
100% Low (75 wt%) 100:0:0 75:25
0% High (90 wt%) 0:50:50 90:10
25% High (90 wt%) 25:37.5:37.5 90:10
75% Hight (90 wt%) 75:12.5:12.5 90:10
100% High (90 wt%) 100:0:0 90:10
PBS 
High or low saline content 
% of sequences with LGPA 
0% 25% 100% 75% 
Sample Analysis (d7) 
Fold Swelling = Wet Weight/Dry Weight (n=5) 
Mesh size (n=5) Collagenase 
Figure 4.1.  Research design for hydrogel degradation study. 
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hydrogel weight in air after cross-linking (Wa,r), weight in non-solvent hexane after cross-
linking (Wn,r), weight in air after swelling in PBS overnight (Wa,s), weight in hexane after 
swelling in PBS (Wn,s), weight in air swelling then vacuum drying (Wa,d), and weight in 
hexane after vacuum drying (Wn,r).  Mesh size (ξ) was calculated according to (1). 







To calculate ξ (2) and (3) are required. 





To calculate v2,s (4) and (5) are required. 
(4) Vp=(Wa,d-Wn,d)/ρn 
(5) Vg,s=(Wa,s-Wn,s)/ρn 
ρn is the density of hexane (0.66 g/cm
3
).  To calculate r
2
0 (6) is required.  Cn is the 
characteristic ratio (4.1 in this case) and L is the weighted bond length of the polymer 
(1.47 Å). 
(6) N = #Mc/Mr 
To calculate N (7) is required.  # is the number of bonds in the repeat unit of the polymer 






To calculate Mc (8) and (9) are required.  vbar is the specific volume of the polymer 
(0.871 ml/g).  V1 is the molar volume of the swelling agent (18.1 ml/mol).  X is the Flory 
OPF-water interaction parameter (0.426). 
(8)  v2,s=Vp/Vg,s 
(9) v2,r=Vp/Vg,r 
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Equations (4) and (5) can be used to calculate Vp and Vg,s and are listed above.  To 
calculate Vg,r (10) is required. 
(10) Vg,r = (Wa,r-Wn,r)/ρn 
4.2.4 Cell Culture 
hMSCs obtained at passage 0 were seeded into tissue culture flasks at 3,333 
cells/cm
2
 and grown in mesenchymal stem cell growth medium.  Cells were passaged 
after reaching approximately 80% confluency using a one to three expansion.  At passage 
5 (p5), cells were cryopreserved for future use.  Culture medium was changed every 2-3 
days.  hMSCs from four unique donors were pooled in equal numbers at p5 and cultured 
in Dulbecco‟s modified Eagle‟s medium with 4.5 g/L glucose and sodium pyruvate, 10% 
fetal bovine serum, 1% non-essential amino acids, 1% HEPES buffer (VWR), 1% 
antibiotic/antimycotic, and ascorbic acid (50 µg/ml).  Four different donors (Table 3.1) 
were used in order to minimize effects that could be due to variation between donors.  
Medium was changed every 2-3 days (Note: FBS was pre-screened for the highest 
promotion of cell growth and collagen I, collagen III, and tenascin-C gene expression, 
with cell growth being the primary criteria). 
Human anterior cruciate ligament (hACL) fibroblasts were isolated from the ACL 
of a human donor undergoing knee surgery.  The ACL tissue was cut into approximately 
1-3 mm
3
 pieces and distributed into T-75 flasks (Thermo Fisher Scientific) with a 
collagenase solution.  The collagenase solution consisted of Dulbecco‟s modified Eagle‟s 
medium with 4.5 g/L glucose and sodium pyruvate, 10 ml/L of penicillin/streptomycin 
(EMD biosciences, Darmstadt Germany), 10 ml/L kanamycin sulfate (EMD biosciences), 
1 ml/L gentamicin sulfate (VWR), 1 ml/L fungizone antimycotic (Invitrogen), and 40 
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mg/L collagenase type II (Invitrogen).  After 1-2 days of gentle agitation, when the tissue 
was fully degraded, the solution was removed and filtered through a syringe filter holder 
(Pall Corporation) with a 74 µm nylon mesh (Small Parts).  Cells in the resultant solution 
were pelleted and frozen down for future use.  For experiments involving encapsulation 
of hACL fibroblasts, these cells were thawed and cultured in cultured in Dulbecco‟s 
modified Eagle‟s medium with 4.5 g/L glucose and sodium pyruvate, 10% fetal bovine 
serum, 1% non-essential amino acids, 1% HEPES buffer, 1% antibiotic/antimycotic, and 
ascorbic acid (50 µg/ml).  Medium was changed every 2-3 days (Note: FBS was pre-
screened for the highest promotion of cell growth and collagen I, collagen III, and 
tenascin-C gene expression, with cell growth being the primary criteria). 
4.2.5 Cell Encapsulation 
For experiments involving encapsulated cells, polymers were prepared with the 
same compositions used for low saline content hydrogels in the degradation study 
(above) with the addition of acrylated-PEG GRGDS adhesion peptides at a concentration 
of (1 µmol GRGDS)/(g of hydrogel after swelling).  After the solutions were filter 
sterilized using a 0.2 µm filter (Nalgene, Rochester, NY) cells were added at 10 x 10
6
 
cells/ml and the hydrogel solution was cross-linked into 30 µl samples in the shape of a 
thin disc (30 µl, 6 mm dia) as described above.  Experiments involving hMSCs used 
polymer mixtures containing 0%, 25%, 75%, or 100% LGPA by weight (Fig. 4.2).  
Experiments involving human ACL fibroblasts used polymer mixtures containing 0% or 
100% LGPA by weight.  After fabrication, the hydrogels were placed into 24-well plates 
in culture medium.  Cell culture medium was change every 2-3 days. 
4.2.6 Cell Viability and Morphology 
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After 1, 7, 14, 21 days of culture, the hydrogels were removed from their wells 
and soaked in PBS for 1h to remove medium.  After medium was removed, the samples 
were incubated in the LIVE/DEAD fluorescent staining solution (1 nM calcein AM, 1 
nM ethidium homodimer-1 in PBS; Invitrogen) for 1h.  After staining, hydrogels were 
removed from the LIVE/DEAD solution and washed in PBS for 10 minutes to remove 
excess dye before imaging.  An image stack through the entire thickness at the center of 
each hydrogel were acquired (n≥3, Fig. 4.2) using a confocal microscope with a vertical 
distance between sequential images of 10 µm. 
To analyze the cellular morphology for evidence of localized degradation, cellular 
perimeter and area of image stacks (5 images/stack) was analyzed.  Cell perimeter and 
area was calculated for the region 200-400 µm from the surface of the sample (subsurface 
region) or for a deeper 200 µm region in the middle of the sample (core region; usually 
~400 µm from both surfaces).  Image stacks were imported into ImageJ (NIH, Bethesda, 
MD) for morphological analysis.  Five equally spaced slices (50 µm apart) were 
analyzed.  Slices 50 µm apart were used instead of sequential slices in order to minimize 
the possibility of counting a single cell more than once.  Data values for all cells in slices 
of a given sample were averaged.  To calculate spreading, a circularity analysis was done 
Fibroblasts
s 
% of sequences with LGPA 
0% 25% 100% 
hMSCs 
Figure 4.2.  Research design for studies involving encapsulated cells in low 
saline content hydrogels. 
75% 
Sample Analysis (d1, d7, d14, d21) 
Morphology: Live/Dead (n≥3) 
Cell Number: PicoGreen (n=4) 
MMP-1 and MMP-13 production (n=3) 
Gene Expression: Real time RT-PCR (n≥7) 
Protein Production (d1 & d21) : IHC (n=2) 
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with circularity = 4*π*area/(perimeter)
2
, where a circularity value of 1 correlates to a 
perfect circle and values approaching zero indicate increasing spreading. 
4.2.7 Cell Number 
After 1, 7, 14, and 21 days of culture, hydrogels were removed from their wells 
and washed in PBS.  After washing, the wet weight of the hydrogel was recorded.  
Hydrogels were mechanically disrupted using a pellet grinder and suspended in 750 µl of 
ddH2O.  To disrupt cells and release DNA into solution, samples were subjected to three 
cycles of freezing at -80°C for 1h, thawing at room temperature for 30 min., and 
sonicating for 30 min.  DNA content, which can be correlated to cell number, was 
determined (n=4, Fig. 4.2) by assaying the resulting supernatant via PicoGreen with 
lambda DNA used for standards (included in kit).  The PicoGreen assay uses the Hoescht 
33258 fluorophore which binds to double stranded DNA.  The fluorescent signal, which 
is proportional to the amount of double stranded DNA, was measured and compared to 
standards.  Further details regarding the lab protocol used for this assay are found in 
appendix A.7. 
4.2.8 Matrix Metalloproteinase Production 
 The production of MMP-1 and MMP-13, along with their active forms, was 
examined.  MMP-1 and MMP-13 are collagenases that are known to target collagen I and 
collagen III,
147
 the most prevalent components of ligament/tendon tissue
154
 and were 
examined as potential mediators of enzymatic degradation in this system (see section 
2.2.6 for more information on MMPs).  Six hydrogels per sample type were used in these 
assays.  Medium from the wells of 24 well plates containing hydrogel samples was 
collected on days 1, 3, 5, 7, 9, 11, 14, 16, 18, and 21 of culture for MMP analysis (Fig. 
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4.2).  Cumulative production of total and active amounts of MMP-1 and MMP-13 
proteins was assessed at 1, 7, 14, and 21 days of culture (n=3) using fluorokine kits 
(R&D Systems, Minneapolis, MN).  As appropriate, medium on different days of culture 
was pooled to assess the production of MMPs during a given range of time.  More 
specifically, to measure MMP production after 1 day of culture, medium from only day 1 
was used.  For MMP production from day 2 to day 7 of culture, medium collected on day 
3, day 5, and day 7 was pooled.  For MMP production from day 8 to day 14 of culture, 
medium collected on day 9, day 11, and day 14 was pooled.  For MMP production from 
day 15 to day 21 of culture, medium collected on day 16, day 18, and day 21 was pooled. 
 Details regarding the protocol used to assay active and total amounts of MMP-1 
and MMP-13 using the fluorokine kits are found in appendix A.9.  Briefly, medium from 
samples was added to 96 well plates.  The MMP of interest (MMP-1 or MMP-13 as 
needed) is specifically bound by monoclonal antibodies immobilized on the surface of the 
wells.  The wells are washed repeatedly in a buffer solution to remove any unbound 
substances.  After washing is complete, p-aminophenylmercuric acetate (APMA), an 
activator of MMPs is added to sample wells that will be used to measure total levels of 
the MMP.  APMA is not added to wells used to measure active MMP.  After incubation 
with APMA, sample wells were washed repeatedly to remove APMA.  After washing a 
fluorogenic substrate is added to sample wells.  The substrate contains a fluorophore and 
a quencher that are connected by a peptide sequence.  When the fluorophore and 
quencher are held in close proximity by the peptide linker a resonance energy transfer 
occurs between the two molecules and prevents fluorescence.  Active MMP present in 
sample wells will cleave the peptide sequence and separate the fluorophore and the 
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quencher, thus creating a fluorescent signal. This signal is read in a plate reader and 
compared to standards of the MMP being examined to determine MMP levels.  For 
statistical analysis the cumulative amount of MMP produced by a given day was used.  
4.2.9 Gene Expression 
 After 1, 7, 14, and 21 days of culture, samples were removed from their wells for 
gene expression analysis (Fig. 4.2).  After washing with PBS, the hydrogels were 
mechanically disrupted using a DNase, RNase-free pellet grinder.  RNA was isolated 
from the hydrogels with the QiaShredder column.  Purification of RNA was achieved 
using the RNeasy mini kit.  cDNA was synthesized with Superscript III RT in the 
presence of a nucleotide mix. 
 Amplification of cDNA through real time RT-PCR was performed using custom 
designed primers and SYBR Green.  To design primers, a search for the gene sequence of 
interest was conducted using the National Center for Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov/guide/) database.  After the gene sequence was obtained, 
the sequence was input into Primer3 (http://fordo.wi.mit.edu/primer3/), a primer design 
tool.  Default values were used to create candidate primer sequences.  Candidate 
sequences were examined using the NCBI BLAST nucleotide database 
(http://blast.ncbi.nlm.nih.gov/) for known homologies with other genes.  Pairs of primers 
were chosen to limit homology with other genes.  Primers where both pairs in the set 
registered homology to the same non-target gene were not considered.  After design, 
candidate primer pairs were obtained (Invitrogen) and used to create melt curves from 
cDNA previously isolated from hMSCs.  Primer pairs that produced melt curves with 
multiple peaks were rejected.  Amplification of cDNA and melt curve production was 
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conducted and recorded using the StepOnePlus
TM
 Real-Time PCR System.  A cycle time 
(Ct) value for a given gene was determined based on when the amplification curve 
crossed a threshold value.  The threshold was set at the same value for all runs (n≥7).  For 
a given gene, if half or more of the samples in a group did not amplify, that group was 
recorded as not amplifying and excluded from figures.  Genes examined included 
collagen I, collagen III, and tenascin-C as markers for ligament/tendon fibroblast gene 
expression.
11
   To explore the potential for differentiation down alternate pathways, genes 
from other lineages were examined including collagen II (chondrogenic 
differentiation
175
), osteocalcin (osteoblastic differentiation
175
), myogenic differentiation 
(myoD, myogenic differentiation
176
), and PPARγ (adipocytic differentiation
177
).  
Sequences for the forward and reverse primers used are listed in Table 3.2.  Further 
details regarding the lab protocol used for this assay are found in appendix A.10. 
4.2.10 Histology 
 After 1 and 21 days of culture, samples with hMSCs were collected for 
histological staining (Fig. 4.2).  IHC was not conducted on hACL fibroblast samples.  
After washing in PBS for 1h to remove excess media, the hydrogels were fixed in 
formalin (Thermo Fisher Scientific) overnight.  Samples were put into PBS for 20 
minutes to wash out the formalin, then manually dehydrated using the following 
schedule: 70% dehydration alcohol (VWR) overnight, 80% dehydration alcohol 
overnight, 90% dehydration alcohol overnight, 95% dehydration alcohol overnight, 100% 
dehydration alcohol overnight.  After dehydration samples were held under a -20 mmHg 
vacuum in paraffin (Thermo Fisher Scientific) for 4 hours to enhance penetration, then 
embedded.  Paraffin-embedded hydrogels were cut into 10 µm sections and placed on 
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glass slides.  Immunohistochemistry was performed (see appendix A.11 for further 
details) on these sections for genes that were significantly upregulated in real time RT-
PCR (n=2).  Primary antibody binding to proteins of interest was accomplished using 
monoclonal IgG mouse anti-human antibodies.  Secondary antibody binding to primary 
antibodies was accomplished using polyclonal goat anti-mouse IgG antibodies 
conjugated to biotin (Abcam).  Further amplification of signal was achieved using the 
Vectastain elite ABC peroxidase kit (Thermo Fisher Scientific).  This amplification is 
achieved through an avidin conjugated horseradish peroxidase which binds to the 
biotinylated secondary antibody.  Sections were exposed to diaminobenzidine (DAB) 
chromogen (Abcam) for 5 minutes to elicit a color change.  Negative controls included 
samples immunostained with the primary antibody omitted. 
4.2.11 Statistics 
 Results are reported as mean ± standard deviation.  A Box-Cox transformation for 
normality was used on dCt values of gene expression data.  Data were analyzed using a 
two-way ANOVA or three-way ANOVA as appropriate.  If both factors were significant, 
but interactions were not significant, a Tukey‟s post hoc test with significance set at p ≤ 
0.05 was used for pairwise comparisons.  If only one factor was significant and 
interactions were not significant one-way ANOVAs were run on the significant factor 
with each level of the non-significant factor fixed.  A Tukey‟s post hoc test with 
significance set at p ≤ 0.05 was used for pairwise comparisons.  If interactions were 
significant, one way ANOVAs were run on the first (and then second) factor with each 
level of the second (and then first) factor fixed.  A Tukey‟s post hoc test with significance 
set at p ≤ 0.05 was used for pairwise comparisons.  
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 For morphological analyses, the factors were day, hydrogel type, and region of 
the hydrogel when comparisons were made across hydrogel type, day, or between 
morphologies in the subsurface or middle regions.  The factors were hydrogel type, day, 
and cell type when comparisons were made between cell types.  For the hydrogel 
degradation study, cell number study, and gene expression analysis, the factors were day 
and hydrogel type.  For the MMP production study the factors were day, hydrogel type, 
and MMP-activity when comparisons were made within a given cell type while the 
factors were day, hydrogel type, and cell type when comparisons were made between cell 
types.  For gene expression analysis the factors were day and hydrogel type.  Statistical 
analysis was carried out using Systat. 
4.3 Results 
4.3.1 Hydrogel Degradation Study 
          All hydrogel formulations cultured in PBS remained intact during the entire culture 
period.  Both high and low saline content hydrogels consisting entirely of enzymatically-
cleavable sequence (100%) degraded in collagenase within 2 days (Fig. 4.3).   
Interestingly, 75% enzymatically-cleavable hydrogels in collagenase degraded within 7 
days when they were fabricated with a high saline content, but not at a low saline content.  
Hydrogels without any enzymatically-cleavable sequences (0%) or with only 25% of the 
polymers consisting of enzymatically-cleavable sequences remained intact in collagenase 
during the entire length of the 7 day culture.  Fold swelling was significantly higher in 
high saline content hydrogels compared to low saline content hydrogels for all groups 
except 100% enzymatically-cleavable hydrogels in collagenase.  Fold swelling was also 
significantly higher in hydrogels cultured in collagenase compared to those cultured in 
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PBS for all groups except low saline content hydrogels containing no enzymatically-
cleavable sequences (0%). 
 Fold swelling showed a generally increasing trend as the amount of 
enzymatically-cleavable sequences in the hydrogel formulation increased.  Specifically, 
in low saline content hydrogels cultured in PBS, fold swelling comparisons between 
hydrogels containing different amounts of enzymatically-cleavable sequences revealed 
that all comparisons between the four formulations were significant.  Similarly, fold 
swelling of low saline content hydrogels cultured in collagenase was significantly 
different for every comparison between hydrogels with different enzymatically-cleavable 
sequence concentrations.  For high saline content hydrogels in PBS, fold swelling was 
significantly different for every comparison between hydrogels with different 
enzymatically-cleavable sequence concentrations except for 0% enzymatically-cleavable 
hydrogels compared to 25% enzymatically-cleavable hydrogels.  For high saline content 
hydrogels in collagenase, fold swelling was significantly different for every comparison 
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Figure 4.3.  Fold swelling of enzymatically-cleavable hydrogels with a low or 
high initial saline content (75wt% PBS or 90wt% PBS) cultured in PBS or 
collagenase, n=5 ±SD.  p<0.05 compared to high saline content hydrogels (*).  
p<0.05 compared to PBS (+).  p<0.05 compared to the 0% (#), 0% and 25% 






















except for 75% enzymatically-cleavable hydrogels compared to 100% enzymatically-
cleavable hydrogels, with both undergoing complete degradation within two days of 
culture. 
 Mesh size of high saline content hydrogels was significantly higher than low 
saline content hydrogels in all samples except 100% enzymatically-cleavable hydrogels 
in collagenase (Fig. 4.4).  Mesh size was also significantly different in low saline content 
100% enzymatically-cleavable hydrogels in collagenase compared to PBS and in high 
saline content hydrogels with 0%, 75%, or 100% enzymatically-cleavable sequences in 
collagenase compared to PBS. 
For low saline content hydrogels mesh size was significantly different between 
100% enzymatically-cleavable hydrogels and 0%, 25%, and 75% enzymatically-
cleavable samples in collagenase.  For low saline content hydrogels in PBS, differences 
were seen for 75% and 100% enzymatically-cleavable hydrogels compared to 0% and 
25% enzymatically-cleavable hydrogels.  For high saline content hydrogels significant 
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Figure 4.4.  Mesh size of enzymatically-cleavable hydrogels with a low or high 
initial saline content (75wt% PBS or 90wt% PBS) cultured in PBS or 
collagenase, n=5 ±SD.  p<0.05 compared to high sailine hydrogels (*).  (+) 
p<0.05 compared to PBS (+).   p<0.05 compared to the 0% (#); 0% and 25% 






















enzymatically-cleavable hydrogels which were both fully degraded.  No differences were 
seen in high saline content hydrogels in PBS between hydrogel types. 
4.3.2 Cell Viability and Morphology 
 Both hMSCs and hACL fibroblasts generally demonstrated green staining 
throughout the entire 21 day culture period, indicating viability (Fig. 4.5G-J and 4.6G-J).  
There were no significant differences in circularity of hMSCs across time, due to 
hydrogel type, or in different regions of the hydrogels (Fig.4.5C, D, E, F).  Similarly, 
there were no significant differences in the circularity of hACL fibroblasts across time or 
due to hydrogel type in the middle region of the hydrogels.  Circularity of hACL 
fibroblasts in subsurface regions was significantly lower in 100% enzymatically-
cleavable hydrogels on day 21 compared to day 7 (Fig. 4.6E) although no other 
comparisons of circularity in these cells were significant in the subsurface region. 
 Cellular area of hMSCs in middle regions was significantly different in 75% and 
100% enzymatically-cleavable hydrogels compared to 0% enzymatically-cleavable 
hydrogels on day 7.  Cellular area of hMSCs in middle regions was also significantly 
different in 0% and 25% enzymatically-cleavable hydrogels on day 7 compared to day 1 
and in 100% enzymatically-cleavable hydrogels on day 7 and day 14 compared to day 1.  
In contrast, cellular area of encapsulated hACL fibroblasts in subsurface regions was 
significantly higher in 100% compared to 0% enzymatically-cleavable hydrogels on day 
14 (Fig. 4.6C) and cell area was also higher in 100% enzymatically-cleavable hydrogels 
on day 21 and day 14 compared to day 7. 
 68 









d1 d7 d14 d21
Middle Region
0% degradable 25% degradable














d1 d7 d14 d21
Subsurface Region
0% degradable 25% degradable










d1 d7 d14 d21
Subsurface Region
0% degradable 25% degradable










d1 d7 d14 d21
Middle Region
0% degradable 25% degradable










d1 d7 d14 d21
Middle Region
0% degradable 25% degradable










d1 d7 d14 d21
Subsurface Region
0% degradable 25% degradable
75% degradable 100% degradable
E
G 0% 
Figure 4.5.  Cellular perimeter (A, B), area (C, D) , or circularity (E, F) of 
encapsulated hMSCs in subsurface (A, C, E) or middle (B, D, F) regions of the 
hydrogels over 21d of culture (n≥3±SD).  LIVE/DEAD images of hMSCs in 
subsurface (G, H) or middle (I, J) regions in 0% (G, I), or 100% (H, J) 
enzymatically-cleavable hydrogels at d21.  p<0.05 compared to d1 (+).   p<0.05 
compared to the 0% (*).  Scale bar = 100 µm. 














































































































































Figure 4.6.  Cellular perimeter (A, B), area (C, D), or circularity (E, F) of 
encapsulated hACL fibroblasts in subsurface (A, C, E) or middle (B, D, F) 
regions over 21d of culture (n≥3±SD).  LIVE/DEAD images of hACL fibroblasts 
in subsurface (G, H) or middle (I, J) regions of 0% (G, I) or 100% (H, J) 
enzymatically-cleavable hydrogels at d21. p<0.05 compared to non-cleavable, 0% 
degradable hydrogels (*). p<0.05 compared to d7 hydrogels(+). Scale bar = 100 
µm. 






















































 There were no significant differences in perimeter seen with hMSCs across time, 
due the hydrogel type, or in different regions of the hydrogel (Fig. 4.5A&B).  In contrast, 
cellular perimeter of encapsulated hACL fibroblasts in subsurface regions of the hydrogel 
was significantly higher in 100% compared to 0% enzymatically-cleavable hydrogels by 
day 14 (Fig. 4.6A). In addition, perimeter of hACL fibroblasts was significantly higher in 
100% enzymatically-cleavable hydrogels on day 14 and day 21 compared to day 7.  
There were no significant differences in hACL fibroblast perimeter in middle regions or 
between different regions of the hydrogel (Fig. 4.6A&B).  Images of hMSCs and hACL 
fibroblasts in the hydrogels matched well with the quantitative data (Fig. 4.5G-J and 
4.6G-J).  
 4.3.3 Cell Number 
No differences in cell number of hMSCs were seen across time or due to hydrogel 
type (Fig. 4.7).   Conversely, hACL fibroblasts showed a decrease in cell number on day 
1, day 14, and day 21 in 100% enzymatically-cleavable hydrogels compared to 0% 

















Figure 4.7.  DNA content of enzymatically-cleavable hydrogels 
with hMSCs or fibroblasts (n=5 ±SD).  p<0.05 compared to non-
enzymatically cleavable, 0% LGPA hydrogels (*).  p<0.05 













































fibroblasts on day 7, day 14, and day 21 compared to day 1 in 0% enzymatically-
cleavable hydrogels.  In addition, decreases in cell number were seen with hACL 
fibroblasts in 100% enzymatically-cleavable hydrogels on day 14 compared to day 1 and 
day 7 and on day 21 compared to day 1. 
4.3.4 Matrix Metalloproteinase Production 
hMSCs produced detectable levels of MMP-1 by day 7 while hACL fibroblasts 
produced detectable MMP-1 by day 1 (Fig. 4.8).  hACL fibroblasts produced higher 
amounts of MMP-1 than hMSCs in both 0% and 100% enzymatically-cleavable 
hydrogels at all time points.  Levels of MMP-1 produced by hMSCs were significantly 
higher by day 21 compared to day 1 and day 7 and on day 14 compared to day 1 in all 
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Figure 4.8.  Cumulative production of total MMP-1 and MMP-13 in hMSCs and 
hACL fibroblasts in enzymatically-cleavable hydrogels over 21d of culture (n=3 
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on day 7 compared to day 1 in 0% and 100% enzymatically cleavable hydrogels.  The 
MMP-1 produced by hACL fibroblasts rose significantly at each time point, peaking at 
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Figure 4.9.  Cumulative production of active MMP-13 in hMSCs and hACL 
fibroblasts in enzymatically-cleavable hydrogels over 21d of culture (n=3 ±SD).  
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Table 4.2.  Table of statistical significance for cumulative production of MMP-1 
and MMP-13 by hMSCs in enzymatically-cleavable hydrogels over 21d of culture 
(n=3 ±SD).  p<0.05 compared to fibroblasts (*).  p<0.05 compared to d1 (+), d7 
(++), d14 (+++), or d21 (++++).  p<0.05 compared to 0%(#), 25% (##), 75% (###), 
or 100%(####).  p<0.05 compared to active MMP ($). 
hMSC Total MMP-1 Total MMP-13 Active MMP-1 Active MMP-13
d1 0% *,++,+++,++++,$ *,++,+++,++++,$ *,++++
25% +++,++++,$ ++,+++,++++ ++++
75% +++,++++,$ +,++,+++
100% *,++,+++,++++ *,++,+++,++++ *,++++








d21 0% *,##,+,++,$ *,##,###,+,++ *,+
25% #,####,+,++,$ #,###,####,+,++ +
75% +,++,$ #,##,####,+,++,$
100% *,##,+,++,$ *,##,###,+,++,+++ *,+
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hMSCs cultured in 25% enzymatically-cleavable hydrogels produced 
significantly higher levels of MMP-1 on days 7, 14, and 21 than hMSCs in 0% or 100% 
enzymatically-cleavable hydrogel formulations.  While hMSCs did not show significant 
differences in MMP-1 production between 100% enzymatically-cleavable and 0% 
enzymatically-cleavable hydrogels at any time point, hACL fibroblasts produced 
significantly less MMP-1 in 100% enzymatically-cleavable hydrogels compared to 0% by 
day 7.  Neither hMSCs nor hACL fibroblasts produced detectable levels of active MMP-1 
at any time in the culture period.  As a result of the lack of active MMP-1 production, 
total levels of MMP-1 were significantly higher than active MMP-1 with hMSCs and 
hACL fibroblasts in all hydrogel types by day 7.  
While no active MMP-1was produced by either cell type, both hMSCs and hACL 
fibroblasts produced modest levels of active MMP-13 (Fig. 4.9).  Interestingly, there was 
no significant difference in the amount of active MMP-13 and total MMP-13 produced 
by hMSCs except in 75% enzymatically-cleavable hydrogels on days 7, 14, and 21. This 
Table 4.3.  Table of statistical significance for cumulative production of MMP-1 
and MMP-13 by hACL fibroblasts in enzymatically-cleavable hydrogels over 21d 
of culture (n=3 ±SD).  p<0.05 compared to d1(+), d7(++), d14(+++), or d21 
(++++).  p<0.05 compared to 0%(#) or 100%(####).  p<0.05 compared to active 
MMP($). 
Fibroblast Total MMP-1 Total MMP-13 Active MMP-1 Active MMP-13
d1 0% ++,+++,++++,$ ++,+++,++++,$ ++,+++,++++
100% ++,+++,++++,$ ++,+++,++++,$ ++,+++,++++
d7 0% +,+++,++++,$ +,+++,++++,$ +,+++,++++
100% +,+++,++++,#,$ +,$ +,+++,++++,#
d14 0% +,++,++++,$ +,++,++++,$ +,++,++++
100% +,++,#,$ +,$ +,++,++++
d21 0% +,++,+++,$ +,++,+++,$ +,++,+++
100% +,++,#,$ +,$ +,++,+++
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suggests that the MMP-13 secreted by hMSCs was in an active form in most cases.  
Conversely, hACL fibroblasts produced significantly more total MMP-13 than active 
MMP-13 in both hydrogel types at all time points.  hACL fibroblasts produced 
significantly more total MMP-13 than hMSCs in all hydrogel types by day 7.  While 
hACL fibroblasts generally produced more total MMP-13, hMSCs often produced more 
MMP-13 in an active form.  Specifically, hMSCs produced more active MMP-13 than 
hACL fibroblasts in 0% and 100% enzymatically-cleavable hydrogels on day 1 and day 
21 and in 0% enzymatically-cleavable hydrogels on day 14. 
  Active MMP-13 was significantly higher with hMSCs in 0%, 25%, and 100% 
enzymatically cleavable hydrogels on day 21 compared to day 1.  No significant 
differences were seen with active MMP-13 in hMSCs due to the hydrogel type.  The total 
MMP-13 produced by hMSCs rose significantly at each time point, peaking at day 21, 
except from day 14 to day 21 in 0%, 25%, and 75% enzymatically-cleavable hydrogels.  
In addition, total MMP-13 produced by hMSCs was significantly different between 25% 
enzymatically-cleavable hydrogels compared to 0% and 100% enzymatically-cleavable 
samples on days 7, 14, and 21; between 75% enzymatically-cleavable hydrogels 
compared to 100% enzymatically-cleavable samples on days 14 and 21; and between 
75% enzymatically-cleavable hydrogels compared to 0% and 25% enzymatically-
cleavable samples on day 21. 
The active MMP-13 produced by hACL fibroblasts rose significantly at each time 
point, peaking at day 21 in both 0% and 100% enzymatically-cleavable hydrogels.  In 
addition, total MMP-13 produced by hACL fibroblasts in 0% enzymatically-cleavable 








































produced by hACL fibroblasts in 100% enzymatically-cleavable hydrogels was 
significantly higher on days 7, 14, and 21 compared to day 1.  There were no differences 
in total or active MMP-13 production by hACL fibroblasts across hydrogel types except 
for active MMP-13 on day 7. 
4.3.5 Gene Expression 
Neither hMSCs nor hACL fibroblasts showed any significant differences in 
GAPDH gene expression (Ct) at any time point due to the hydrogel formulation 
(Supplementary Fig. B.2).  In addition, there was no significant difference in GAPDH 
expression between hMSCs and hACL fibroblasts on day 7, day 14, or day 21.  However, 
hMSCs had a significantly higher Ct values for GAPDH compared to hACL fibroblasts 
on day 1. 
Collagen I gene expression was higher (Fig. 4.10A, 4.10B) in hACL fibroblasts 
compared to hMSCs in 0% and 100% enzymatically-cleavable hydrogels on day 1, day 7, 
and day 21.  Collagen III gene expression was significantly different (Fig. 4.10C, 4.10D) 
in hACL fibroblasts compared to hMSCs in 0% enzymatically-cleavable hydrogels on 
day 1, day 7, day 14, and day 21 and in 100% enzymatically-cleavable hydrogels on day 
1, day 7, and day 14.   
Tenascin-C gene expression was significantly different (Fig. 4.10E, 4.10F) in 
hACL fibroblasts compared to hMSCs in 0% and 100% enzymatically-cleavable 
hydrogels at all time points.  
hMSCs showed significantly different collagen I gene expression on day 14 and 
day 21 compared to day 1 and day 7 in 0%, 25%, and 75% enzymatically-cleavable 
hydrogels (Fig. 4.10A).  Significant differences in 100% enzymatically-cleavable 
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hydrogels with hMSCs were seen on day 7, day 14, and day 21 compared to day 1; and 
day 21 compared to day 14.  Collagen I was upregulated in hACL fibroblasts in 0% 




















































































































































































Figure 4.10.  Collagen I (A, B), collagen III (C, D), and tenascin-C (E, F) gene 
expression in hMSCs (A, C, E) or fibroblasts (B, D, F) in enzymatically-
degradable hydrogels (n≥7 ±SD). p<0.05 compared to the 0%(#); 0% and 
25%(##); or 0%, 25%, and 75%(###) hydrogels; respectively, for the given time 
point. p<0.05 compared to d1(+); d1 and d7(++); or d1, d7, and d14(+++); 
respectively, for the given hydrogel type. p<0.05 compared to fibroblasts (*) for 


















































































































7 and 14 compared to day 1, and in 100% enzymatically-cleavable hydrogels on day 7 
compared to day 1, on day 14 compared to day 1 and day 7, and on day 21 compared to 
day 14 and day 1 (Fig. 4.10B). 
hMSCs showed upregulation of collagen III gene expression on day 7, day 14, 
and day 21 compared to day 1 in all hydrogel types (Fig. 4.10C).  In addition, collagen III 
was upregulated in hMSCs in 0%, 25%, and 75% enzymatically-cleavable hydrogels on 
day 14 and day 21 compared to day 7, in 75% enzymatically-cleavable hydrogels on day 
21 compared to day 14, and in 100% enzymatically-cleavable hydrogels on day 21 
compared to day 7.  Collagen III was upregulated in hACL fibroblasts in 0% 
enzymatically-cleavable hydrogels on day 7, day 14, and day 21 compared to day 1 and 
on day 21 compared to day 7 and day 14  (Fig. 4.10D).  Collagen III was significantly 
different in hACL fibroblasts in 100% enzymatically-cleavable hydrogels on day 7, day 
14, and day 21 compared to day 1, day 14 compared to day 7, and day 21 compared to 
day 14. 
All comparisons of tenascin-C gene expression across time points were 
statistically significant in hMSCs for all hydrogel types except in 100% enzymatically-
cleavable hydrogels on day 21 compared to day 7 (Fig. 4.10E).  Tenascin-C was 
upregulated in hACL fibroblasts in 0% MMP hydrogels on day 7, day 14, and day 21 
compared to day 1, day 14 and day 21 compared to day 7, and day 21 compared to day 14 
(Fig. 4.10F).  Upregulation was seen in hACL fibroblasts in 100% enzymatically-
cleavable hydrogels on day 7, day 14, and day 21 compared to day 1. 
 hMSCs showed upregulation of collagen I gene expression on day 7 and day 14 in 
100% enzymatically-cleavable hydrogels compared to 0%, 25%, and 75% enzymatically-
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cleavable hydrogels (Fig. 4.10A).  hACL fibroblasts showed upregulation of collagen I 
gene expression on day 1 and day 14 in 100% enzymatically-cleavable hydrogels 
compared to 0% enzymatically-cleavable hydrogels (Fig. 4.10B). 
 hMSCs generally showed upregulation of collagen III gene expression in response 
to increase concentrations of MMP-cleavable peptides (Fig. 4.10C).  Specifically, 
collagen III was upregulated in hMSCs on d7 in 100% MMP-cleavable hydrogels 
compared to 0%, 25%, and 75% enzymatically-cleavable hydrogels and on day 14 and 
day 21 in 100% enzymatically-cleavable hydrogels compared to 0% enzymatically-
cleavable hydrogels.  Conversely, collagen III was downregulated in hACL fibroblasts on 
day 14 and day 21 in 100% enzymatically-cleavable hydrogels compared to 0% cleavable 
hydrogels (Fig. 4.10D).  Collagen III was also downregulated in hACL fibroblasts on day 
1 in 0% enzymatically-cleavable hydrogels compared to 100% cleavable hydrogels. 
 hMSCs showed upregulation of tenascin-C on day 7 in 100% enzymatically-
cleavable hydrogels compared to 75%, 25%, and 0% enzymatically-cleavable hydrogels, 
on day 14 in 100% enzymatically-cleavable hydrogels compared to 0% enzymatically-
cleavable hydrogels, and on day 21 in 100% enzymatically-cleavable hydrogels 
compared to 25% enzymatically-cleavable hydrogels (Fig. 4.10E).  Tenascin-C was 
downregulated in hACL fibroblasts on day 7, day 14, and day 21 in 100% enzymatically-
cleavable hydrogels compared to 0% enzymatically-cleavable hydrogels (Fig. 4.10F). 
 Collagen II, osteocalcin, myoD, and PPARγ were generally expressed at low 
transcript levels (Fig. 4.11 and 4.12) with some samples failing to reach detectable levels.  
Specifically, in hMSCs collagen II was not detected on day 14 of 25% enzymatically-
cleavable hydrogels, on day 21 of 75% enzymatically-cleavable hydrogels; osteocalcin 
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was not detected on day 1 in any samples; and PPARγ was not detected on day 1 or day 
21 in any samples, on day 7 in 0% or 75% enzymatically-cleavable hydrogels, or on day 
14 in 0% or 100% enzymatically-cleavable hydrogels.  PPARγ was not detected in any 
hydrogels containing hACL fibroblasts at any time point. 
 hMSCs showed downregulation of collagen II in 0% enzymatically-cleavable 
hydrogels on day 7, day 14, and day 21 compared to day 1; in 25% enzymatically-
cleavable hydrogels on day 7 compared to day 1; and in 100% enzymatically-cleavable 
hydrogels on day 14 compared to day 1 (Fig. 4.11A).  hACL fibroblasts showed 







































































Figure 4.11.  Collagen II (A, B) and osteocalcin (C, D) gene expression in hMSCs 
(A, C) or fibroblasts (B, D) in enzymatically-degradable hydrogels (n≥7 ±SD). 
p<0.05 compared to fibroblasts (*), p<0.05 compared to the 0% hydrogels (#), for 
the given time point. p<0.05 compared to d1(+); d1 and d7(++); or d1, d7, and 













































































21 compared to day 1; in 100% enzymatically-cleavable hydrogels on day 7, day 14, and 
day 21 compared to day 1, and on day 14 compared to day 7; and on d14 in 100% 
enzymatically-degradable hydrogels compared to 0% enzymatically degradable 
hydrogels (Fig. 4.11B). 
hMSCs showed upregulation of osteocalcin gene expression on day 21 in all 
hydrogel types compared to day 7 and day 14 (Fig. 4.11C).  In addition, osteocalcin was 
upregulated in hMSCs on day 7 in 100% enzymatically-cleavable hydrogels compared to 
25% and 75% enzymatically-cleavable samples.  Osteocalcin was upregulated in hACL 
fibroblasts in 0% enzymatically-cleavable hydrogels on day 7 compared to day 1, day 14, 
and day 21; and on day 21 compared to day 1 and day 14 (Fig. 4.11D).  In addition, 
osteocalcin was upregulated in hACL fibroblasts in 100% enzymatically-cleavable 
hydrogels on day 1 and day 7 compared to day 21; on day 1 in 100% compared to 0% 
enzymatically-cleavable hydrogels; and on day 21 in 0% compared to 100% 
enzymatically-cleavable hydrogels. 
hMSCs showed significant differences in myoD gene expression in 0% 
enzymatically-cleavable hydrogels on day 7 and 14 compared to day 1, and on day 21 
compared to day 7; in 25% enzymatically-cleavable hydrogels on day 7 compared to day 
1, day 14, and day 21; in 75% enzymatically-cleavable hydrogels on day 7, day 14, and 
day 21 compared to day 1; and in 100% enzymatically-cleavable hydrogels on day 7 
compared to day 1 (Fig. 4.12A).  hACL fibroblasts showed significant differences in 
myoD gene expression in 0% enzymatically-cleavable hydrogels on day 14 compared to 
day 1, day 7, and day 21; in 100% enzymatically-cleavable hydrogels on day 14 
compared to day 1 and day 7, and day 1 compared to day 21; and on day 1 in 0% 
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enzymatically-cleavable hydrogels compared to 100% enzymatically-cleavable hydrogels 
(Fig. 4.12B). 
PPARγ was not detected in hMSCs except in the 4 sample groups shown in Fig. 
4.12C.  Comparisons among these groups yielded statistical significance on day 7 
between 25% and 100% enzymatically-cleavable samples, on day 14 between 25% and 
75% enzymatically-cleavable samples, and in 25% enzymatically cleavable samples on 
day 14 compared to day 7.  PPARγ was not detected in hACL fibroblasts in any samples 






















































Figure 4.12.  myoD (A, B) and PPARγ (C) gene expression in hMSCs (A, C) or 
fibroblasts (B) in enzymatically-degradable hydrogels (n≥7 ±SD).  PPARγ did not 
amplify in hMSCs except for the 4 samples displayed in C.  PPARγ did not 
amplify in hACL fibroblasts in any hydrogel type or at any time point.  p<0.05 
compared to fibroblasts (*) for the given day and hydrogel type.  p<0.05 
compared to 0% hydrogels(#) for the given time point.  p<0.05 compared to 




























































4.3.6 Histology  
 IHC staining was performed only on samples with hMSCs.  This staining 
indicated the presence of collagen I pericellularly in 100% enzymatically-cleavable 
hydrogels with hMSCs on day 1 and day 21 (Fig. 4.13).  Minimal staining for collagen I 
Figure 4.13.  IHC for collagen I, collagen III, or tenascin-C in 0% or 100% 
enzymatically-degradable hydrogels with hMSCs on day 21 or day 1.  Brown 
color indicates staining for the particular protein.  Arrow indicates pericellular 
staining. Scale bar = 20 µm. 
 





























was seen in 0% enzymatically-cleavable hydrogels even by day 21.  Staining for collagen 
III and tenascin-C was seen pericellularly in 100% enzymatically-cleavable hydrogels 
with hMSCs by 21 (Fig. 4.13). However, little to no staining for collagen III or tenascin-
C was seen in 0% hydrogels or on day 1.  No staining was seen in control sections with 
the primary antibody omitted suggesting that neither the secondary antibody nor the 
Vectastain elite ABC peroxidase kit exhibited significant non-specific binding and that 
there was minimal endogenous staining from the contrast agent.  However it should be 
noted that no isotype control was used so the possibility of non-specific binding of the 
primary antibody can not be eliminated.  
4.4 Discussion 
 This hydrogel system provides an environment that can take advantage of 
enzymatic degradation of the biomaterial carrier.  The changes in fold swelling that were 
seen in enzymatically-cleavable hydrogels in collagenase (Fig. 4.3), including complete 
degradation of some samples, showed that the cleavable LGPA motifs can be targeted for 
enzyme-mediated degradation, in agreement with previous results.
112,113
  In addition, the 
studies in this chapter showed that the susceptibility of the biomaterial environment to 
enzyme-mediated degradation can be tailored through changes in the saline content of the 
hydrogels and through the combination of the LGPA motifs with non-enzymatically-
cleavable polymers.  Interestingly, enzymatically-cleavable sequences seemed to have a 
greater affect on fold swelling than mesh size of hydrogels (Fig. 4.4), suggesting that 
mesh size may not be as sensitive to degradation. 
 Collagen I, collagen III and tenascin-C mRNA transcripts were found at higher 
levels in hMSCs in 100% enzymatically-cleavable hydrogels, which possessed the 
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highest total degradability (Fig. 4.3), compared to samples with lower concentrations of 
cleavable peptides (Fig. 4.10).  The higher transcript levels in hMSCs did not appear to 
occur in a dose-dependant manner across hydrogel formulations, as there were no 
significant differences between 0%, 25%, and 75% enzymatically cleavable hydrogels.  
An upregulation of collagen I, collagen III, and tenascin-C was seen in both hMSCs and 
hACL fibroblasts for all hydrogel types on day 21 compared to day 1 (Fig. 4.10).  hMSCs 
cultured in collagen-based hydrogels have shown a similar time-dependant upregulation 
of collagen I and collagen III,
179
 suggesting that upregulation of ligament/tendon ECM 
genes occurs over time in a variety of biomaterial systems.  In contrast, changing the cell 
type seems to promote diverse responses to the enzymatically-cleavable hydrogel 
environments.  Upregulation of ligament fibroblast gene expression was promoted in 
hMSCs in 100% enzymatically-cleavable hydrogels (Fig. 4.10).  Other studies with 
bovine chondrocytes in enzymatically-degradable hydrogels using a different peptide 
sequence have shown upregulation of cartilage-related gene expression.
197
  The 
upregulation of ligament fibroblast-related or cartilage-related gene expression depending 
on cell type suggests that cell responses in enzymatically-degradable hydrogels can be 
adapted to different applications depending on the cell type used.  The particular 
cleavable sequence employed may also be an important factor to consider and may need 
to be tailored to the specific application and cell type.  In addition, the percentage of the 
hydrogel that is susceptible to enzymatic degradation may also need to be altered 
according to the particular application and cell type chosen.  This is supported by the 
upregulation or downregulation of ligament/tendon ECM gene expression seen in 
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enzymatically cleavable hydrogels compared to non-cleavable samples depending on the 
cell type used (Fig. 4.10). 
 In addition to promoting changes in gene expression, the 100% enzymatically-
cleavable hydrogels, which possessed the highest total degradability (Fig. 4.3), also 
seemed to facilitate the production of ECM proteins by hMSCs (Fig. 4.13, IHC was not 
conducted on hACL fibroblasts), in agreement with previous results using synthetic 
enzymatically-cleavable hydrogels.
197,198
  Hydrogels with lower levels of degradability 
produced minimal ECM production.  Natural scaffolds made of collagen I possess the 
enzymatically-cleavable motifs that are similar to those used in synthetic enzymatically-
cleavable hydrogels so similar patterns of protein production would be expected.  While 
some studies using collagen I scaffolds with hMSCs in static culture have shown collagen 
III protein production,
100
 other studies using collagen I scaffolds with bovine MSCs 
(bMSCs) have shown minimal collagen III production.
11
  As discussed above, responses 
to enzymatically-degradable environments appear to vary with the cell type used, so the 
minimal collagen III production by bMSCs may be related to that specific cell type.  The 
matrix production that has been seen in our system and in other studies is likely related to 
degradation of the scaffold, as increased degradation of hydrogel biomaterials has been 
linked to greater ECM production.
101
  Interestingly, production of collagen I and collagen 
III ECM by hMSCs has also been seen in synthetic PLLA scaffolds with limited 
degradability.
193
  This matrix production may be explained by the knitted pattern used 
with the PLLA scaffolds which creates a macroporous structure.  This porosity provides 
the void space required for ECM production without the need of degradation. 
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 MMP-1 did not appear to play a role in hydrogel degradation or the gene 
expression and protein production changes as this enzyme was not produced at detectable 
levels in an active form.  MMP-13 may play a role in degradation of the hydrogel 
environment, and thus cellular responses observed, since modest levels of this enzyme in 
an active form were produced by both hMSCs and hACL fibroblasts (Fig. 4.9).  Other 
MMPs or proteases that were not measured in this study may also play a role in the 
responses seen. 
 The higher gene expression levels of collagen I, collagen III, and tenascin-C that 
were generally seen with hACL fibroblasts compared to hMSCs lends credence to the 
idea that upregulation of these genes is a sign that hMSCs are developing a phenotype 
closer to a ligament/tendon fibroblast.  However, it should be noted that the hACL 
fibroblasts used in this study were obtained from a patient undergoing knee surgery.  
Since these cells were obtained from only one donor, their responses may not be widely 
applicable.  Using cells from multiple donors could strengthen conclusions related to the 
hACL fibroblasts in this study.  In addition, the behavior of the hACL fibroblasts may not 
be representative of hACL fibroblasts in a healthy tissue environment.  Cadaveric tissue 
or ACL tissue obtained after total knee replacements that do not involve and ACL rupture 
may be other potential sources of hACL fibroblasts, however the health of the tissue 
environment in both of these cases is also problematic.  Consequently, a perfect source of 
hACL fibroblasts may not be feasible at this time. 
 The upregulation of collagen I, collagen III, and tenascin-C expression in hMSCs 
in 100% enzymatically-cleavable hydrogels compared to other hydrogel formulations 
(Fig. 4.10), combined with the IHC results, suggests that the enzymatically-cleavable 
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biomaterial environments facilitated production of ligament/tendon ECM components by 
hMSCs.  While staining of hydrogels containing hMSCS showed the presence of ECM 
components in ligament/tendon tissues, it can not be specified whether this ECM is 
similar to hACL fibroblasts in similar hydrogels as IHC was not conducted on those 
samples.  The ECM production that was seen with hMSCs may be due to the 
susceptibility of the LGPA polymers to cleavage.  Cleavage of the LGPA polymers might 
be achieved by MMPs or other enzymes secreted by encapsulated cells.  This would 
allow for localized degradation of the hydrogel matrix which may facilitate production of 
ligament/tendon ECM components by providing void space needed for their elaboration.  
Further confirmation that the enzymatically-cleavable peptides are responsible for the 
phenomenon seen could be provided through future studies using a scrambled peptide 
that is not expected to undergo enzymatic degradation, through the use of an MMP 
inhibitor such as GM6001, or by using an enzymatically-cleavable fluorogenic 
substrate.
113
  If the effects seen in the enzymatically cleavable hydrogels disappear in 
samples where a scrambled sequence or MMP inhibitor is used, it would suggest that 
enzymatic-degradation of the biomaterial environment was necessary for the observed 
responses.  An enzymatically-cleavable fluorogenic substrate could also be used to 
visually confirm that cleavage is occurring in the hydrogel environment. 
 Cell number (Fig. 4.7) and the morphology (Fig. 4.5) of the hMSCs do not appear 
to play a role in the changes in ECM production observed seen as these factors are not 
significantly different between hydrogel types.  However, other factors that change across 
the different biomaterial formulations (Table 4.1) could affect the responses seen.  The 
initial mesh size of the hydrogels is one factor that is different between some of the 
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biomaterial formulations (Fig. 4.4), but this feature does not appear to be sufficient to 
explain the changes in gene expression seen with hMSCs.  Initial mesh size was not 
significantly different between 75% and 100% enzymatically-cleavable hydrogel samples 
(Fig. 4.4).  However, there were significant differences in gene expression levels of 
collagen I, collagen III, and tenascin-C in hMSCs in 100% enzymatically-cleavable 
hydrogels compared to 75% enzymatically cleavable hydrogels.  The 75% and 100% 
enzymatically-cleavable hydrogels did have different overall levels of susceptibility to 
enzymatic degradation (Fig. 4.4) which suggests that may be a more important reason 
why differences were seen between these two sample types.  
 Another potential factor that may change across hydrogel formulations is the 
cross-linking of the hydrogels which can be affected by the number of double bonds 
available for cross-linking and the relative reactivities of the bonds.  The increased fold 
swelling (Fig. 4.3) and mesh size (Fig. 4.4) seen in hydrogels formed from 
enzymatically-cleavable polymers compared to non-enzymatically cleavable hydrogels 
suggests that the enzymatically cleavable hydrogels have a lower cross-linking density 
than non-enzymatically cleavable samples.
186
  Changes in the cross-linking density have 
the potential to affect the elastic modulus of samples which could potentially play a role 
in cell responses seen.
186,199
   However, the differences in mesh size that were seen in 
these samples are not expected to be large enough to significantly affect mechanical 
properties, as comparable mesh size changes in other OPF-based hydrogels did not result 
in significant differences of tensile modulus, fracture strength, or toughness of the 
samples.
186
  Tensile testing of these hydrogels could be useful to provide confirmation 
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that mechanical properties do not change significantly between the hydrogel formulations 
used in this study. 
 Variations in the presentation of the RGD adhesion peptides in these samples also 
have the potential to play a role in the differences seen between sample types.  For 
example, the efficiency of incorporation of RGD peptides could change across hydrogel 
formulations and thus affect the presentation of RGD to encapsulated cells.  This could 
occur due to different reactivities of fumarate and acrylate bonds,
200
 which are present in 
different concentrations in the hydrogel formulations used in this study.  Changes in the 
distance between cross-links could also affect the presentation of the adhesion peptides to 
the cells.  However, the cross-link density is not expected to play a major role in the 
presentation of RGD peptides in these hydrogels as the concentration of double bonds 
available for cross-linking in all sample types is almost 2 orders of magnitude higher than 
the number of RGD peptides.  In addition, the incorporation of RGD peptides into a 
variety of hydrogel formulations did not significantly affect the fold swelling of those 
samples (supplementary Fig. B.3), suggesting that the addition of these sequences has a 
limited effect on the cross-linking density.  Further characterization of the RGD peptide 
concentration after cross-linking could be achieved through methods such as 
radiolabeling of the peptide or amino acid analysis.  These would provide greater insight 
into if the efficiency of RGD peptide incorporation varied in different hydrogel 
formulations. 
 The upregulation of relevant ligament ECM gene expression seen in hMSCs in 
enzymatically-degradable hydrogels produced expression levels approaching those 
observed in hACL fibroblasts (Fig. 4.10) which suggests that an enzymatically-
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degradable environment may be an important factor for differentiation of hMSCs toward 
a ligament/tendon fibroblastic phenotype.  The similarities in expression levels do not 
seem to be related to differences in GAPDH levels as hMSCs and hACL fibroblasts did 
not have significant differences in GAPDH gene expression except at day 1 
(supplementary figure B.2).  However, neither cell surface markers that are characteristic 
of hMSCs nor the differentiation potential of the cells after culture was examined.  
Further investigation of these factors could further illuminate whether the encapsulated 
hMSCs are undergoing a differentiation response or are expressing transient 
modifications of gene expression patterns without terminal differention.  It should be 
noted that even if terminal differentiation is not achieved, the production of 
ligament/tendon ECM proteins as was seen in enzymatically-degradable hydrogels may 
be sufficient for tissue engineering applications that seek to replace ligament/tendon 
ECM. 
 The differences in the responses between hMSCs and hACL fibroblasts to the 
enzymatically-cleavable biomaterial carrier suggest that further work is required to 
produce hMSCs with a ligament fibroblast phenotype.  Some of the differences seen 
between cells types were the generally higher production of MMPs (Fig, 4.7) and higher 
gene expression levels of collagen I, collagen III, and tenascin-C (Fig. 4.9) in hACL 
fibroblasts compared to hMSCs.  hACL fibroblasts also seemed to demonstrate changes 
in cellular perimeter in enzymatically-cleavable biomaterial environments (Fig. 4.6) that 
were not seen with hMSCs (Fig. 4.5).  The changes in cell perimeter seen with hACL 
fibroblasts agree with previous studies showing morphological changes in human 




However, hMSCs have also been reported to demonstrate spreading in enzymatically-
cleavable hydrogels,
203
 in contrast to the lack of morphological changes seen with 
hMSCs in this study.  This discrepancy may be related to differences in the biomaterial 
systems employed including variations between the enzymatically-cleavable sequences 
used, as sequence differences can affect the degradation kinetics.
204,205
 
 It is possible that the changes in cell perimeter that were seen in this study with 
hACL fibroblasts may be related to cell clustering, as previous studies have provided 
evidence that degradation of the biomaterial environment can lead to cell clustering.
197,206
  
This would also explain why there were fewer significant differences in hACL fibroblast 
area and circularity compared to perimeter.  Cells in close proximity, similar to what was 
seen in these hydrogels, can mask changes in circularity, area, and perimeter and thus the 
analysis used may not show all of the differences that existed between sample types.  A 
single cell spreading and spread cells in close proximity can create offsetting effects in 
area and circularity readings, compared to a round cell.  Perimeter readings would not be 
expected to have such offsetting effects.  Therefore it is expected that measurements of 
cell perimeter most accurately reflect differences seen in cell morphology/clustering in 
this system. 
 Another difference seen between cell types was the apparent decrease in cell 
number of hACL fibroblasts over time and in 100% enzymatically-cleavable hydrogels 
compared to 0% enzymatically-cleavable samples, while hMSCs maintained a steady cell 
number in all sample types (Fig. 4.7).  The prevalence of green staining of hACL 
fibroblasts at all time points, indicating live cells, suggests that changes in cell number 
are not due to cell death.  Alternate explanations include the possibility that hACL 
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fibroblasts did not adhere to the hydrogels as well as hMSCs and thus a non-adherent 
population was lost from the hydrogel or that the hACL fibroblasts had a greater 
propensity to migrate out of the hydrogels than hMSCs.  Further, study is needed to 
examine these possibilities. 
 Perhaps the most interesting distinction between the hMSCs and hACL fibroblasts 
was the difference in gene expression responses in different biomaterial environments 
(Fig. 4.10).  While some upregulation of collagen I, collagen III, and tenascin-C was seen 
with hMSCs in enzymatically-cleavable hydrogels, an opposite trend was seen in hACL 
fibroblasts with upregulation seen in non-cleavable hydrogels.  This data suggests that a 
biomaterial environment that facilitates stem cell differentiation may be different from 
the biomaterial environment needed for a terminally differentiated cell.  Sophisticated 
biomaterial carriers that can respond to differentiation of encapsulated cells may be 
needed to adapt to the changing needs of differentiating cells.  Alternately, stem cells 
differentiated in an enzymatically degradable biomaterial, could be harvested from the 
hydrogel by digesting it in collagenase.  Terminally differentiated cells isolated from 
their biomaterial carrier could then be encapsulated in a new biomaterial environment 
that is more conducive to the desired function.  In this way, the biomaterial system 
employed in this study could serve as a means to provide different biomaterial 
environments to encapsulated stem cells as they differentiate. 
 Further study with this biomaterial system could include applications that involve 
harvesting encapsulated cells or the ECM they produce through degradation of the 
hydrogel in collagenase.  The release of cells and ECM molecules facilitates analysis that 
is not possible while they are encapsulated in the biomaterial carrier, such as 
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measurement of surface marker expression.   It should be noted that harvesting of 
collagenous ECM components may require modifications of this hydrogel system that 
make it susceptible to enzymes that do not target collagens. 
4.5 Conclusions 
In addition to providing evidence of promotion of gene regulation and protein 
production in hMSCs that is indicative of an hACL fibroblast phenotype, the studies 
described in this chapter provide insight into behavioral differences between hMSCs and 
hACL fibroblasts in response to the enzymatically-cleavable biomaterial environments 
used in this study.  These studies also highlight the capacity of this model system to adapt 
to the changing biomaterial requirements needed for stem cell differentiation compared to 
culture of terminally differentiated cells.  Additional work is essential to further elucidate 
biomaterial factors that stimulate a gene expression and protein production pattern in 
hMSCs that is characteristic of an hACL fibroblast phenotype.  Further study 
investigating the biomaterial conditions needed for culture at different stages of 
differentiation is also needed. 
Previous studies conducted in our laboratory with non-degradable gels 
demonstrated hMSC differentiation toward a ligament/tendon fibroblast phenotype under 
tensile strain.
125
  Therefore, the next chapter describes work that uses this well-defined 
carrier material to better understand how changes to the cell-biomaterial environment that 
occur over time affect cellular responsiveness to tensile loading, thereby providing basic 
parameters for next-generation biomaterial/bioreactor combinations to be used in 
production of tissue-engineered ligament grafts.  
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CHAPTER 5 
EFFECTS OF PRECULTURE ON THE EXPRESSION OF KEY 
LIGAMENT FIBROBLAST ECM GENES IN MSCS UNDER SHORT-
TERM TENSILE STRAIN 
5.1 Introduction 
 As the predominant cell type in ligament/tendon tissue, fibroblasts are often used 
for ligament/tendon tissue engineering applications.
4
  Unfortunately, the lack of a suitable 
source of autologous ligament/tendon fibroblasts has limited their usefulness.
10
   As a 
result, tissue engineering techniques for ligament/tendon engineering often use tensile 
strain to differentiate MSCs toward a ligament fibroblast phenotype.
11,125
  Gene 
upregulation and production of major ligament/tendon matrix components such as 
collagen I, collagen III, and tenascin-C are often examined as signs of ligament fibroblast 
phenotypic differentiation.
11,193,195
  Previous studies implicating tensile forces in the 
differentiation of MSCs toward a ligament/tendon fibroblast phenotype have required 14 
days or more before upregulation of relevant genes was detected compared to static 
controls.
11,125
  In this time frame upregulation of relevant ligament/tendon ECM gene 
expression has been seen compared to early time points in static controls.
125
  Changes to 
the extracellular environment of the cells have also occurred due to the production of 
ligament/tendon ECM proteins over time.
11,100,125
  Since gene expression and the ECM 
environment can change over multiple weeks of culture time, it is not certain whether the 
mechanical responses measured in MSCs are due to a) a multi-week stimulation response 
or b) an interaction between shorter amounts of tensile culture and alterations in the cell-
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biomaterial system.  If the gene expression regulation that arises from multiple weeks of 
tensile culture is due to interactions with the changing cell-biomaterial system, a period 
of static preculture combined with short-term loading may be sufficient to achieve 
responses created with longer-term tensile loading.  Further elucidation of these possible 
interactions could provide insight into how the timing of tensile stimulation can affect 
MSC differentiation toward a ligament/tendon phenotype.  This knowledge could 
facilitate improvements in future loading protocols for hMSC differentiation, thus aiding 
in the development of methods to provide an alternate source of autologous 
ligament/tendon fibroblasts or, eventually, tissue-engineered ligament/tendon grafts. 
 Therefore, this study was designed to determine whether the response of MSCs to 
short-term tensile stimulation, as compared to static culture, would be affected by a 
preculture period.  Short-term tensile strains (24 hours) were examined in order to 
minimize the effect of further alterations in the cell-biomaterial environment such as 
matrix protein production, gene expression regulation, or biomaterial degradation that 
may occur during the tensile stimulation period.  In particular, in these studies, hMSCs 
were encapsulated in 100% protease-cleavable hydrogels and precultured for 21 days or 
used without a preculture period.  Non-precultured samples provided a baseline cell-
biomaterial environment.  Constructs undergoing preculture provided an extracellular 
environment that was expected to be different from non-preculture baseline samples since 
changes in the ECM environment over 21 days had been seen in similar constructs 
cultured statically (Fig. 4.13).  Constructs undergoing preculture as well as samples 
without preculture were exposed to a repeating cyclic tensile strain regimen that was 
previously used with these hMSCs (Chapter 3) to promote upregulation of 
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ligament/tendon ECM (collagen I, collagen III, tenascin-C) gene expression.
125
  This 
strain regimen consisted of 10% strain, 1Hz, and 3 hours without stimulation followed by 
3 hours of cyclic tensile stimulation.  Constructs cultured statically at 0% strain were 
used as controls.  After 24 hours of strain, differences in cell number and gene expression 
(collagen I, collagen III, tenascin-C) between non-precultured and precultured samples 
were examined.  Baseline values for each of these metrics were also measured before the 
initiation of mechanical stimuli.  Specifically, this study sought to determine whether 
hMSCs precultured in 100% enzymatically-cleavable hydrogels would demonstrate an 
upregulation of ligament/tendon fibroblast ECM genes (collagen I, collagen III, tenascin-
C) in tensile constructs compared to statically cultured constructs.  The particular 
hypothesis of this study was that preculture in these hydrogels would correlate with 
upregulation of gene expression of ligament/tendon fibroblast ECM genes (collagen I, 
collagen III, tenascin-C) in hMSCs in response to short-term tensile strain. 
5.2 Materials and Methods 
5.2.1 Peptide Conjugation 
To allow presentation of RGD ligands to encapsulated cells, the GRGDS adhesion 
peptide was conjugated to a 3,400 Da MW acrylated-PEG-succinimidyl valerate spacer 
according to previous protocols.
108
  Briefly, conjugation was achieved by adding the A-
PEG-SVA to the GRGDS adhesion peptide dissolved in a sodium bicarbonate buffer 
solution under gentle stirring over a three hour period.  The mixed solution was 
transferred into 1,000 Da molecular weight cut-off dialysis tubing and dialyzed for two 
days to remove unreacted peptides.  Conjugated peptide was then lyophilized and stored 
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at -20°C.  The same batch of acrylated GRGDS peptide was used in all of these studies.  
Further details regarding this conjugation are found in appendix A.4. 
To provide cellular mediated degradation of the biomaterial environment the 
enzymatically-degradable peptide, GGGLGPAGGK, was conjugated on both ends to 
3,400 Da MW A-PEG-SVA using the peptide conjugation protocol mention above.  
Briefly, conjugation was achieved by adding A-PEG-SVA to the GGGLGPAGGK 
peptide dissolved in a sodium bicarbonate buffer solution under gentle stirring over a 
three hour period.  The mixed solution was transferred into 3,500-5,000 Da molecular 
weight cut-off dialysis tubing and dialyzed for two days to remove unreacted peptides.  
Conjugated GGGLGPAGGK peptide (LGPA) was then lyophilized and stored at -20°C.  
All batches of LGPA were subjected to fold swelling measurements to screen out poorly 
conjugated batches.  The exact same set of LGPA batches were used when possible and 
at least 4 batches of LGPA were used in each group of hydrogels in order to minimize the 
effects of batch to batch variability.  Further details regarding this synthesis are found in 
appendix A.3. 
5.2.2 Construct Fabrication 
 The tensile constructs are fabricated by injecting polymer solutions into a mold 
between two polyethylene end blocks (75-110 µm pore size).  The polymer solution 
invades the porous end blocks and forms an integrated tensile construct hydrogel after 
cross-linking.  The final tensile construct (Fig. 3.2A, inset) contains a cell-hydrogel 
section (12.5 mm x 9.5 mm, 1.6 mm) flanked by the porous end blocks.  One end block is 
placed over a stationary peg in the culture wells and the other end block interfaces with 
the tensile rake of this bioreactor (Fig. 3.2B).  The high stiffness of the end blocks 
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5.2.3 Cell Culture 
 hMSCs obtained at passage 0 were seeded into tissue culture flasks at 3,333 
cells/cm
2
 and grown in mesenchymal stem cell growth medium.  Cells were passaged 
after reaching approximately 80% confluency using a one to three expansion.  At passage 
5 (p5), cells were cryopreserved for future use.  Culture medium was changed every 2-3 
days.  hMSCs from four unique donors were pooled in equal numbers at p5 and cultured 
in Dulbecco‟s modified Eagle‟s medium with 4.5 g/L glucose and sodium pyruvate, 10% 
FBS, 1% non-essential amino acids, and 1% antibiotic/antimycotic.  Four different 
donors (Table 3.1) were used in order to minimize effects that could be due to variation 
between donors.  Medium was changed every 2-3 days (Note: FBS was pre-screened for 
the highest promotion of cell growth and collagen I, collagen III, and tenascin-C gene 
expression, with cell growth being the primary criteria).  Ascorbic acid (50 µg/ml) was 
added during feedings to the medium composition described above after cells were 
encapsulated into constructs. 
5.2.4 Cell Encapsulation in Constructs 
 For experiments involving encapsulated hMSCs, constructs were fabricated using 
low water content (75 wt% PBS) 100% LGPA hydrogels (see Table 4.1) with acrylated-
PEG GRGDS adhesion peptide at a concentration of (1 µmol GRGDS)/(g of hydrogel 
after swelling).  After the solutions were filter sterilized using a 0.2 µm filter, hMSCs 
were added at a concentration of 10 x 10
6
 cells/ml and the hydrogel solution was cross-
linked for 15 min using the same techniques described in section 3.2.4.  After fabrication, 
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the tensile constructs were placed into 6-well plates in culture medium and allowed to 
swell overnight.  After swelling, the time was designated as day 0. 
5.2.5 Tensile Culture 
 After equilibrium swelling was achieved, non-precultured constructs were used to 
produce a baseline cell-biomaterial environment (non-precultured baseline).  Constructs 
precultured for 21 days were used to produce an altered cell-biomaterial environment 
(precultured baseline).  After the preculture period, constructs were loaded into the tensile 
culture bioreactor for 24 hours of cyclic tensile loading (Fig. 5.1).  The cyclic loading 
regimen for these studies was chosen based on parameters previously used with this 
system to promote collagen expression and production.
125,171,172
  Specifically, constructs 
were maintained under a sinusoidal cyclic tensile strain regimen of 3 hours at 0% strain 
followed by 3 hours of 10% strain (5% offset, 5% amplitude) at 1 Hz.  This regimen was 
Figure 5.1.  Schematic of Tensile Culture Studies 
Sample Analysis (Before or After Mechanical Loading) 
Cell Number: PicoGreen (n≥5) 
Gene Expression: Real time RT-PCR (n≥8) 






















maintained for 24 hours.  Control hydrogels were loaded into a similar culture system, 
but held at 0% strain (static culture).  Culture medium was replaced every 2-3 days. 
5.2.6 Histology 
 Two groups of constructs were analyzed; non-precultured baseline constructs and 
precultured baseline constructs.  This analysis was used to confirm the absence or 
presence of relevant ECM proteins before mechanical stimulation.  After the respective 
cultures, end blocks were removed and the hydrogel portion of the constructs was cut in 
half using a scalpel.  One half was washed in PBS and the other half was set aside for 
other assays.  After washing in PBS, the hydrogels were fixed in formalin overnight.  
Samples were put into PBS for 20 minutes to wash out the formalin, then manually 
dehydrated using the following schedule.  70% dehydration alcohol overnight, 80% 
dehydration alcohol overnight, 90% dehydration alcohol overnight, 95% dehydration 
alcohol overnight, 100% dehydration alcohol overnight.  After dehydration samples were 
held under a -20 mmHg vacuum in paraffin for 4 hours to enhance penetration and 
embedded.  Paraffin-embedded hydrogels were cut into 10 µm sections and placed on 
glass slides.  IHC was performed on these sections for collagen I, collagen III, and 
tenascin-C (n=2).  Primary antibody binding to proteins of interest was accomplished 
using monoclonal IgG mouse anti-human antibodies.  Secondary antibody binding to 
primary antibodies was accomplished using polyclonal goat anti-mouse IgG antibodies 
conjugated to biotin.  Further amplification of signal was achieved using the Vectastain 
elite ABC peroxidase kit.  This amplification is achieved through an avidin conjugated 
horseradish peroxidase which binds to the biotinylated secondary antibody.  Sections 
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were exposed to DAB chromogen for 5 minutes to elicit a color change.  Negative 
controls included samples immunostained with the primary antibody omitted.   
5.2.7 Cell Number 
 Six groups of constructs were analyzed; non-precultured baseline constructs, 
precultured baseline constructs, non-precultured with cyclic tensile stimulation, 
precultured with cyclic tensile stimulation, non-precultured with static stimulation, and 
precultured with static stimulation.  After the respective cultures, end blocks were 
removed and the hydrogel portion of the constructs was cut in half using a scalpel.  One 
half was washed in PBS and the other half was set aside for other assays.  After washing, 
the wet weight of the hydrogel was recorded.  Hydrogel portions were mechanically 
disrupted using a pellet grinder (VWR) and suspended in 750 µl of distilled, deionized 
water (ddH2O).  To disrupt cells and release DNA into solution, samples were subjected 
to three cycles of freezing at -80°C for 1h, thawing at room temperature for 30 min., and 
sonicating for 30 min.  DNA content, which can be correlated to cell number, was 
determined (n≥5) by assaying the resulting supernatant via PicoGreen (Invitrogen) with 
lambda DNA used for standards (included in kit).  The PicoGreen assay uses the Hoescht 
33258 fluorophore which binds to double stranded DNA.  The fluorescent signal, which 
is proportional to the amount of double stranded DNA, was measured and compared to 
standards.  The results were normalized to the weight of the hydrogel after culture to 
account for potential differences in the mass of individual hydrogels.  Further details 
regarding the lab protocol used for this assay are found in appendix A.7. 
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5.2.8 Gene Expression 
 Six groups of constructs were analyzed; non-precultured baseline constructs, 
precultured baseline constructs, non-precultured with cyclic tensile stimulation, 
precultured with cyclic tensile stimulation, non-precultured with static stimulation, and 
precultured with static stimulation.  After the respective cultures, end blocks were 
removed and the hydrogel portion of the constructs was cut in half using a scalpel.  One 
half was washed in PBS and the other half was set aside for other assays.  After washing 
with PBS, the hydrogels were mechanically disrupted using a pellet grinder.  RNA was 
isolated from the hydrogels with the QiaShredder column (Qiagen).  Purification of RNA 
was achieved using the RNeasy mini kit (Qiagen).  cDNA was synthesized with 
Superscript III RT (Invitrogen) in the presence of a nucleotide mix (Promega, Madison, 
WI). 
 Amplification of cDNA through real time RT-PCR was performed using custom 
designed primers and SYBR Green.  The process was conducted and recorded using the 
StepOnePlus
TM
 Real-Time PCR System.  A cycle time (Ct) value for a given gene was 
determined based on when the amplification curve crossed a threshold value.  The 
threshold was set at the same value for all runs.  For statistical analysis, dCt values (cycle 
time for glyceraldehyde phosphate dehydrogenase (GAPDH) subtracted from the cycle 
time for the given gene) were used For statistical analysis, the number of transcripts for 
a given gene normalized to GAPDH was used (n≥8).  Data is represented normalized to 
GAPDH then to preculture for the given day using the ∆∆Ct method.  Genes examined 
included collagen I, collagen III, and tenascin-C as markers for ligament/tendon 
fibroblast gene expression.
11
  Primers were designed as described in previous chapters 
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(Sections 3.2.10 and 4.2.9).  Sequences for the forward and reverse primers used are 
listed in Table 3.2.  Further details regarding the lab protocol used for this assay are 
found in appendix A.10. 
5.2.9 Statistics 
 Results are reported as mean ± standard deviation.  A Box-Cox transformation for 
normality was used on dCt values of gene expression data.  Data were analyzed using a 
two-way ANOVA.  If both factors were significant, but interactions were not significant, 
a Tukey‟s post hoc test with significance set at p≤0.05 was used for pairwise 
comparisons.  If only one factor was significant and interactions were not significant one-
way ANOVAs were run on the significant factor with each level of the non-significant 
factor fixed.  A Tukey‟s post hoc test with significance set at p ≤ 0.05 was used for 
pairwise comparisons.  If interactions were significant, one way ANOVAs were run on 
the first (or second) factor with each level of the second (or first) factor fixed.  A Tukey‟s 
post hoc test with significance set at p ≤ 0.05 was used for pairwise comparisons.  For the 
cell number study and gene expression analysis, the factors were day and 























Figure 5.2.  Representative IHC images for collagen I, collagen III, or tenascin-C 
after no preculture (0d) or with preculture (21d) in 100% enzymatically-
degradable hydrogels with hMSCs.  Top two rows are at 20x.  Bottom two rows 
are at 40x.  Brown color indicates staining for the particular protein.  Arrow 
indicates pericellular staining. Inset of images are control sections where 
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 IHC staining indicated the presence of collagen I pericellularly in both non-
precultured and precultured constructs (Fig. 5.2A, D, G, J).  While, the level of staining 
for collagen I varied within sections, samples undergoing preculture appeared to stain 
more strongly for collagen I that non-precultured samples.  IHC staining indicated the 
presence of collagen III pericellularly after preculture (Fig. 5.2E, K), although the level 
of staining varied within sections.  No collagen III was detected without preculture (Fig. 
5.2B, H).  IHC staining indicated the presence of tenascin-C pericellularly in both non-
precultured and precultured constructs (Fig. 5.2C, F, I, L).  There did not appear to be a 
difference in the level of staining for tenascin-C between non-precultured and precultured 
constructs, although, like the other proteins, the level of staining for tenascin-C varied 
within sections.  Cells in IHC sections generally showed a spread morphology.  No 
staining was detected in negative control sections with the primary antibody omitted (Fig. 
5.2 insets), suggesting that neither the secondary antibody nor the Vectastain elite ABC 
peroxidase kit exhibited significant non-specific binding and that there was minimal 
endogenous staining from the contrast agent.  However it should be noted that no isotype 
control was used so the possibility of non-specific binding of the primary antibody can 
not be eliminated. 
5.3.2 Cell Number 
 No differences in DNA content/sample weight (an indicator of cell number) were 
seen between static constructs, tensile constructs, and baseline constructs under either 
preculture condition (Fig. 5.3).  However, a significant decrease in DNA content/sample 













5.3.3 Gene Expression 
Collagen I, collagen III, and tenascin-C gene expression was upregulated (Fig. 
5.4) in hMSCs in all precultured hydrogels compared to non-precultured samples.  
Collagen I gene expression levels were higher in static hydrogels after preculture 
compared to baseline samples while collagen I gene expression levels were lower in 
static and cyclic hydrogels without preculture compared to baseline samples.  Collagen 
III gene expression levels were significantly different in static hydrogels compared to 
baseline samples both before and after preculture.  Collagen III gene expression was also 
significantly different before preculture in static hydrogels compared to cyclic samples.  
Tenascin-C gene expression levels in static samples before preculture were significantly 
different compared to both baseline and tensile gene expression levels.  Tenascin-C gene 
expression was also significantly different after preculture in static and cyclic hydrogels 

















Figure 5.3.  DNA content of hMSCs 
normalized to sample weight of 100% 
enzymatically-cleavable hydrogels after 
preculture or 24h of static or tensile 
stimulation (n≥5 ±SD). p<0.05 compared 
























































































































Figure 5.4.  Collagen I, collagen III, and tenascin-C gene expression in hMSCs in 
100% enzymatically-degradable hydrogels before mechanical stimulation 
(baseline) or after 24h of static or tensile culture at the given time point (n≥8 ±SD).  
Top row: gene expression normalized to baseline of that group (non-precultured 
or precultured).  Bottom row: gene expression normalized to baseline values in the 
non-precultured group.  p<0.05 compared to non-precultured hydrogels(+).  
p<0.05 compared to baseline hydrogels(*).  p<0.05 compared to static 
















































































































































































 The enzymatically-degradable hydrogel system employed in this study provided a 
model system for elucidation of the effect of preculture on cellular responses to tensile 
stimuli.  The preculture period was successful in producing changes in the baseline ECM 
environment (Fig. 5.2) and the baseline gene expression response (Fig. 5.4) compared to 
non-precultured samples.  Interestingly, preculture was insufficient to produce 
upregulation of the examined genes after 24 hours of tensile culture compared to static 
controls, despite the changes in the cell-biomaterial environment. This is in agreement 
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with previous studies without preculture periods that have similarly shown no change in 




 While no difference was seen in gene expression of precultured samples in this 
study after 24 hours of tensile stimulation compared to static culture, MSC gene 
expression and protein production has been shown to be responsive to short-term cyclic 
loading in other studies using this tensile culture system.  Bovine MSCs under tensile 
strain after a preculture period have demonstrated upregulation of collagen II, aggrecan, 
sox-9, and collagen I gene expression after 3 hours of stimulation along with 
proteoglycan synthesis after 24 hours of stimulation.
208
  The upregulation of gene 
expression with this study, in contrast with results presented in this chapter, may be 
related to the different cell types, biomaterial environments, preculture periods, and genes 
examined. 
Other studies without preculture have shown modest collagen I and collagen III 
protein production and upregulation of collagen I, collagen III, and tenascin-C gene 
expression in hMSCs after 1 day of cyclic tensile strain.
209,210
  However, it should be 
noted that these studies strained cells in a 2D environment which may explain the 
differences in cell responses, as ligament/tendon gene expression can have diverse 
regulation patterns in 2D compared to 3D environments.
179
  The ECM environment, 
especially collagen, has been found to play an important role in the gene expression of 
mesenchymal cell types
211
 and their differentiation responses.
212
  The gene expression of 
MSCs under cyclic tensile strain has also been affected depending on whether the cells 
were cultured on a collagen substrate or an elastin substrate
209
 which suggests that 
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changes in the ECM environment can influence cellular responses to mechanical loading.  
A well-defined biomaterial environment, such as the one employed in this study, could 
facilitate the controlled studies required to further elucidate the interaction of the diverse 
effects of differences in biomaterial biochemistry and substrate material properties on 
cellular differentiation in 3D.   
 Similarly, further studies are required to determine whether a period of tensile 
stimulation that is longer than 24 hours, but shorter than the multi-week stimulation 
normally required for upregulation, can facilitate upregulation of relevant gene 
expression after a static preculture period in 3D constructs such as those used in these 
studies.  These studies could provide further insight into possible interactions between 
changes in the extracellular environment and tensile stimulation.  However, conclusions 
drawn from such studies may need to be limited as there are a number of potential 
changes in the cell-biomaterial environment that can occur during preculture including 
differentiation of cells, changes in gene expression regulation, degradation of the 
biomaterial carrier, and changes in cell shape over time.  These factors provide a complex 
network of stimuli that have the potential to influence cellular responses in diverse ways.  
As a result, if an interaction between preculture and mechanical stimulation is discovered, 
further characterization of the changes that occur in the extracellular environment during 
preculture may be required to understand the mechanism behind this interaction. 
 When developing outcome measures for future studies, scleraxis may be an 
important gene to consider evaluating.  Scleraxis is a transcription factor involved in 
ligament development that has been upregulated in hMSCs after 1d of cyclic strain while 
collagen I and collagen III upregulation occurred at later time points.
179
  The early 
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upregulation of scleraxis compared to other relevant ligament/tendon genes suggests that 
it may respond to differentiation stimuli before other markers of a ligament/tendon 
fibroblast phenotype and thus may be an important gene to examine in future short-term 
loading experiments. 
 The production of collagen III seen (Fig. 5.2) was a confirmation of findings in 
previous studies (Fig. 4.11) that showed the presence of collagen III on day 21 in 100% 
enzymatically-cleavable hydrogels, but no staining for collagen III by day 1.  In contrast 
to collagen III, tenascin-C showed similar matrix production at both time points in this 
study.  Cell spreading seen in IHC sections contrasted with the generally round 
morphology seen in previous studies (Fig. 3.5 and 4.11).  The contrast in cell shape seen 
in this work compared to previous work may be related to a) the use of enzymatically-
degradable hydrogels in this study facilitating the creation of space for cells to spread 
(compared to chapter 3) and b) the use of larger hydrogel constructs (compared to chapter 
4) which may have reduced the kinetics of diffusion of cell-produced MMPs or other 
enzymes out of the gel and therefore facilitated localized degradation.  More work is 
needed to rigorously examine these possibilities. 
 That lack of changes in DNA content (Fig. 5.3) in response to culture conditions 
confirm that the short-term strain regimens used in this study do not affect cell number, in 
agreement with previous results.
133,207
  However, a decrease in cell number was seen due 
to culture time.  The high viability seen at day 21 in similar constructs (Fig. 3.3 and 4.7) 
suggests that the decrease in cell number is not due to cell death.  An alternative 
explanation is that cells are migrating from the hydrogels (either the surface or interior) 
and are preferentially adhering to the surrounding tissue culture wells by day 21.  The 
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presence of adherent cells in tissue culture wells containing hydrogel samples has been 
seen at earlier time points, but not at later time points (visual observation) which provides 
support of this possibility.  The absence of changes in cell number in similar hydrogels 
over time (Fig. 4.7) may be due to the relative size differences between the constructs.  
Smaller hydrogels (such as samples in chapter 4) will have proportionately greater 
surface areas than larger samples.  The lower height of small constructs along with the 
relatively larger surface area may provide greater opportunity for cells to leave the 
surface of small hydrogels and thus facilitate a faster migration of cells to the tissue 
culture surfaces.  However, the possible migration of cells the hydrogels was not 
measured so the reason for the decreased cell number seen in larger constructs can not be 
confirmed. 
5.5 Conclusions 
 This study provides one of the first examinations of responses to tensile stimuli in 
relation to preculture for ligament/tendon tissue engineering applications.  Evidence was 
provided suggesting that a 21 day preculture period was not sufficient to promote 
upregulation of ligament/tendon matrix protein gene expression in hMSCs after short-
term, 24 hour tensile stimulation.  Tensile stimulation periods longer than 24 hours 
appear to be required for ligament/tendon tissue engineering strategies that seek to 
promote upregulation of relevant ligament/tendon fibroblast gene expression in hMSCs.  
Questions still remain as to whether preculture can promote ligament/tendon fibroblast 
phenotypic upregulation in hMSCs in conjunction with longer periods of tensile strain.  If 
tensile strain does interact with preculture to promote changes in gene expression, 
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additional work will be required to further characterize changes that occur during the 




CONCLUSIONS AND RECOMMENDATIONS 
6.1 Summary 
 Ligament/tendon tissue engineering has the potential to provide therapies that 
overcome the limitations of incomplete natural healing responses and inadequate graft 
materials.  Finding a suitable cell type and biomaterial environment for current tissue 
engineering strategies are some of the challenges that still remain to be resolved.  While 
ligament/tendon fibroblasts are an obvious choice of cell type for these applications, 
difficulties associated with the availability of cell sources have limited their utility.  
MSCs are seen as a viable alternative since they can be harvested through routine medical 
procedures and can be differentiated toward a ligament/tendon fibroblast lineage.  Tensile 
stimulation is one common method employed to differentiate MSCs toward a 
ligament/tendon fibroblast phenotype.  However, further study is needed to create a 
biomaterial/mechanical environment for ligament/tendon fibroblastic differentiation.  The 
overall goal of this dissertation was to improve the understanding of the role that 
biomechanical stimulation and the biomaterial environment play, both independently and 
combined, on hMSC differentiation toward a ligament/tendon fibroblast phenotype.  
Specifically, the effects of cyclic tensile stimuli were studied in a biomaterial 
environment that provided controlled presentation of biological moieties.  The influence 
of an enzymatically-degradable biomaterial environment on hMSC differentiation was 
investigated by creating hydrogels containing enzymatically-cleavable moieties.  The role 
that preculture may play in tensile responses of hMSCs was also explored.  Together, 
these studies provided insights into the contributions of the biomaterial environment and 
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the biomechanical environment to hMSC differentiation toward a ligament/tendon 
fibroblast phenotype. 
 The studies presented in chapter 3 investigated the effects of cyclic tensile loading 
on hMSCs in an OPF-based biomaterial.  The OPF biomaterial provided a hydrogel 
environment with well controlled presentation of bioactive moieties.  In response to 
cyclic tensile strain, upregulation in gene expression of major ligament/tendon ECM 
proteins was seen.  Specifically, upregulation of collagen III and tenascin-C gene 
expression was observed by day 21 and upregulation of collagen I was detected by day 7.  
In addition, the production of collagen I and tenascin-C matrix proteins were detected 
with greater staining for tenascin-C seen in cyclically strained constructs on day 21.  
These results indicated that ligament fibroblast phenotypic changes were induced in 
hMSCs due to cyclic tensile strain.  Interestingly, upregulation of these genes was also 
seen in static constructs over time, which suggested that medium conditions and the 
biomaterial environment could promote some degree of phenotypic change even in the 
absence of tensile strain.  No staining for collagen III was detected in either cyclically 
strained constructs or static samples, which suggested that additional cues were needed to 
facilitate hMSC differentiation.  Additional tensile experiments on laminated hydrogel 
scaffolds provided a proof-of-concept for possible future side-by-side co-culture studies 
involving tensile stimulation. 
 The studies in chapter 4 explored the effects of an enzymatically-cleavable 
biomaterial environment on hMSCs.  Enzymatically-cleavable sequences that are 
believed to be susceptible to MMPs were introduced into the biomaterial system and 
provided the bioactive motifs needed to facilitate local cleavage of bioactive sequences.  
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hACL fibroblasts served as controls to provide an estimate of the degree to which hMSCs 
had achieved a ligament fibroblast phenotype.  Upregulation of gene expression levels of 
collagen I, collagen III, and tenascin-C along with protein production in hydrogels with 
enzymatically-cleavable motifs suggested that the enzymatically-cleavable biomaterial 
carriers facilitated the development of a ligament/tendon fibroblast phenotype in hMSCs.  
However, gene expression in hMSCs did not reach the levels seen in hACL fibroblasts, 
suggesting that the biomaterial cues were not sufficient to fully differentiate hMSCs over 
21 days of culture.  Characterization of cell surface markers of hMSCs before and after 
experimentation may be important for further confirmation of their differentiation state.  
Perhaps the most interesting finding in chapter 4 was that hMSCs and hACL fibroblasts 
responded differently to the enzymatically-cleavable hydrogels.  hMSCs generally 
showed upregulation and hACL fibroblasts generally showed downregulation of relevant 
gene expression in the presence of enzymatically-cleavable peptides compared to non-
enzymatically cleavable sequences.  This data provided evidence that the biomaterial 
environment needed for hMSC differentiation may be different from the biomaterial 
environment needed for culture of hACL fibroblasts.  
 The studies in chapter 5 examined the effect of a 21 day preculture period on the 
response of encapsulated hMSCs to short-term tensile strain (24 hours).  hMSCs were 
encapsulated in enzymatically-cleavable hydrogels and either precultured for 21 days or 
were not precultured.  Baseline changes in the extracellular environment that were 
observed in precultured compared to non-precultured samples included changes in gene 
expression of collagen I, collagen III, and tenascin-C and differences in ECM proteins 
produced.  Despite these changes in the extracellular environment after preculture, gene 
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expression levels of hMSCs in hydrogels under 24 hours of cyclic tensile strain remained 
similar to static constructs.  The results of this study suggested that preculture does not 
influence the response of encapsulated hMSCs to short-term tensile strains.  Overall the 
findings in this dissertation provided a significant elucidation of the roles that 
biomechanical cues and the extracellular environment play in the promotion of a 
characteristic ligament/tendon fibroblast gene expression and protein production profile 
in hMSCs. 
6.2 Conclusions 
 In addition to confirming the responsiveness of hMSCs to tensile loading, the 
studies in this dissertation demonstrated the feasibility of this novel system for 
examination of cellular differentiation under tensile loading in response to controlled 
physicochemical changes in the extracellular environment.  In chapter 3, the upregulation 
of collagen I, collagen III, and tenascin-C gene expression in cyclic constructs compared 
to static samples by day 21 suggested that, under the loading conditions chosen, cyclic 
strain promoted a ligament/tendon fibroblastic phenotype in hMSCs by 21 days.  This 
was in agreement with previous studies that have employed three-dimensional 
constructs.
11,100,213
  While, an enzymatically-cleavable biomaterial environment also 
appeared to promote a ligament fibroblast phenotypic response in hMSCs (Fig. 4.9), 
tensile strain appears to be the more potent stimulus. 
 Collagen I gene expression generally correlated with pericellular matrix 
deposition in enzymatically-cleavable hydrogels (Fig. 4.11, 5.2) with enzymatically-
cleavable sequences correlating with an apparent increase in the levels of collagen I 
proteins produced by hMSCs.  In cyclically cultured hydrogels little collagen III staining 
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was observed at day 21, despite upregulation of collagen III expression levels.  This lack 
of collagen III protein production may be related to the non-degradable biomaterial 
environment used in chapter 3 studies, as work in chapter 4 showed collagen III protein 
production in statically cultured enzymatically-degradable hydrogels at day 21 even 
without tensile strain (Fig. 4.11).  Similar to the results seen in chapter 3, no collagen III 
protein production was detected in non-degradable hydrogels or at day 1 for any hydrogel 
type (Fig. 4.11).  Taken together, these results suggest that the biomaterial environment 
had a significant role in the ability of hMSCs to produce collagen III even in the absence 
of tensile strain stimuli.  Specifically, it appears that a hydrogel system that is responsive 
to cell-mediated degradation (such as our enzymatically-cleavable hydrogels) can 
facilitate the production of collagen III ECM.  Previous reports demonstrated collagen III 
production in response to cyclic strains when MSCs were cultured in collagen I gels,
11,100
 
providing further evidence of the ability of the biomaterial environment to affect collagen 
III production.  These studies provided insights into the importance of both cyclic strain 
and the biomaterial environment in gene expression and protein production.  Since 
collagen is the largest component of the ligament/tendon ECM,
1,12,15
 systems the promote 
upregulation of collagen gene expression and protein production, similar to the ones used 
in these studies, may be important for production of tissue engineered ligaments and 
tendons.  Early collagen III production may be especially important for strategies that 




 Tenascin-C is another important protein to examine in ligament/tendon tissue 
engineering.  This protein is often expressed in organogenesis, but generally disappears 
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or decreases in prevalence in fully developed organs,
214
 although it maintains a high 
expression at insertion sites of ligaments and tendons to bone.
192
  Tenascin-C is generally 
regarded as an anti-adhesive protein as it prevents the adhesion of cells, including 
fibroblasts, to fibronectin.
215
  However, tenascin-C interacts with different cell types in 
diverse ways and can actually promote adhesion in some cell types.
214
  In this work, 
tenascin-C generally appeared to be localized pericellularly, similar to developmental 
expression patterns.
192
  Biomaterial and biomechanical environments both appeared to 
affect tenascin-C production.  Cyclic culture increased the production of tenascin-C 
compared to static controls (Fig. 3.5B and 3.5E).  In addition, enzymatically-cleavable 
hydrogels allowed tenascin-C production by day 21 in static culture, whereas this was not 
found in non-cleavable hydrogels (Fig. 4.11).  Taken together these results suggest that 
tensile culture and enzymatically-degradable environments both improve the production 
of tenascin-C by encapsulated hMSCs.  Since tenascin-C is mainly present at insertion 
sites of ligament/tendon,
192
 approaches that target tenascin-C expression to well-defined 
areas of a biomaterial construct may be needed to produce fibrous ligament tissues and 
their insertion sites.  The laminated constructs described in chapter 3 of this dissertation 
are a hydrogel system that can provide regional differences in biomaterial properties in 
one unified construct.  Thus, these laminated hydrogel biomaterials could provide a 
valuable system to facilitate production of tissue engineering ligaments/tendons that are 
well integrated with their insertion sites.  Overall, culture methods that encourage 
upregulation of gene expression and protein production of collagen I, collagen III and 
tenascin-C, similar to our system, show promise as techniques for tissue engineering of 
ligaments and tendons. 
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 Chapter 4 investigated the effect of cell-mediated degradation through the use of a 
biomaterial environment containing enzymatically-cleavable peptides.  In addition to 
promoting changes in gene expression, enzymatically-cleavable hydrogels also seemed to 
facilitate the production of ECM proteins (Fig. 4.13), in agreement with previous results 
using synthetic enzymatically-cleavable hydrogels.
197,198
  Natural scaffolds made of 
collagen I possess the enzymatically-cleavable motifs that are used in synthetic 
enzymatically-cleavable hydrogels so similar patterns of protein production would be 
expected.  While some studies with collagen I scaffolds with hMSCs in static culture 
have shown collagen III protein production,
100
 other studies using collagen I scaffolds 
with bMSCs have shown minimal collagen III production.
11
  Since responses to 
enzymatically-degradable environments appear to vary with the cell type used, the 
minimal collagen III production by bMSCs may be related to that specific cell type.  The 
matrix production that has been seen in our system and in other studies is likely related to 
degradation of the scaffold, as increased degradation of hydrogel biomaterials has been 
linked to greater ECM production,
101
 although other factors could also play a role.  
Collagen I and collagen III ECM has also been produced by hMSCs in synthetic PLLA 
scaffolds.
193
  While the PLLA scaffolds have limited degradability, void space in the 
constructs is made available by the knitted pattern which creates a macroporous structure.  
This void space may facilitate ECM production even in the absence of degradation.  
Overall, this data suggested that ECM production could be facilitated though the use of 
enzymatically degradable sequences in the biomaterial carrier. 
 The data presented in chapter 5 suggested that preculture does not influence the 
response of encapsulated hMSCs to short-term tensile strains in our hydrogel system.  
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The presence of preculture (0 days vs. 21 days preculture) did not appear to have an 
effect on cellular responses to tensile strain as hMSCs in constructs under tensile strain 
for 24 hours showed similar gene expression levels of collagen I, collagen III, and 
tenascin-C compared to static samples (Fig. 5.4).  While 24 hours of tensile culture was 
insufficient to produce upregulation of the examined genes, it is possible that a longer 
period of stimulation could produce upregulation in conjunction with a preculture period.  
hMSCs generally showed upregulation of collagen I, collagen III, and tenascin-C at day 
21 compared to day 1, confirming that static culture alone can produce upregulation of 
relevant ligament/tendon ECM gene expression over 21 days in this biomaterial system 
although not at the same levels as tensile strain.   
 An unexpected finding that arose out of comparisons in chapter 4 between hMSCs 
and hACL fibroblasts was the difference in gene expression across enzymatically-
cleavable biomaterial environments (Fig. 4.9).  While some upregulation of collagen I, 
collagen III, and tenascin-C was seen with hMSCs in enzymatically-cleavable hydrogels, 
an opposite trend was seen in hACL fibroblasts with upregulation seen in non-cleavable 
hydrogels.  This data suggested that the ideal biomaterial environment for hMSC 
differentiation toward an hACL fibroblastic phenotype may be different from the 
biomaterial environment needed to promote matrix production by hACL fibroblasts.  
Further analysis of the ECM produced by both cell types after culture in these gels will be 
needed to confirm this.  The enzymatically-cleavable hydrogels employed in this 
dissertation have great potential to take advantage of this information by adapting the 
biomaterial environment to the changing needs of differentiating cells – i.e. by harvesting 
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cells from a degraded enzymatically-cleavable hydrogel and re-encapsulating in a new 
biomaterial environment.   
6.3 Future Directions 
 The findings in this dissertation elucidated the roles that biomechanical 
stimulation and extracellular cues play, both independently and combined, on hMSC 
differentiation toward a ligament/tendon fibroblast phenotype.  Significant study is still 
required to provide further understanding of how these types of factors interact to affect 
hMSC differentiation responses. 
 While preculture did not influence cellular responses to short-term (24 hours) 
cyclic tensile strains, it remains unclear whether hMSC responses to longer periods of 
strain may be influenced by preculture.  No upregulation of relevant gene expression was 
seen due to short-term tensile strains, but work in chapter 3 showed that up to 21 days of 
cyclic tensile strain can be required to promote gene expression responses in hMSCs.  
Therefore, encapsulated cells may require periods of strain longer than 24 hours to 
provoke changes in gene expression in response to a preculture period.  Similar 
experiments involving static preculture periods that expose encapsulated hMSCs to 
longer (~7d-14d) tensile strain periods would provide a significant advancement in the 
understanding of the impact of the timing and duration of cyclic tension stimulation on 
hMSCs. 
 In addition to the cell-produced ECM environment, studies that investigate 
whether “priming” of hMSC gene expression plays a role in responses to tensile strain 
could also prove instructive.  As shown in chapter 3 and chapter 4, over time 
encapsulated hMSCs can upregulate collagen I, collagen III, and tenascin-C gene 
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expression in constructs that are cultured without tensile strain.  While this upregulation 
did not reach the same levels seen with tensile stimulation it did attain statistical 
significance.  Since 21 days of culture were required before cyclic tensile strain promoted 
changes in collagen III and tenascin-C gene expression, it is possible that early weeks of 
tensile culture did not produce any effects, but allowed a temporal upregulation of 
relevant gene expression.  Once gene expression reached a sufficient level it may have 
become more susceptible to tensile strain stimuli and manifested this sensitivity with 
upregulation of gene expression in response to biomechanical perturbations.  Studies that 
employ various preculture periods to produce different levels of gene expression for 
relevant genes could elucidate the role of already present gene expression patterns in 
tensile strain responses.  One complicating factor is that different ECM environments 
would also be produced during this preculture time.  The effects of these two influences 
could be decoupled by culturing cells in enzymatically-degradable hydrogels and 
harvesting the cells from degraded hydrogels after preculture.  In this way, cells whose 
gene expression profiles were “primed” with different lengths of preculture could be 
reintroduced into new biomaterial environments without cell-produced ECM proteins.  
Future studies that create different gene expression patterns and reintroduce the cells into 
new biomaterial environments exposed to tensile culture would be valuable in elucidating 
the role that these patterns play on responses to biomechanical perturbations. 
 While the production of a certain external environment may be needed before 
hMSCs can respond to tensile stimulation, an alternative hypothesis is that tensile 
stimulation directly influences cell responses during the entire tensile period, but that 
phenotypic changes measured in these studies are downstream effects that take weeks to 
 123 
manifest.  It is known that cells respond to mechanical strains through a number of 
mechanisms including stretch induced ion channels, integrin-dependant signaling, and 
cytoskeletal tensegrity.
216
  Mechanical regulation can also occur through signal 
transduction pathways such as those mediated by Rho kinase, ERK1/2, and MAP kinase 
cascades.
217
  It is probable that known mechanisms of mechanotransduction are important 
in the cellular responses seen in these studies.  Interference with these signaling 
mechanisms could potentially block the phenotypic changes that were observed.  
Disruption of these pathways during the first week of tensile stimulation would be 
expected to prolong the time needed to manifest phenotypic changes only if tensile strain 
at the early time periods were an important part of cell responses at later time periods.  
Gadolinium and streptomycin, cytochalasin and phallotoxin, and Y-27632 are potential 
agents for that could be used for inhibition of mechanotransduction pathways.  These 
inhibitors block stretch activated ion channels, actin cytoskeletal assembly and 
disassembly, and Rho kinase activity, resepectively.
216,218
  Use of these inhibitors in 
future studies that disrupt known mechanotransduction pathways at early time points 
could help to elucidate the necessity of tensile strain in early phases of culture.  In 
addition, these inhibitors could aid in the understanding of the role of 
mechanotransduction through these specific pathways in hMSC responses to tensile 
stimulation. 
 Transcript levels of collagen I, collagen III, and tenascin-C gene expression seen 
in hMSCs in cyclically strained constructs (chapter 3), reached the same levels measured 
in hACL fibroblasts in static culture in similar biomaterial environments (chapter 4).  
Increases in transcript levels were also seen with hMSCs in response to enzymatically-
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cleavable biomaterial environments, although they did not reach the levels achieved 
through tensile stimulation.  It is unclear whether these gene expression responses are 
facilitated by differentiation of hMSCs to a ligament fibroblast cell type or if 
upregulation is achieved through mechanical stimulation without a differentiation 
response.  Probing of cell surface markers associated with MSCs along with examination 
of adipogenic, osteogenic, and chodrogenic potential, according to established 
protocols,
219,220
 could help elucidate the level of differentiation of MSCs in response to 
extracellular cues and biomechanical stimuli.  Probing for cell surface markers associated 
with ligament/tendon fibroblast cells would also be valuable, although further study is 
required to establish cell surface markers for this cell type.  In addition, probing for 
surface markers associated with non-ligament/tendon fibroblast mesenchymal cell 
lineages could provide indirect evidence of levels of ligament/tendon fibroblastic 
differentiation.  These studies would be facilitated by the ability to harvest cells after 
encapsulation in enzymatically-cleavable biomaterials, such as the ones used in this 
dissertation, by using collagenase to degrade the biomaterial matrix. 
 Results obtained through the studies in chapter 4 suggested that the optimal 
biomaterial environment for differentiation of hMSCs may be different from the optimal 
biomaterial environment for culture of hACL fibroblasts.  The enzymatically-degradable 
hydrogels employed in those studies provide a valuable system that can be used to adapt 
the biomaterial environment in response to these differences.  After differentiation of 
hMSCs is achieved in an enzymatically-degradable biomaterial environment, the cells 
can be harvested by degrading the hydrogel in collagenase.  The differentiated cells can 
then be cultured in a new biomaterial environment.  Thus, the enzymatically-degradable 
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hydrogel system may be a useful tool in future studies that adapt the biomaterial 
environment to the changing needs of encapsulated stem cells as they differentiate. 
 In addition to applications that involve the harvesting of encapsulated cells, an 
enzymatically-degradable hydrogel system, similar to the one used in this dissertation, 
may be a useful tool in studies that harvest ECM proteins produced by encapsulated cells.  
It should be noted that for harvesting of collagenous ECM environments, such as those 
produced by MSCs and ligament/tendon fibroblasts, a degradable hydrogel system 
susceptible to enzymes that don‟t target collagenous matrix proteins would need to be 
used.  One possible application would involve growing hMSCs in an ECM environment 
produced by encapsulated ligament/tendon fibroblasts.  An ECM microenvironment 
produced by ligament/tendon fibroblasts has the potential to provide differentiation cues 
for hMSC induction toward a ligament/tendon fibroblast phenotype.  This ECM 
microenvironment could be produced by culturing the ligament/tendon fibroblasts in 
enzymatically-degradable hydrogels.  After production of relevant proteins was 
accomplished, the ECM could be harvested by degrading the hydrogels, thus releasing 
the encapsulated proteins.  hMSCs would then be encapsulated in new hydrogels with the 
harvested proteins.  Thus, the enzymatically-degradable hydrogel system may be a 
valuable tool in future studies that seek to explore hMSC differentiation through exposure 
to a ligament/tendon fibroblast-produced ECM environment. 
 The biomaterial/biomechanical system employed in this dissertation provides a 
versatile scaffold-bioreactor system for the study of the effects of the local ECM 
environment and mechanical loading on cellular differentiation.  The ability to 
incorporate specific ECM moieties makes this an attractive system for controlled studies 
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to tease out the independent effects of various key ECM components in cellular responses 
to tensile strain.  Enzymatically-degradable peptides are useful tools for a variety of 
applications and can be employed to create a biomaterial environment that can be 
targeted for cell-mediated degradation, or, depending on the exact sequence, can allow 
for harvest of cells post-culture using exogenous enzymes.  Future studies similar to the 
experiments presented in this work could provide significant advances in the 





A.1 OPF Synthesis 
Fumaryl Chloride (FuCl) Distillation (if necessary) 
Warning: Fumaryl chloride has a very pungent odor.  Work only in the fume hood with 
the sash down as far as possible.  Double glove, and leave jars, glassware, used gloves in 
the hood overnight to air out.   
1. Wash and dry:  
2 x 500 ml round-bottom flasks,  
1 x joint for thermometer,  
1 x thermometer to fit joint (~160°C),  
1 x large condenser,  
1 x glass elbow,  
1 x joint for desiccators,  
1 x glass stopper,  
1 x glass funnel,  
1 x egg-shaped FuCl stir bar.   




3. Replace the 500 ml collection flask with a 100 ml round bottom flask to collect 
the first 30 ml of distillate.   
4. Clamp the apparatus to the scaffolding in the back of the fume hood.  
5. Vacuum grease and clamp all connections.   
6. Run cold, ice water UP the condenser tube using the circulation pump. This 
allows any bubbles to flow up and out of the condenser.  Make sure that the 
circulation pump is not actively heating the water by turning the temperature 
control all the way down to -20°C. 
7. Tie a KimWipe around the bottom of the condenser to catch external 
condensation.  
8. Use the funnel to pour 150 ml (100 g) of FuCl into a 500 ml round-bottom flask.   
9. Add the FuCl stir bar into the FuCl flask.   
10. Vacuum grease the FuCl flask, and connect the flask to apparatus.   
11. Place the flask in heating mantle with magnetic stirring at ~3.   
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12. Insulate the flask and neck with glass wool all the way up to the condensing tube 
to promote boiling and prevent condensation.   
13. Start the transformer at 40 units.   
14. Increase the transformer by 10 units, every 5 minutes.   
15. Increase the transformer until the vapor temperature is 160°C (~80 units on 
transformer).   
16. Dispose of the first ~30 ml of distillate by turning the neck up, removing the 1st 
100 ml collection flask, and quickly replacing it with a clean 500 ml round-
bottom flask.  
17. FuCl distillate should be a light amber color.   
18. The solution in the heated FuCl flask will become darker and more viscous.   
19. When ~50-75 ml remains the heated FuCl flask and the solution is dark brown, 
turn off the transformer, remove the glass wool, turn the condenser off, and 
replace the heating mantle with a cork ring.  
20. Stopper the FuCl distillate, parafilm the stopper, cover the flask with aluminum 
foil, and label it.   
21. Store the distillate in the 4°C explosion-proof refrigerator.   
22. Dilute the FuCl waste with tap water, and leave it in the hood overnight.  Be 
careful of HCl production in the reaction with water, and pour the water in 
SLOWLY.   
23. On the next day, use a spatula to break up the FuCl waste, retrieve the stir bar, and 
disposed of the waste in the aqueous waste container.   
24. Glassware can be cleaned with acetone and the base bath.  
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Methylene Chloride (MeCl) Distillation 
Warning: Use nitrile or silver-shield gloves when handling MeCl. 
1. Wash and dry:  
1 x 1000 ml round-bottom flask,  
1 x joint for thermometer,  
1 x thermometer to fit joint (~40°C),  
1 x large condenser,  
1 x glass elbow,  
1 x joint for desiccators,  
1 x glass stopper,  
1 x glass funnel.   




3. Replace the 500 ml collection flask with a 100 ml round bottom flask to collect 
the first 30 ml of distillate. Clamp the apparatus to the scaffolding in the back of 
the fume hood.  
4. Vacuum grease and clamp all connections.   
5. Run cold, ice water UP the condenser tube using the circulation pump. This 
allows any bubbles to flow up and out of the condenser.  Make sure that the 
circulation pump is not actively heating the water by turning the temperature 
control all the way down to -20°C. 
6. Tie a KimWipe around the bottom of the condenser to catch external 
condensation.  
7. Use funnel to add 750 ml of MeCl and calcium hydride (CaH2, if needed) into the 
existing MeCl + CaH2 flask.   
8. Vacuum grease the MeCl flask, and connect the flask to apparatus.   
9. The MeCl + CaH2 flask already contains a stir bar.  Place the flask in heating 
mantle with magnetic stirring at ~4.   
10. Insulate the flask and neck with glass wool all the way up to the condensing tube 
to promote boiling and prevent condensation.   
11. Set the transformer to 35 units.   
12. Vapor temperature should increase to ~40°C.   
13. Dispose of the first ~30 ml of distillate by turning the neck up, removing the 1st 
collection flask, and quickly replacing it with a clean 1000 ml round-bottom flask.  
14. When ~150-200 ml remains in the heated MeCl flask, turn off the transformer, 
remove the glass wool, turn the condenser off, and replace the heating mantle 
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with a cork ring.  You should have ~500 ml MeCl distillate in your collection 
flask (need 340-380 ml for remaining steps).  
15. Vacuum grease the glass stopper, and stopper the MeCl distillate, and label it.   
16. Store the anhydrous MeCl distillate in the hood overnight.  Do not parafilm the 
stopper.   
17. Vacuum grease the original MeCl + CaH2 stopper, stopper the undistilled MeCl + 
CaH2, and store it in the back of the hood.   
18. Dispose of the MeCl waste in the chlorinated organic solvents waste container.   
19. Glassware can be dried in the hood, and then cleaned normally.  
Azeotropic Distillation of PEG 
Warning: Use nitrile or silver-shield gloves when handling toluene.  
1. Wash and dry:  
1 x 500 ml or 1000 ml round-bottom flask,  
1 x Dean stalk,  
1 x condenser,  
1 x glass stopper,  
1 x Kontes #2  glass valve with LARGE hole,  
1 x egg-shaped stir bar, 
1 x glass funnel,  
1 x 250 ml glass graduated cylinder.   
2. Set up the distillation apparatus as shown, without the PEG/toluene flask: 
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3. Clamp the apparatus to the scaffolding in the back of the fume hood.  
4. Vacuum grease and clamp all connections.   
5. Run cold, ice water UP the condenser tube using the circulation pump. This 
allows any bubbles to flow up and out of the condenser.  Make sure that the 
circulation pump is not actively heating the water by turning the temperature 
control all the way down to -20°C. 
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6. Tie a KimWipe around the bottom of the condenser to catch external 
condensation.  
7. Weigh 50 g PEG 3.4K or 10K in the 500 ml round-bottom flask.  
8. Use the graduated cylinder and funnel to add 200 ml of toluene to the PEG in the 
500 ml flask.   
9. Add the stir bar to the flask, vacuum grease the flask, and connect the flask to 
apparatus.   
10. Place the flask in heating mantle with magnetic stirring at ~5.  The PEG will 
dissolve with stirring and heating.  
11. Insulate the flask and neck with glass wool all the way up to the condensing tube 
to promote boiling and prevent condensation.   
12. Set the transformer to 65 units.   
13. When the Dean stalk fills to 20 ml, dispose of the toluene by draining the solution 
from the Dean stalk into a 250 ml waste beaker. The first few batches of waste 
may be partially cloudy, while others should be clear.   
14. Repeat step 13 seven more times, removing 20 ml toluene at a time until ~160-
180 ml toluene has been removed.  
15. Turn off the transformer, remove the glass wool, turn the condenser off, and 
replace the heating mantle with a cork ring.  2-5 ml extra toluene waste may 
condense as you do this.   
16. Allow the distilled PEG and toluene to cool, and then vacuum grease the glass 
stopper and stopper the distilled PEG.  Parafilm the stopper, and label the flask.   
17. Store the distilled PEG in the hood overnight.  The PEG will solidify as it cools.   
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18. Dispose of the toluene waste in the nonchlorinated organic solvent waste 
container.   
19. Glassware can be dried in the hood, and cleaned normally.  
OPF Reaction 




PEG MW = 3,400 Da 
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50 g PEG = 0.01471 mol PEG 
1 PEG : 0.9 FuCl  10% molar excess for PEG addition to ends of FuCl 
(0.9 mol FuCl / mol PEG) * (0.01471 mol PEG) = 0.01324 mol FuCl 
FuCl MW = 153 g/mol 
(0.01324 mol) * (153 g/mol) = 2.025 g FuCl 
FuCl density = 1.415 g/ml 
(2.0235 g) / (1.415 g/ml) = 1.431 ml FuCl 
 
1 FuCl : 2 TEA  TEA removes Cl from ends of FuCl, 2 Cl per FuCl  Twice as much 
TEA as FuCl 
(2 mol TEA / mol FuCl) * (0.01324 mol FuCl) = 0.02648 mol TEA 
TEA MW = 101.2 g/mol 
(0.02648 mol) * (101.2 g/mol) = 2.6798 g TEA 
TEA density = 0.726 g/ml 
(2.6798 g) / ( 0.726 g/ml) = 3.6912 ml TEA 
 
10K Calculations: 
PEG MW = 10,000 Da 
50 g PEG = 0.005 mol PEG 
1 PEG : 0.9 FuCl  10% molar excess for PEG addition to ends of FuCl 
(0.9 mol FuCl / mol PEG) * (0.005 mol PEG) = 0.0045 mol FuCl 
FuCl MW = 153 g/mol 
(0.01324 mol) * (153 g/mol) = 0.6885 g FuCl 
 137 
Density FuCl = 1.415 g/ml 
(0.6885 g) / (1.415 g/ml) = 0.4866 ml FuCl 
1 FuCl : 2 TEA  TEA removes Cl from ends of FuCl, 2 Cl per FuCl  Twice as much 
TEA as FuCl 
(2 mol TEA / mol FuCl) * (0.0045 mol FuCl) = 0.009 mol TEA 
TEA MW = 101.2 g/mol 
(0.009 mol) * (101.2 g/mol) = 0.9108 g TEA 
TEA density = 0.726 g/ml 
(0.9108 g) / ( 0.726 g/ml) = 1.2545 ml TEA 
 
1. Wash and dry:  
1 x 1000 ml 3-arm round-bottom flask,  
2 x 60 ml dropping funnels,  
1 x joint for the N2 balloon,  
1 x PTFE valve for the N2 balloon,  
2 x Kontes #2 glass valves with LARGE holes,  
2 x glass stoppers, 
1 x 250 ml or 1000 ml glass graduated cylinder. 
2. Use the funnel and graduated cylinder to add 320 ml MeCl to the distilled 
PEG/toluene.  Dissolve PEG with stirring.   
3. Use the funnel to pour the PEG/MeCl into the 3-arm flask.  The PEG distillation 
stir bar can be reused in this step.   




5. Clamp the apparatus to the scaffolding in the back of the fume hood.  
6. Vacuum grease and clamp all connections.  Be careful not to vacuum grease over 
the holes in the valves, or else the FuCl and TEA will not flow through.  Also the 
PTFE valve for the N2 balloon does not require vacuum grease.   
7. Place the 3-arm flask in a small autoclave bin, filled with ice on a large stir plate.  
Optional: Add salt to the ice to keep the ice from melting.   
8. For PEG 3.4K, use glass pipettes to add 30 ml MeCl to volumes of FuCl and TEA 
calculated above (3.4K: 1.431 ml FuCl and 3.6912 ml TEA). Add MeCl to 
dropping funnels first, then FuCl and TEA.  MeCl removes the markings from 
glass pipettes, so exercise care when transferring MeCl.  
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9. For PEG 10K, use glass pipettes to add 10 ml MeCl to volumes of FuCl and TEA 
calculated above (10K: 0.4866 ml FuCl and 1.2545 ml TEA).  Add MeCl to 
dropping funnels first, then FuCl and TEA.  MeCl removes the markings from 
glass pipettes, so exercise care when transferring MeCl. 
10. Flush system with N2 gas, using the N2 tank and hose and the N2 filled balloon.  
Lift the glass stoppers from the dropping funnels slightly to purge excess air.  
Make sure the N2 valve remains open.   
11. Stir PEG solution on the stir plate at ~5.   
12. Start reaction by dropping the FuCl and TEA at the same rate of 1 drop per ~3-4 
seconds.  A slower drop rate will result in a more efficient reaction.   
13. Reaction will turn dark brown.   
14. When necessary, siphon melted water from the ice bin, and replace the ice.   
15. When dropping is complete, allow the reaction to continue on ice for the rest of 
the day.   
16. When necessary, siphon melted water from the ice bin, and replace the ice.   
17. At the end of the day, remove the ice bin, remove the dropping funnels, and 
replace the funnels with glass stoppers.   
18. Allow the reaction to continue at room temperature with stirring on a cork ring for 
at least 2 days.   
19. Check the N2 balloon over the next 2 days, and refill the balloon if necessary 
(close valve when refilling the balloon).   
20. Glassware can be dried in the hood, and cleaned with acetone and the base bath.  
Rotovaporing of MeCl 
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Warning: Use nitrile or silver-shield gloves when handling MeCl. 
1. Wash and dry:  
1 x 1000 ml round-bottom flask,  
1 x glass funnel.  
2. Turn on Rotovapor by switching Vacuum Controller V-800, Rotovapor R-200, 
and Vacuum V-500 on.   
3. Fill the water bath with distilled H2O, and heat to 40°C.   
4. Use the circulating pump to flow cold, ice water through the condensing tube.   
5. Use the funnel to pour the OPF solution into a 1000 ml round-bottom flask.   
6. Clamp and vacuum grease the flask to the Rotovapor.   
7. Lower the flask into the water bath, so the OPF solution and water levels are the 
same.   
8. Slowly rotate the flask in the water bath.   
9. Turn on the vacuum on at 850 mbar (“Set”  Up or down  “Run”).  
10. Gradually decrease the vacuum as necessary to maintain a steady drip of 
condensation into the collecting flask.  Vacuum can be decreased as low as 700 
mbar.   
11. When OPF/MeCl solution is thick and “stew-like” consistency, remove OPF from 
Rotovapor.   
12. Dispose of the MeCl waste in the chlorinated organic solvents waste container.   
13. Glassware can be dried in the hood, and cleaned normally.  
Wash in Ethyl Acetate 
Warning: Use nitrile or silver-shield gloves when handling ethyl acetate. 
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1. Wash and dry: 
2 x 2 L aspiration flasks, 
1-2 x 2 L Erlenmeyer flasks, 
1-2 x 2 L beakers,  
2 x Buchner funnels,  
1-2 x glass funnels,  
1 x stir bar,  
2 x spatulas.  
2. Add ethyl acetate (EA) to the OPF solution until the flask is ~2/3 full.   
3. Stir the solution while heating with the heatgun (low speed, med heat) for 15-20 
min, rotating every 5 minutes.   
4. Solution will become less viscous and salts become visible at the surface.  Ethyl 
acetate is a solvent for the OPF, but not for the salts produced in the TEA 
reaction.   
5. Connect the vacuum and filter the solution through a Buchner funnel with #1 
Whatman filter paper (11 µm pores) into a 2 L aspiration flask.   
6. The salts will be filtered out of the solution by the filter paper.  Discard these 
salts.  
7. Add EA to the OPF to a total volume of 1500-1700 ml.   
8. Stopper the flask with a #9 rubber stopper and parafilm the stopper and aspiration 
neck, and place the flask into the -20°C explosion-proof freezer for at least 2 
hours or overnight if necessary.   
9. If necessary, clean glassware for the next step.  
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10. After cooling, remove the OPF/EA from the freezer.  The decreased temperature 
alters the solubility of the OPF, causing the OPF to precipitate out.   
11. Connect the vacuum and filter the solution through a Buchner funnel with #1 
Whatman filter paper, capturing the OPF in the filter paper and pulling the EA 
into an aspiration flask.   
12. While filtering, stir the solution, allowing the EA to be pulled through the filter 
paper.  Discard the EA.   
13. When nearly dry, transfer the OPF from the filter paper to a beaker.   
14. Add 1 L ethyl acetate to the solution.   
15. Stir the solution while heating with the heat gun to redissolve the OPF in the EA.  
Solution goes from light brown to dark brown and becomes less viscous.  
16. Use a clean glass funnel to transfer the OPF and EA to a 2 L Erlenmeyer flask and 
add EA to a total volume of 1500-1700 ml.   
17. Stopper the flask with a #10 rubber stopper, and recrystallize the OPF/EA 
solution in a 2 L aspiration flask at -20°C for 1.5 hours or overnight.   
18. Dispose of the EA waste in the nonchlorinated organic solvent waste container.   
19. After cooling, filter the solution through a clean Buchner funnel with #4 
Whatman filter paper (20-25 µm pores), capturing the OPF in the filter paper and 
pulling the EA into an aspiration flask.   
20. The second filtering step may proceed much more slowly than the first.  If 
EA/OPF is solid after removing from the freezer, add more EA to the solution.  
Tape 2 spatulas together to scoop product from the bottom of the flask.   
21. Dispose of the EA waste in the nonchlorinated organic solvent waste container.   
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22. Optional: Repeat steps 13-19 for a third filtering step.  This may be necessary if 
OPF appears too dark.  
23. Dispose of the EA waste in the nonchlorinated organic solvent waste container.   
24. Glassware can be dried in the hood, and cleaned normally.  
Wash in Ethyl Ether 
 
Warning: Use nitrile or silver-shield gloves when handling ethyl acetate and/or ethyl 
ether. 
1. Wash and dry: 
1 x 2 L beaker,  
1 x stir bar,  
1 x Buchner funnel,  
2 x PTFE coated jars. 
2. When OPF is nearly dry and EA is mostly gone, add 1 L ethyl ether (EE) directly 
to the funnel to remove the EA. 
3. Once mostly dry, transfer the OPF from the funnel and filter paper to a 2 L 
beaker.   
4. Add 1 L ethyl ether (EE) to the OPF for a second wash with stirring.   
5. Filter the solution through a Buchner funnel with #4 Whatman filter paper (20-25 
µm pores), capturing the OPF in the filter paper and pulling the EE into an 
aspiration flask.   
6. Optional: Add EE to the OPF for a third wash.   
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7. As the EE filters through and the OPF dries, use a spatula to break up any clumps 
of OPF.   
8. By the end, you should have a fine powder that is mostly dry.   
9. Scoop the OPF powder evenly into 2 Teflon-coated jars with the spatula.   
10. Leave the OPF in the hood overnight with the lid on loosely.   
11. Dispose of the EE waste in the nonchlorinated organic solvent waste container.   
12. Glassware can be dried in the hood, and cleaned normally.  
Vacuum Dry OPF 




2. Tape aluminum foil to the top of the OPF jars and poke holes in the foil with a 
small gauge needle.   
3. Add liquid nitrogen to the solvent trap.   
4. Connect the vacuum to the solvent trap.  
5. Close the valves to the samples (3rd and 4th from the top).  Open the valve to the 
manometer (bottom).  
6. The top 2 valves are open to the atmosphere and should remain closed.   
7. Turn on manometer, and then the vacuum pump.   
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8. Once a vacuum is established, gradually open the valves to the samples. Open the 
valve to the first sample until a vacuum is established, then close that valve.  Then 
open the valve to the second sample until a vacuum is established.  Now you can 
reopen the first sample.   
9. Pressure should be less than 10 mbar (preferably 1-2 mbar).  
10. Check the pressure and the liquid nitrogen level every 30-45 minutes.   
11. Refill the liquid nitrogen if necessary.   
12. When OPF is dry and you cannot smell any EE in the powder, open the valve to 
break the vacuum and turn off the pump.   
13. Dispose of solvent from the solvent trap.   
14. Parafilm OPF and store it at -20°C.  
Verify Product 
1. A lighter brown color is preferred.   
2. Polymerize a 100% OPF hydrogel with thermal and photo-initiation to test 
crosslinking.  
3. Run GPC on the OPF in chloroform to verify molecular weight.   
 
A.2 PEG-DA Synthesis 
Reaction Calculations 
Reaction Calculations 
1) Begin with 24 g PEG, MW 3400. 
2) React with 100% excess acryloyl chloride (AcCl; 2 AcCl:1 PEG). 
24 g PEG / (3400 g/mol PEG) = 7.06 mmol PEG 
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7.06 mmol PEG * 2 end groups * 2 (100% excess) = 28.24 mmol AcCl 
0.02824 mol AcCl * 90.51 g/mol / (1.114 g/mL) = 2.294 mL AcCl 
3) React with 1:1 AcCl:triethylamine (TEA) 
0.00706 mmol PEG * 2 end groups = 0.0141 mol TEA 
0.0141 mol TEA * 101.9 g/mol / (.726 g/mL) = 1.982 mL TEA 
4) Workup with anhydrous potassium carbonate (K2CO3) 
0.02824 mol AcCl * 2 mol K2CO3/mol AcCl / 2 M K2CO3 = 28.2 mL 2M K2CO3 (aq) 
138.205 g/mol = 276.41 g in 1L = 27.641 g in 100 mL = 8.2923 g K2CO3 in 30 mL 
ddH2O 
Day 1 – Methylene Chloride Distillation 
Distill MeCl following the instructions in the OPF synthesis protocol. Keep in mind that 
you only need approximately 100 mL. Distillation is necessary to remove aqueous 
contamination (make MeCl anhydrous) that might generate unwanted side reactions in 
Day 2.  
Day 2 – Reaction 
What’s going on? PEG is being acrylated. TEA acts as a catalyst by sequestering HCl to 
allow the reaction to proceed to completion. MeCl is the solvent used for this reaction. 
 
Caution: AcCl doesn‟t smell as bad as FuCl, but it is worse for you (eye, throat irritant)! 
1. Set up 3-arm round bottom flask in 
the fume hood on a stir plate. 
Weigh and add PEG to the flask. 
Add stir bar. 
Equipment: 
1x 500 mL 3-arm round 
bottom flask 
1x dropping funnel 
1x PTFE gas valve 
3x glass stoppers 
1x glass stopcock 
1x PTFE stopcock 
 
1x stirbar 
1x glass funnel 
1x graduated cylinder 
1x balloon 
Glass pipettes 
1x stir plate 
1x clamp 










2. Attach one dropping funnel, with a glass stopper, and a PTFE valve for N2 gas 
flow. Vacuum grease glass-glass connections for the dropping funnel (excluding 
glass stopper) and the PTFE valve. Do not grease the PTFE valve itself. 
3. Hook up N2 tubing to the valve. Continually purge the whole system as you add 40 
mL MeCl to the round bottom flask through the ungreased arm using a glass 
funnel. Stir. Gently float a glass stopper in the arm on the air being pushed out. 
4. When dissolved, use a glass pipette to add TEA. Vacuum grease a glass stopper 
and gently float the dropping funnel‟s glass stopper as before. Let stir for 5 min. 
5. Use a glass pipette to add 20 mL MeCl and the appropriate amount of AcCl to the 
dropping funnel. Be aware that MeCl (and its fumes) will remove markings from 
glass pipettes. Vacuum grease and stopper the funnel while you are adding and 
turn off N2 flow. 
6. Remove the N2 hose and attach an N2 balloon. 
7. Drip the AcCl/MeCl mixture into the round bottom flask (about 1 drop every 3-4 
seconds). Drip AcCl in MeCl very slowly (about 1 drop every 4 seconds). 
8. After dripping is complete, you can replace the funnels with stopcocks. 
9. Let stir overnight. 
Day 3 – Workup 
What’s going on? To remove TEA-HCl, we first react the 
mixture with potassium carbonate to produce KCl, which will 
transfer to the aqueous phase. Some TEA will remain in the 
organic phase for Day 3 filtration. 
1. Use a glass funnel to transfer the mixture from the 
Equipment: 
1x 250 mL separatory 
funnel 
1x glass stopper 
1x glass funnel 
1x glass stopcock 






round bottom flask to a separatory funnel with a 
greased stopcock. (Don‟t forget to close the stopcock 
prior to transfer. Also, remember to wipe vacuum 
grease from connections before pouring.) 
2. Add appropriate amount of 2M K2CO3 to the 
separatory funnel. 
3. Stopper funnel, hold vertically, and give it a quick 
shake or two. Immediately open the stopper to release CO2. Repeat a few times. 
4. Hold the separatory funnel horizontally, but with the tip tilted higher. One hand 
should hold the glass stopper, the other holding the stopcock knob up. Rotate 
vigorously, and open the stopcock periodically to release CO2. Repeat until all gas 
is released. Solution should have the consistency of a milky-white emulsion. 
5. Leave overnight. Place a beaker underneath to capture any leaked product. 
Day 4 – Filtration and Drying 
What’s going on? We isolate the mixture from KCl in the aqueous phase, add MgSO4 to 
remove any additional aqueous solution, and precipitate PEG-DA in ethyl ether. TEA 
should remain in solution. 
 
1. Drain the two organic phases into a 250 mL beaker on a stir plate with stir bar. 
2. While stirring, add MgSO4 until the mixture goes from a lumpy consistency to a 
well dispersed mixture of powder and organic solvent. It should appear as opaque 
milk – if it doesn‟t look like milk, add more MgSO4. Add ~20-40 mL MeCl to 
keep the PEG-DA in solution (may help to have a smaller bottle or beaker with 
Equipment: 
2x 250 mL beakers 
1x 1L aspiration beaker 
1x 2-3L beaker 
2x stir bars 
2x Buchner funnels 










MeCl). The goal here is to add as little MeCl as possible to keep the solution 
saturated with PEG-DA. But, if you add too much, no sweat. 
3. Prepare a Buchner funnel with aspiration flask and filter paper and pre-wet the 
filter paper with MeCl. 
4. Pour the mixture into the filter and a clear liquid should be collected (containing 
PEG-DA). If the liquid is cloudy, filtration should be performed again. The 
vacuum will also begin to evaporate MeCl. Thus, you can elect to evaporate MeCl 
if necessary. 
5. Prepare a 2L beaker with 1.7L ethyl ether and a stir bar. Pour in the PEG-DA 
solution and wait 10 min to precipitate PEG-DA. 
6. Prepare another Buchner funnel with two filter paper sheets, and pre-wet with ethyl 
ether. 
7. Filter to separate PEG-DA. If the filtrate is not clear, re-filter. Pound into bits. See 
an older grad student to measure your performance. 
8. Dry under vacuum until no ether can be smelled (at least 5 hours). At least some of 
this vacuum drying must be performed immediately after filtration. 
9. Store at -20ºC. Expected recovery is approximately 75%. 
Note: If necessary, you may need to dialyze the resulting product to remove impurities. 
Use a 1000 MWCO dialysis membrane at 0.2 g/mL and lyophilize after dialysis. 
A.3 LGPA Synthesis 
Purpose: To attach PEG-acrylate to each end of an enzymatically-cleavable peptide. 
Materials: 
Plastic conical vial, 200-250 mL beaker, 2-3L beaker, stir plate 
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Acrl-PEG-NHS (SVA) [MW: 3400 Da]; GGGLGPAGGK peptide [MW: 769.86 Da] 
Dialysis tubing (3500-5000 Da MWCO; Spectrapor 131201/131204) and clips 
Preparation: 
1) Wash glassware and dialysis clips (Alconox, water, dH2O) 
2) Make a 50mM sodium bicarbonate buffer solution and pH to 8.5.  For reacting 
100 mg peptide, this means 420 mg sodium bicarbonate in 100 mL ddH2O in the 
200-250 mL beaker. Shield your beaker from light. 
3) Calculate amounts of Acrl-PEG-NHS (2.2:1 moles of NHS to peptide) needed for 
cleavable peptide. For 100 mg peptide, you need 971.6 mg Acrl-PEG-SVA. 
Reaction: 
4) Dissolve the peptide in 20% of your buffer in a 15 or 50 mL conical (100 mg in 
20 mL). 
5) Dissolve the Acrl-PEG-NHS in the buffer that‟s left in your beaker (971.6 mg in 
80 mL). The beaker should be shielded from light. 
6) Immediately add peptide solution to your beaker, stir (~6) and cover with 
parafilm. 
7) Allow to stir for >3 hours at room temperature. 
8) Prepare tubing for dialysis. One (super-wide, 131204) strip should be used for 
every 10 mL solution. 100 mg peptide = 100 mL buffer = 10 tubes. 
9) Rinse dialysis tubing 4x in a 2L beaker, 15 min between each rinse, to remove 
sodium azide. 
10) Close one end of each dialysis strip with a weighted closure. Due to potential 
leakage, fold over the tubing before sealing with the closure.  
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11) Use a transfer pipette to add the solution to each tube. Close the open end of the 
tubing with a non-weighted closure. 
12) Dialyze to remove byproducts for 2 overnights. If starting on the morning of the 
first day change the water the morning and night of the second day. Keep from 
light. 
Lyophilization: 
13) Weigh empty scintillation vials and record the weight. 
14) Transfer solution from tubes to vials. Two scintillation vials should be used for 
each tube of dialysis product. 
15) Remove the caps from the scintillation vials and place aluminum foil over the 
tops and tape this foil down. Poke holes in the top of the foil with a needle to let 
air escape. 
16) Freeze vials in liquid nitrogen and lyophilize the product for 2 overnights. 
17) Reweigh the scintillation vials so that the mass of the product inside the vial can 
be determined. 
18) Parafilm and store the resulting product at -20°C. 
A.4 RGD Conjugation 
Purpose:  To attach the acrylated PEG spacer arm to the desired peptide. 
Materials: 
2-3L beaker x2 (1 to wash tubing, 1 to do purification) 
100 ml beaker 
Peptide (GRGDS) [MW: 490.47] (generally 25mg) 
Spacer arm (A-PEG-NHS): (346.7 mg/25mg RGD) 
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Sodium bicarbonate 
Dialysis tubing (need about 3, MWCO 1000) 
Dialysis clips (need 2/tubings or about 6/25 mg RGD) 
Teflon tape  
Stir plate 
Stir bar x2 
Days: Prepare day 1, refresh water day 2, freeze dry days 3-5. 
 
Preparation: 
1. Wash glassware (water, dH2O, acetone) 
2. Wash dialysis clips (water, dH2O, ethanol) 
3. Wash stir bars (water, dH2O, ethanol) 
4. Make sodium bicarbonate buffer (pH 8.1 – 8.3) 
Use 10 mL ddH2O per 0.02 g of sodium bicarbonate.   
The total amount of the buffer should be 1 ml of buffer per 1 mg peptide that will 
be used. 
5. Calculate amounts of peptide and A-PEG-NHS (1:2 molar ratio)   





6. Pour the peptide into the buffer and mix.  In order to get all of the peptide from the 
vial add 1 ml of the buffer solution to the vial.  Close the vial and shake.  Pour the 
remaining contents into the buffer solution.  Dissolve peptide into the buffer 
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solution at room temperature. 
7. Add A-PEG-NHS (approximately 50 – 100 mg every 15 min) to the peptide 
solution with stirring (stirrer ~ 6).  Put paraffin over the top of the beaker while 
stirring. 
8. Maintain reaction for 2.5 hour at room temperature 
9. Cut the dialysis tubing into strips a little shorter than the beaker that will be used 
for dialysis. 
10. Since the dialysis tubing is stored in sodium azide it needs to be rinsed.  To do 
this put the dialysis tubing in a beaker with about 1L of dH2O and mix.  Refresh 
the dH2O every 15 minutes (3x) in order to thoroughly rinse the tubing. 
11. After the tubing is thoroughly rinsed remove it from the beaker and close one end 
of the dialysis tubing with a weighted closure.  After the reaction in step 7 is 
complete, use a transfer pipette to add the mixture to the tubing until the tubing is 
about half full.  Close the open end of the tubing with a non-weighted closure and 
place into beaker of distilled water. 
12. Dialyze to remove by-products for 2 overnights.  If starting on the morning of the 
first day change the water the morning and night of the second day. 
 
Freeze dry the product: 
13. Weigh the empty scintillation vials and record the weight. 
14. Carefully remove the dialyzed products from the water and remove the clip at the 
top of one of the membranes. 
15. Two scintillation vials will be used for each tube of dialysis products.  Use a 
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transfer pipette to relocate about half of the dialysis products from one tube to a 
scintillation vial.  Pour the rest into the same vial. 
16. Pour about half of the dialyzed product in the scintillation vial into a second 
scintillation vial.  Each of the vials should have about half of the products from 
the dialysis tubing. 
17. Repeat steps 15-17 for each dialysis membrane. 
18. Fill a styrofoam container with liquid nitrogen to a height that is about one half to 
three fourths the height of the scintillation vials. 
19. Remove the caps from the scintillation vials and place aluminum foil over the 
tops and tape this foil down.  Poke holes in the top of the foil with a needle to let 
air escape. 
20. Using long tweezers carefully place the scintillation vials in the liquid nitrogen.  
They should be sitting on the bottom of the container and surrounded by liquid 
nitrogen, but not completely covered by it. 
21. Leave the vials in the liquid nitrogen for 2-3 min. until the product becomes 
frozen. 
22. Lyophilize the product overnight twice. 
23. Reweigh the scintillation vials so that the mass of the product inside the vial can 
be determined. 
24. Store the resulting product at -20°C in a scintillation vial that has been sealed with 
paraffin. 
A.5 Ligament Fibroblast Isolation Protocol 
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Purpose: Ligament was digested to remove matrix (i.e. collagen) and isolate the 
fibroblasts for use in experiments. 
Procedure for Cell Isolation 
1. Prepare DMEM+ a.k.a. Arnold (overnight antiobiotics for tissue samples) 
a. Use sterile high glucose DMEM. Add 10 ml/L PSN (stock @ 100x), 10 
ml/L kanamycin (stock @ 100x), 1 ml/L gentamicin (stock @ 1000x), and 
1 ml/L fungizone (stock @ 1000x). 
2. Prepare 0.4% collagenase digest solution 
a. In DMEM+ (see above) add 0.4% collagenase.  Make enough for 10 ml 
digest solution per 1 gram tissue + extra volume. 
b. CALCULATION: [total mass of tissue]*10 ml/g tissue * 0.004 = ___ g of 
collagenase. 
c. Sterile filter collagenase solution using 60 ml syringe and 0.2 µm filter. 
3. Dice the tissue into roughly 1-3 mm3 cubes. 
4. Record weight of empty Petri dish.  Aspirate excess PBS and weigh tissue in Petri 
dish to get tissue only weight. 
5. Place tissue into T-75 flasks so that there is about 2-3 grams of tissue per flask. 
6. Add 10 ml of 0.4% collagenase digest solution per 1 gram of tissue to each T-
flask.  T-flasks should be placed on their sides and secured firmly to the shaker 
plate.  The whole assembly is then placed into the incubator for 12-48 hours.  
Agitate at 3-5 Hz. 
After digestion (~48 hr) 
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7. When fully digested, filter cell suspension by pipetting suspension into a 60 ml 
syringe attached to a metal cell strainer with 74µm mesh.  Strain cell solution into 
a 50 ml conical. Dilute the suspension 1:1 with warm PBS to decrease the 
viscosity of the collagenase solution. 
8. Centrifuge all samples at 1300 rpm for 10 minutes.  For ligament and tendon the 
solution above the pellet may appear murky due to cells that did not completely 
separate out during the centrifugation.  If this occurs leave at least 5 ml of solution 
above the pellet when aspirating.  Then, dilute and repeat centrifugation to get the 
maximum number of cells to pellet down. 
9. Aspirate off collagenase solution and resuspend cells in 10 ml sterile PBS w/o 
IONS or DMEM.  Recombine and repeat if necessary. 
10. Count cells to determine how much mediumto later add for the desired cell 
density. 
11. Spin the cells at 1000 rpm for 10 min.  Aspirate off the PBS. 
12. Add an appropriate amount of mediumwith 10% FBS and 10% DMSO.  Use the 
auto to pipette up and down to mix cells thoroughly throughout the solution. 
13. Add 1 ml of cell solution to each tube you will be freezing down. 
14. Place the cell vials in the appropriate cooling container and place them in a -80°C 
freezer. 
15. After enough time has passed put the now cold vials into the liquid nitrogen for 
long-term storage. 
A.6 Cell Encapsulation 




Medium(prepared day before) 
Sterile PBS 
6 Scintillation vials 
Weigh paper 
2(3) 15 ml falcon tubes 
1(2) 50 ml falcon tubes 
5(7) 1 ml syringes 
2(4) 18G needle 
2(3) Filter caps 
2 Racks 
4(6) 6 well plates 
2(4) 12 well plates 





1. Add polymers to a scintillation vial in appropriate amounts for the experiment.  If 
desired vials containing polymers can be stored overnight at 4°C or for longer 
periods at -20°C.  If the vials are stored they should be parafilmed and covered in 
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aluminum foil.  Note: ~400-700 μl of the original solution is lost during filter 
sterilization. 
 
Day of encapsulation 
1. If necessary, remove vials from the freezer/refrigerator and warm to room 
temperature. 
2. Add appropriate amount of PBS to polymers, vortex, and place the vial in the 
incubator at 37 °C for about one hour or until bubbles have left the solution. 
3. Create 0.3 M stock solutions of APS and TEMED (10 ml will be made). 
a. APS: 0.684 g/ 10 mL PBS 
b. TEMED: 0.348 g/ 10 mL PBS 
4. Filter sterilize the APS and TEMED solutions.  Make sure to cover the vials with 
aluminum foil to prevent photoinitiation. 
5. Remove the polymer solutions from the incubator and allow to cool at room 
temperature 
6. Filter sterilize the polymer solution.  Aliquot it out into individual 15 ml tubes as 
appropriate for each cross-linking step that is needed. 
7. Cells needed for encapsulation should have been plated for at least 3 days before 
using them.  Wash, trypsinize, and resuspend cells at the required concentration 
(typically 50x10
6 
cells/ml) according to established lab protocols. 
 
Crosslinking/encapsulation 
8. Add appropriate amount of APS and vortex at low speed for about 5 seconds. 
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9. Add the appropriate amount of the cell solution and quickly mix with pipette.  
The concentrated cell solution typically is used at a concentration of 50x10
6
 
cells/ml with the resultant concentration being 10x10
6
 cells/ml.   
10. Similarly, add the appropriate amount of TEMED and quickly mix with pipette. 
11. Pipette the appropriate amount of the solution (typically 30 µl for small hydrogels 
and 350 µl for tensile constructs) into the mold that is being used.   
12. Cover mold and place it in the incubator. 
13. Heat the molds at 37 °C for 10 min. 
14. Remove from the heat and put the gels into well plates with mediumas 
appropriate. 
Note: Only ~14 30 µl hydrogels and 3-4 tensile construct hydrogels can be 
created at one time before the solution cross-links with the APS and TEMED.  In 
addition, only a limited number of plates can be trypsinized effectively at one 
time.  Therefore, the trypsinization process may need to be repeated on different 
sets of plates and the cross-linking process may also need to be repeats as 
appropriate. 
A.7 Cell Number/PicoGreen 
Purpose:  The Pico Green assay quantifies the amount of DNA present which is an 
indirect measure of the number of cells. 
Materials: 





96 well plates 
 
For Hydrogels 
1. Remove media. 
2. Add 2ml iPBS. 
3. Remove iPBS. 
4. Add 2-4ml iPBS (covering sample). 
5. Place in incubator for 30 min to an hour.  Leave in incubator until gels are no 
longer the color of the mediumand have become clear. 
6. Transfer the gels between pieces of weigh paper to remove excess water and 
weigh the gels.  Then put the gels in 1.5 ml eppendorf tubes. 
7. Homogenize the gels with a pellet grinder in the tubes.  Be careful not to loose 
any of the gel. 
8. When the gel is well ground add ddH2O to the tube depending on the size of the 
gel (750 μl for those cast in the caps).  Some of the ddH2O can be used to wash 
the pellet grinder tip into the tube and to wash the side of the tube.  This will 
maximize the amount of gel that is available for the bioassay. 
9. Let sit at room temperature for 30 min. 
10. Store at -20 °C if needed. 
Lysing the cells 
11. Freeze the cells at -80 °C for a minimum of 1 hour. 
12. Thaw at room temperature for 30 minutes. 
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13. Sonicate for 30 min. to lyse the cells. 
Note: The sonicator will heat up after each usage.  Ice should be added to the 
water in order to cool the sonicator down.  If this is not done the DNA in the 
sample could break down. 
Safety note: The sonicator is meant to lyse the cells.  Do not put fingers into the 
water bath while the sonicator is on or cells in your fingers will be lysed. 
14. Repeat steps 11-13 two additional times. 
15. If the samples are being stored before the assay is done freeze them at -80°C . 
For Plated Cells in a well plate 
1. Aspirate liquid from the wells of the plate 
2. Add 2 ml PBS to rinse. 
3. Repeat steps 1-2. 
4. Add 1 ml distilled, deionized water (ddH2O). 
5. Let sit at room temperature for 30 min. 
6. Store at -20 °C if needed. 
Lysing the cells 
7. Freeze the cells at -80 °C for a minimum of 1 hour. 
8. Thaw at room temperature for 30 minutes. 
9. Sonicate for 30 min. to lyse the cells. 
Note:  The sonicator will heat up after each usage.  Ice should be added to the 
water in order to cool the sonicator down.  If this is not done the DNA in the 
sample could break down. 
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Safety note: The sonicator is meant to lyse the cells.  Do not put fingers into the 
water bath while the sonicator is on or cells in your fingers will be lysed. 
10. Repeat steps 7-9 two additional times. 
Making the plates 
Standards 
1. Make sure to thaw out samples and PicoGreen reagents for about 20 minutes 
before doing the assay. 
2. Make up buffer solution and PicoGreen according to the PicoGreen calculator.  
Vortex both solutions to make sure they are mixed thoroughly. 
 Note: When creating the buffer solution make sure to take the volume in the DNA 
standards into account.  Also, cover the PicoGreen solution in aluminum foil to 
protect it from light. 
3.   Make up DNA standards according to the table below. 




0.5 50 of 5 ug/ml 450
0.3 50 of 3 ug/ml 450
0.1 50 of 1 ug/ml 450
0.05 50 of 0.5 ug/ml 450
0.03 50 of 0.3 ug/ml 450
0.01 50 of 0.1 ug/ml 450
0 0 1000  
4. Add 43 μl of your sample solutions into the appropriate wells of a 96 well plate.  
Make sure to change tips between samples. 
5. Add 107 μl of the buffer solution into the wells. 
6. Add 150 of the PicoGreen Solution to the wells. 
7. Read in a plate reader: ex 485, em 528. 
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A.8 Live/Dead Assay 
Purpose: This assay uses calcein and ethidium homodimer-1 to stain cells so that live 
cells vs. dead cell can be differentiated via fluorescence.  Calcein (494/517 nm) is 
permeable in the cell membrane of living cells and is cleaved in the cytosol to fluoresce 
green indicating healthy cells.  This cleavage occurs when the cells is undergoing its 
normal metabolic processes.  Ethidium (528/617 nm) can not permeate the cell‟s 
membrane so it only enters cells whose membrane has been ruptured.  Ethidium binds to 










1. Remove mediumfrom well plate with hydrogels or transfer hyrogels to well plates 
as appropriate. 
2. Add 1 ml of 1X PBS to rinse the wells, then remove the PBS. 
3. Add PBS to the wells and place them in the incubator for at least 30 min or until 
gels are no longer the color of the mediumand have become clear.  This serves to 
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rinse out mediumwhich would otherwise autofluoresce in the Live/Dead assay 
and cause imaging interference. 
4. Create live/dead solution using the amounts below (scale to your number of 
samples).  Cover the tube with the solution in aluminum foil to prevent 
photobleaching of the live dead solution. 
 
Dye Amounts: 
For 6 samples (1 ml dye/sample, makes 6.75 ml staining solution): 
6.8 μl @ 1 mM or 1.70 μL calcein @ 4 mM (1 mM ≈ 1 mg/ml) 
3.38 μL eth. 
6.75 ml PBS 
 
5. Wait about 45 min – 1hr before imaging.  Remove PBS and add 1 ml of dye.  
Cover these wells in foil to prevent photobleaching and place in incubator for 45 
min – 1hr. 
6. Move gels to new wells and add 2 ml of fresh PBS to rinse out excess dye.  To 
prevent the gels from drying out leave the gels in PBS until you are ready to 
image them. 
7. Move gels to the cell chamber and image using an inverted fluorescence 
microscope or confocal microscope.  Be careful to avoid photobleaching during 
imaging. 
A.9 MMP Production 
A.9.1 Protocol for Measurement of MMP-1 
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A human MMP-1 flurokine kit (RND systems, F1M00) was used. 
1. Reconstitute MMP-1 standard in calibrator diluents RD5-25 solution to produce a 
stock solution of 25 ng/ml.  Allow standard solution to sit for a minimum of 15 
minutes with gentle agitation before making dilutions. 
2. Prepare standards according to table below. 
Conc. (ng/ml) MMP (ul) Calibrator diluent RD5-25 (ul)
12.5 500 500
6.25 500 of 12.5 ng/ml 500
3.12 500 of 6.25 ng/ml 500
1.56 500 of 3.12 ng/ml 500
0.78 500 of 1.56 ng/ml 500
0.39 500 of 0.78 ng/ml 500
0 0 500  
3. Remove excess black strips from plate and return to pouch.  Reseal pouch and 
store. 
4. Add 100 μl of RD1-64 to wells. 
5. Add 150 μl of your sample solutions into the appropriate wells of a 96 well plate.  
Make sure to change tips between samples.  Cover with an adhesive strip. 
6. Incubate 3h on a shaker table (450-550 rpm) at RT. 
7. Prepare wash buffer. 
# of Wells Wash buffer dH2O Total buffer
32 4.2 ml 105 ml 109.2 ml
64 8 ml 200 ml 208 ml
96 10 ml 250 ml 260 ml  
8. Aspirate solution from wells, add 400 μl wash buffer. 
9. Repeat previous step three times. 
10. Prepare APMA solution within 15 minutes of use.   
# of Wells APMA stock Reagent diluent 2 Total APMA
32 42 ul 6.96 ml 7 ml
64 83 ul 13.92 ml 14 ml
96 135 ul 22.5 ml 22.64 ml  
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11. Aspirate solution from wells. 
12. Invert plate and blot against a clean paper towel. 
13. Add 200 μl APMA to standards and desired wells.  Add 200 ul of Reagent 
 iluents 2 to other wells.  Make sure to change tips between samples.  Cover with 
an adhesive strip.  APMA activates any MMPs present so do not add if you are 
measuring endogenous active MMPs.  Always add APMA to standards. 
14. Incubate for exactly 2h at 37 °C in humid environment. 
15. Aspirate solution from wells, add 400 μl wash buffer. 
16. Repeat previous step three times. 
17. Prepare substrate solution within 15 minutes of use. 
# of Wells Substrate stock Reagent diluent 2 Total Substrate
32 109 ul 6.89 ml 7 ml
64 219 ul 13.78 ml 14 ml
96 360 ul 22.5 ml 22.88 ml  
18. Aspirate solution from wells. 
19. Add 200 μl of substrate to each well.  Cover with a new adhesive strip.  Incubate 
for 17-20h at 37 °C in dark, humid environment. 
20. Read at ex 320 nm, em 405 nm. 
A.9.2 Protocol for Measurement of MMP-13 
A human MMP-13 flurokine kit (RND systems, F13M00) was used.\ 
1. Reconstitute MMP standard in distilled water to produce a stock solution of 32 
ng/ml.  Allow standard solution to sit for a minimum of 15 minutes with gentle 
agitation before making dilutions. 
2. Prepare standards according to table below. 
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Conc. (ng/ml) MMP (ul) Calibrator diluent RD5-25 (ul)
16 700 700
8 700 of 16 ng/ml 700
4 700 of 8 ng/ml 700
2 700 of 4 ng/ml 700
1 700 of 2 ng/ml 700
0.5 700 of 1 ng/ml 700
0.25 700 of 0.5 ng/ml 700
0 0 700  
3. Remove excess black strips from plate and return to pouch.  Reseal pouch and 
store. 
4. Add 200 μl of your sample solutions into the appropriate wells of a 96 well plate.  
Make sure to change tips between samples.  Cover with an adhesive strip. 
5. Incubate 3h on a shaker table (450-550 rpm) at RT. 
6. Prepare wash buffer. 
# of Wells Wash buffer dH2O Total buffer
32 4.2 ml 105 ml 109.2 ml
64 8 ml 200 ml 208 ml
96 10 ml 250 ml 260 ml  
7. Aspirate solution from wells, add 400 μl wash buffer. 
8. Repeat previous step three times. 
9. Prepare APMA solution within 15 minutes of use.   
# of Wells APMA stock Reagent diluent 2 Total APMA
32 42 ul 6.96 ml 7 ml
64 83 ul 13.92 ml 14 ml
96 135 ul 22.5 ml 22.64 ml  
10. Aspirate solution from wells. 
11. Invert plate and blot against a clean paper towel. 
12. Add 200 μl APMA to standards and desired wells.  Add 200 ul of Reagent diluent 
2 to other wells.  Make sure to change tips between samples.  Cover with an 
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adhesive strip.  APMA activates any MMPs present so do not add if you are 
measuring endogenous active MMPs.  Always add APMA to standards. 
13. Incubate for exactly 1h at 37 °C in humid environment. 
14. Aspirate solution from wells, add 400 μl wash buffer. 
15. Repeat previous step three times. 
16. Prepare substrate solution within 15 minutes of use. 
# of Wells Substrate stock Reagent diluent 2 Total Substrate
32 115 ul 6.89 ml 7 ml
64 230 ul 13.78 ml 14 ml
96 375 ul 22.5 ml 22.88 ml  
17. Aspirate solution from wells. 
18. Add 200 μl of substrate to each well.  Cover with a new adhesive strip.  Incubate 
for 17-20h at 37 °C in dark, humid environment. 
19. Read at ex 320 nm, em 405 nm. 
 
A.10 Real Time RT-PCR 
RNA Extraction 
Extract RNA using Qiagen RNeasy Mini Kit  
(Consult the RNeasy kit manual for more specific protocols depending on your 
cell/tissue source) 
Materials 
Molecular BioProducts RNase Away Spray (VWR 17810-491; 475 ml) 
Aerosol Filter Pipette Tips for Rainin LTS, 20 μl (VWR 83009-688; pack of 960) 
Aerosol Filter Pipette Tips for Rainin LTS, 200 μl (VWR 82003-196; pack of 960) 
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Aerosol Filter Pipette Tips for Rainin LTS, 1000 μl (VWR 82003-198; pack of 576) 
QIAshredder (Qiagen 79654 or 79656; 50 or 250 runs) 
RNeasy Mini Kit (Qiagen 74104 or 74106; 50 or 250 runs) 
Optional Alternative: RNeasy Protect Mini Kit (Qiagen 74124 or 74126; 50 or 
250 runs) 
EMD 2-Mercaptoethanol (VWR EM-6010; 100 ml) 
RNAse-free DNase Set (Qiagen 79254; 50 runs) 
Protocol 
For plated cells 
I. Trypsinize cells and centrifuge (10 min, 1000 rpm). 
II. Aspirate supernatant, resuspend pellet in media, and centrifuge (10 min, 1000 
rpm). 
III. Aspirate supernatant, rinse pellet with PBS, and centrifuge again (10 min, 1000 
rpm), aspirate PBS. 
For gels 
I. Soak gels in PBS for ~ 1h to remove media. 
II. Transfer the gel to an RNase free, DNase free microcentrifuge tube. 
III. Break the gel into small pieces using a pellet grinder. 
1. Lyse cell pellet or cells in gel in 350 µl Buffer RLT with β-mercaptoethanol 
(add 10 µl BME per 1 ml Buffer RLT). 
2. Put solution in purple QIAshredder column and centrifuge (2 min, 14000 rpm). 
3. Discard filter and add 350 µl 70% ethanol to eluted substance.   
4. Transfer suspension to pink RNeasy column and centrifuge (15 sec, 14000 rpm). 
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5. Discard eluted substance and put filter back on.  (Do NOT mix Buffer RLT or 
RW1 with bleach when discarding.  Contact with acids forms highly reactive 
guanidine salts and liberates very toxic gas) 
6. Add 350 µl Buffer RW1 to column and centrifuge (15 sec, 14000 rpm).   
7. Discard eluted substance and put filter back on. 
8. Add 10 µl DNase I (lyophilized DNase I is resuspended in 550 µl RNase-free 
water) to 70 µl Buffer RDD for each sample. 
9. Add 80 µl of DNase/RDD solution directly onto RNeasy membrane and incubate 
at room temperature for 15 min. 
10. Add 350 µl Buffer RW1 to column and centrifuge (15 sec, 14000 rpm). 
11. Discard eluted substance and put filter back on. 
12. Add 500 µl Buffer RPE (add 44 ml of 96-100% ethanol to starting 11 ml of 
Buffer RPE concentrate before first time use) to column and centrifuge (15 sec, 
14000 rpm). 
13. Discard eluted substance and put filter back on. 
14. Add 500 µl Buffer RPE to column and centrifuge (2 min, 14000 rpm). 
15. Discard eluted substance and transfer column to new 2 ml collection tube. 
16. Centrifuge (1 min, 14000 rpm).   
17. Discard 2 ml collection tube, and transfer column to new 1.5 ml collection tube 
with cap. 
18. Add 30-50 µl RNase-free water and centrifuge (1 min, 14000 rpm). 




Quantify and check purity of RNA 
Materials 
MP Biomedicals RNase, DNase-free water (VWR IC821739; 500 ml) 
Corning UV Transparent 96-well plate (Fisher 07-200-623; pack of 25) 
Protocol 
1. In a UV-transparent 96-well plate, add 2 µl of extracted RNA and 98 µl RNase-
free water to 3 wells (dilution factor = 50). 
2. In 3 more wells, add 100 µl RNase-free water. 
3. Take absorbance readings at 260 nm and 280 nm light. 
4. Quantity of RNA can be calculated using the following equations: 
 Corrected A260 = average sample A260 – average blank A260 
 Concentation in µg/ml = (corrected A260) * (44 µg/ml) * (dilution factor) 
(using above protocol, dilution factor = 50) 
 Total mass in µg = (µg/ml concentration value) * (µl volume) / 1000 
(volume of RNA extraction sample; using above extraction protocol, volume 
= 30-50 µl) 
 Volume in µl needed for 1 µg RNA = (1 µg RNA) * 1000 / (µg/ml 
concentration value) 
(1 ng to 5 µg RNA can be used for Reverse Transcription) 
 Volume of water in µl needed  = 10 µl total volume – RNA volume 
determined above 
5. Purity of RNA can be calculated using the following equation: 
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 Purity = A260 / A280 
 This value should be between 1.5 and 1.9. 
 
Reverse Transcription 
Reverse Transcription with SuperScript III Reverse Transcriptase 
Materials 
Oligo(dT)15 Primer (Promega C1101; 20 µg) 
PCR Nucleotide Mix, 10 mM (Promega C1141; 200 µl) 
SuperScript III Reverse Transcriptase (Invitrogen 18080-093 or 18080-044; 2000 or 
10000 units) 




1. Add the following components to a nuclease-free PCR tube: 
 1 ng to 5 µg total RNA: 10 µl 
 Oligo(dT)15 (500 µg/ml): 1 µl 
 dNTP Mix (10 mM each): 1 µl 
 RNase, DNase-free water: to 12 µl final volume 
2. Heat mixture to 65˚C for 5 min and chill on ice for at least 1 min. Collect the 
contents of the tube by brief centrifugation and add: 
 5X First-Strand Buffer (250 mM Tris-HCl, 375 mM KCl, 15 mM MgCl2): 
4 µl 
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 0.1 M DTT: 1 µl 
 RNaseOUT (40 units/µl): 1 µl 
3. Mix contents of the tube gently.  Incubate at 42˚C for 2 min.  
4. Add 1 µl (200 units) of SuperScript III RT and mix by pipetting gently up and 
down.  
5. Incubate at 50˚C for 30-60 min. 
6. Inactivate the reaction by heating at 70˚C for 15 min. 
7. Store cDNA at -20˚C. 
8. Amplification of PCR targets (>1 kb) may require the removal of RNA 
complementary to the cDNA. To remove RNA complementary to the cDNA, add 
1 µl (2 units) of E. coli RNase H and incubate at 37˚C for 20 min. 
 
Primer Preparation 
Reconstitute primers (100 μM) 
Materials 
Custom Primers/Oligonucleotides, desalted (Invitrogen; 25 nmol) 
 
Protocol 
1. Find the total nmoles from the information sheet that came with the primer. 
2. The volume of DNase-free water needed to create a 100 μM stock can be 
calculated using the following equation:  
 Volume of DNase-free water in μl = (nmoles of primer) *1000 / (100 μM) 
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Make 10 μM aliquots 
Protocol 
1. Briefly spin the primers and add the needed amount of water for a 10-fold 
dilution. 
2. Make a 10-fold dilution (1 part primer: 9 parts DNase-free water) to obtain a 10 
μM aliquot. 
 
Polymerase Chain Reaction 
Run PCR 
Materials 
SYBR Green Master Mix (Applied Biosystems 4309155; 5 ml) 
Applied Biosystems StepOnePlus Real-Time PCR System and Materials 
 MicroAmp Fast 96-Well Reaction Plates, 0.1 ml (Applied Biosystems 
4346906; 20 plates) 
 MicroAmp Optical Adhesive Films (Applied Biosystems 4360954; 25 films) 
OR  
 MicroAmp Fast 8-Tube Strips, 0.1 ml (Applied Biosystems 4358293; 125 
strips) 
 MicroAmp Optical 8-Cap Strips (Applied Biosystems 4323032; 300 strips) 





1. Thaw the following components on ice: 
 SYBR Green mix 
 10 µM forward primer of interest 
 10 µM reverse primer of interest 
 Sample cDNA 
2. To make Master Mix, count the number of wells needed for each primer, add 2, 
and multiply this number by the following to obtain enough Master Mix for all 
wells of the primer: 
 12.5 µl SYBR Green mix 
 10.5 µl DNase-free water 
 0.5 µl 10 µM forward primer 
 0.5 µl 10 µM reverse primer 
3. Load PCR wells: 
 Load 24 µl of Master Mix into each well for that primer (target sequence of 
interest). 
 Add 1 µl of sample cDNA into the well with Master Mix and mix by 
pipetting up and down.  
(change pipette tips between each well) 
4. After all wells are loaded, cover with optical tape or caps, and put entire plate on 
ice until ready to run PCR.  
5. Load plate into StepOnePlus system: 
 Load plate into machine (A1 in upper-left, H12 in lower-right). 
 Open “StepOne Software v2.0” program.  
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 Click “Advanced Setup” button.  
 Under “Experiment Properties,” enter an Experiment Name, select 
“StepOnePlus Instrument (96 Wells)” for the instrument, select “Quantitation 
– Comparative CT (ΔΔCT)” for the experiment, select “SYBR Green 
Reagents” for the reagent (melt curve is optional), and select “Standard” for 
the ramp speed.   
 Under “Plate Setup,” add your targets and samples under “Define Targets and 
Samples,” changing the Reporter to “SYBR” and the Quencher to “None.”  
Under “Assign Targets and Samples,” assign the appropriate targets and 
samples to each well, selecting your control sample as the reference sample, 
GAPDH as the endogenous control, and “ROX” as the “dye to use as a 
passive reference.”   
 Under “Run Method,” change the reaction volume to 25 μl and set the method 
to the following: 
- Hold at 95˚C for 10 min (100% ramp). 
- Cycle 40 times at 95˚C for 15 sec and 60˚C for 1 min, collecting data 
at 60˚C.  
- Optional melt curve: 95˚C for 15 sec, 60˚C for 1 min, and +0.3˚C 
ramp, ending at 95˚C for 15 sec and collecting data during the +0.3˚C 
ramp.   
 Save the file.   
(Templates can be saved to reduce setup time.) 
 Select “Start Run.”   
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 After the run, click “Analyze” (settings can be modified under “Analysis 
Settings”) and resave the file.   
 Export results to Excel by clicking “Export…” and export “Results” as “One 
File” with “.xls” file type.   
6. Analyze data using the following ΔΔCT equation: 
 ΔCT, sample = CT, sample, target – CT, sample, GAPDH 
 ΔCT, reference = CT, reference, target – CT, reference, GAPDH 
 ΔΔCT = ΔCT, sample – ΔCT, reference 
 Fold regulation = 2 –ΔΔCT  
= 2










 –(CT, sample, target – CT, sample, GAPDH) 
 / 2
–(CT, reference, target – CT, 
reference, GAPDH) 
= 2
 (CT, sample, GAPDH – CT, sample, target)
 / 2








1. Section samples at 10 um. 
2. Deparaffinize using the autostainer. 
3. Draw a circle around the samples using the PAP pen. 
4. Wash by adding PBS to sections, remove PBS, repeat. 
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5. Antigen Retrieval: Add trypsin for 10 min at 37°C. 
6. Wash by adding PBS to sections, remove PBS, repeat. 
7. Peroxidase Blocking: Incubate sections in 0.3% H2O2 in Methanol solution 
for 15 minutes at room temperature. 
a. 10 ml methanol 
b. 100 µl H2O2. 
8. Wash by adding PBS to sections, remove PBS, repeat. 
9. Serum Blocking: incubate sections in normal serum (20 min) – species same 
as secondary antibody. 
a. Normal Goat Serum Block Solution (3ml):  
i. (2.6 ml of this solution) 1%BSA (stabilizer) 
ii.  (60 ul) 2% goat serum (blocking)  
iii.  (300 ul 1% gelatin) 0.1% cold fish skin gelatin (blocking) – do 
not use if staining for collagen 
iv. (30 ul) 0.1% Triton X-100 (penetration enhancer) 
v. (15 mg) 0.05% sodium azide (preservative) 
vi. Mix and store at 4 ºC. 
10. Prepare the working dilution of the primary antibody in 1% BSA in 1X PBS 
(if using Ab for the first time you will need to run a series of dilutions to 
determine the optimal working concentration). 
11. Blot off the blocking solution. 
12. Use a 10 ul pipette to apply primary antibody to just the parts of the section 
with your specimen. 
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13. Incubate sections in a humid chamber overnight. 
14. Wash by adding PBS to sections, remove PBS, repeat. 
15. Secondary Antibody: incubate sections in secondary antibody conjugated to 
biotin in PBS for 30 minutes at room temperature – try a range of 
concentrations. 
16. Wash by adding PBS to sections, remove PBS, repeat. 
17. Add ABC reagent for 30 min. 
a. 5 ml PBS 
b. 2 drops A 
c. 2 drops B 
d. Let sit for 30 min before use 
18. Wash by adding PBS to sections, remove PBS, repeat. 
19. Chromagen/Substrate: incubate sections in peroxidase substrate solution 
(DAB) for 5-10 min (generally 5 min - prepare solution just before use). 
a. 1 ml substrate 
b. 20 ul chromogen 






B.1 Adhesion Studies 
 OPF-3k or OPF-10k and PEG-DA were combined in a 1:1 wt/wt ratio and 
suspended in saline (75 wt% liquid).  Polymer solutions were cross-linked in thin (0.7 
mm) disc-shaped (14 mm radius) molds (10 min at 37 °C) using APS and TEMED 
thermal radial initiators (0.018 M).  Hydrogels were fabricated with 0, 0.1, or 1 μmol 
RGD/g swollen hydrogel.  Bovine ligament fibroblasts or bovine MSCs were seeded 
(39,750 cells/cm
2
) on top of the thin or thick hydrogels in an area confined by stainless 
steel annuli (19 mm long, ID: 9.8 mm, OD: 15.5 mm).  At 24 hours hydrogels were 
rinsed with saline to remove non-adherent cells and at least four representative phase 
contrast images per sample were taken.  For quantification, the number of cells per image 
was counted and cell numbers from multiple hydrogels in a particular group were 
















Figure B.1.  Number of adherent cells after 24h on OPF-3K hydrogels (left) or 
OPF-10K hydrogels  (right) (n=4 ± std. dev.).  p<0.05 compared to fibroblasts(*).  









































cellular density in cells/cm
2
.  Data from studies was analyzed for significance using 
ANOVA followed by Tukey‟s Multiple Comparison Test (p<0.05). 
B.2 GAPDH Gene Expression for Chapter 4 Samples. 
B.3 Fold Swelling With or Without RGD. 
 OPF-3k or OPF-10k and PEG-DA were combined in a 60:40 or 50:50 wt/wt ratio 
and suspended in saline (75 wt% liquid).  Polymer solutions were cross-linked in thin      
(0.5 mm) disc-shaped (12 mm radius) molds (10 min at 37 °C) using APS and TEMED 
thermal radial initiators (0.018 M).  Hydrogels were fabricated with 0 or 1 μmol RGD/g 
swollen hydrogel.  After 7 days of culture, samples were removed (n≥4).  Fold swelling 
was calculated by Ww/Wd where Ww is the weight of the hydrogel after culture and 
before drying, and Wd is the weight of the hydrogel after vacuum-drying.  Data between 



















Figure B.2.  GAPDH gene expression in hMSCs or hACL fibroblasts over 21 
days of culture in a range of enzymatically-cleavable hydrogels (n≥6 ±SD).  
GAPDH levels were similar in all sample types at a given time point except for 
day 1.   p<0.05 compared to hMSCs in 0%, 25%, 75%, and 100% enzymatically-












significance using two-tailed, homoscedasctic, t-tests (p<0.05).  No significant 
differences were seen in fold swelling after the addition of the RGD peptide sequences. 
 
Figure B.3.  Fold swelling of hydrogels fabricated without any RGD or with 1 
µmol RGD/g swollen hydrogel (n≥4 ±SD).  No significant differences were found 
between samples with RGD peptides and samples without these sequences.  60:40 
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